


**CUMULATIVE  
SUPPLEMENT 5  
MAY 2020**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2020**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**Cumulative Supplement 5  
May 2020**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Product Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**40<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 5  
MAY 2020**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH  
(AMNEAL PHARMS CO)

AMNEAL EU LTD  
(AMNEAL EU)

ANDA REPOSITORY LLC  
(ANDA REPOSITORY)

PHARMACEUTICS INTERNATIONAL INC  
(PII)

AMERICAN ANTIBIOTICS INC  
(AM ANTIBIOTICS)

BELCHER PHARMACEUTICALS INC  
(BELCHER PHARMS)

AMERICAN ANTIBIOTICS LLC  
(AM ANTIBIOTICS)

BELCHER PHARMACEUTICALS INC  
(BELCHER PHARMS)

ACP NIMBLE BUYER INC  
(ACP NIMBLE)

COSETTE PHARMACEUTICALS INC  
(COSETTE)

SUVEN LIFE SCIENCES LTD  
(SUVEN LIFE)

SUVEN PHARMACEUTICALS LTD  
(SUVEN PHARMS)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u>	<u>DEC</u>	<u>MAR</u>	<u>JUN</u>	<u>SEP</u>	<u>DEC</u>
<u>COUNTED</u>	<u>2019</u>	<u>2020</u>	<u>2020</u>	<u>2020</u>	<u>2020</u>

DRUG PRODUCTS LISTED SINGLE SOURCE	20567 2743 (13.3%)	20367 2635 (12.9%)
MULTISOURCE	17824 (86.7%)	17732 (87.1%)
THERAPEUTICALLY EQUIVALENT	17740 (86.3%)	17659 (86.7%)
NOT THERAPEUTICALLY EQUIVALENT	84 (0.4%)	73 (0.4%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	17	24
NUMBER OF APPLICANTS	1162	1166

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code
CTNA	Change. Trade Name
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>A> AB DR REDDYS LABS LTD 250MG A208416 001 May 18, 2020 May NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@ EMCURE PHARMS LTD 25MG

A202271 001 Feb 07, 2012 Mar DISC

@ 50MG

A202271 002 Feb 07, 2012 Mar DISC

@ 100MG

A202271 003 Feb 07, 2012 Mar DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ HIKMA PHARMS 325MG;50MG;40MG

A089718 001 Jun 12, 1995 Feb DISC

>D> AA SPECGX LLC 325MG;50MG;40MG

A087804 001 Jan 24, 1985 May DISC

>A> @ 325MG;50MG;40MG

A087804 001 Jan 24, 1985 May DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ACTAVIS LABS FL INC 300MG;5MG

A206470 001 Jun 02, 2016 Feb DISC

@ 300MG;7.5MG

A206470 002 Jun 02, 2016 Feb DISC

@ 300MG;10MG

A206470 003 Jun 02, 2016 Feb DISC

>D> AA PAR PHARM 300MG;5MG

A205001 001 Jul 05, 2016 May DISC

>A> @ 300MG;5MG

A205001 001 Jul 05, 2016 May DISC

>D> AA 300MG;7.5MG

A205001 002 Jul 05, 2016 May DISC

>A> @ 300MG;7.5MG

A205001 002 Jul 05, 2016 May DISC

>D> AA 300MG;10MG

A205001 003 Jul 05, 2016 May DISC

>A> @ 300MG;10MG

A205001 003 Jul 05, 2016 May DISC

@ XIROMED 325MG;5MG

A211690 001 Feb 07, 2020 Mar DISC

AA 325MG;5MG

A211690 001 Feb 07, 2020 Feb CAHN

AA 325MG;5MG

A211690 001 Feb 07, 2020 Jan NEWA

@ 325MG;7.5MG

A211690 002 Feb 07, 2020 Mar DISC

AA 325MG;7.5MG

A211690 002 Feb 07, 2020 Feb CAHN

AA 325MG;7.5MG

A211690 002 Feb 07, 2020 Jan NEWA

@ 325MG;10MG

A211690 003 Feb 07, 2020 Mar DISC

AA 325MG;10MG

A211690 003 Feb 07, 2020 Feb CAHN

AA 325MG;10MG

A211690 003 Feb 07, 2020 Jan NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART INC 300MG/5ML;10MG/5ML

A202142 001 Nov 27, 2018 Feb CMFD

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>D> AA GRANULES PHARMS 325MG;2.5MG

A211708 001 Oct 31, 2019 May DISC

>A> @ 325MG;2.5MG

A211708 001 Oct 31, 2019 May DISC

>D> AA 325MG;5MG

A211708 002 Oct 31, 2019 May DISC

>A> @ 325MG;5MG

A211708 002 Oct 31, 2019 May DISC

>D> AA 325MG;7.5MG

A211708 003 Oct 31, 2019 May DISC

>A> @ 325MG;7.5MG

A211708 003 Oct 31, 2019 May DISC

>D> AA 325MG;10MG

A211708 004 Oct 31, 2019 May DISC

>A> @ 325MG;10MG

A211708 004 Oct 31, 2019 May DISC

@ WATSON LABS 325MG;5MG

A040171 001 Oct 30, 1997 Apr DISC

@ 325MG;7.5MG

A040535 001 Sep 05, 2003 Apr DISC

@ 325MG;10MG

A040535 002 Sep 05, 2003 Apr DISC

@ XIROMED 325MG;5MG

A207574 001 Dec 13, 2016 Mar DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ APOTEX 325MG;37.5MG

A078778 001 Apr 07, 2014 Feb DISC

@ GRAVITI PHARMS 325MG;37.5MG

A076914 001 Jul 26, 2006 Apr CAHN

>D> AB MACLEODS PHARMS LTD 325MG;37.5MG

A206885 001 May 02, 2017 May DISC

>A> @ 325MG;37.5MG

A206885 001 May 02, 2017 May DISC

@ NOSTRUM LABS INC 325MG;37.5MG

A078778 001 Apr 07, 2014 Apr CAHN

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB	BRECKENRIDGE	125MG	A207503	001	Apr 30, 2020	Apr	NEWA
AB		250MG	A207503	002	Apr 30, 2020	Apr	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	! XGEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Feb	CAHN
----	---------------	--------------------	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Mar	CAHN
----	-----------------	----	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

>A>	AT	COSETTE	2%;1%	A040609	001	Feb 06, 2006	May	CAHN
>D>	AT	VINTAGE	2%;1%	A040609	001	Feb 06, 2006	May	CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>D>	AB	DAVA PHARMS INC	200MG	A074833	001	Apr 22, 1997	May	DISC
>A>		@	200MG	A074833	001	Apr 22, 1997	May	DISC

CREAM;TOPICAL

ACYCLOVIR

AB	! PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan	CHRS
AB	+ BAUSCH	5%	N021478	001	Dec 30, 2002	Jan	CHRS

OINTMENT;TOPICAL

ACYCLOVIR

AB	SOLARIS PHARMA CORP	5%	A212495	001	Apr 07, 2020	Mar	NEWA
AB	XIROMED	5%	A201501	001	Jan 29, 2020	Jan	NEWA

SUSPENSION;ORAL

ACYCLOVIR

AB	HERITAGE PHARMS INC	200MG/5ML	A212718	001	Apr 23, 2020	Apr	NEWA
----	---------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

ACYCLOVIR

AB	! HETERO LABS LTD V	800MG	A203834	002	Oct 29, 2013	Jan	CHRS
	+ @ MYLAN	400MG	N020089	001	Apr 30, 1991	Jan	DISC
	+ @	800MG	N020089	002	Apr 30, 1991	Jan	DISC

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

@ MYLAN LABS LTD 3MG/ML

A078640	001	Mar 21, 2014	Apr	DISC
---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

ALBUTEROL SULFATE

AB1	CIPLA	EQ 0.09MG BASE/INH	A209959	001	Apr 08, 2020	Mar	NFTG	
AB2	PERRIGO PHARMS CO	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CTEC	
AB		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Feb	NFTG	
	PROAIR HFA							
AB2	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Mar	CTEC	
AB	+!	EQ 0.09MG BASE/INH	N021457	001	Oct 29, 2004	Feb	CFTG	
	PROVENTIL-HFA							
>D>	AB1	+! 3M DRUG DELIVERY	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN
	AB1	+!	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	Mar	CFTG
>A>	AB1	+! KINDEVA	EQ 0.09MG BASE/INH	N020503	001	Aug 15, 1996	May	CAHN

SOLUTION;INHALATION

ALBUTEROL SULFATE

AN	AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Apr	NEWA
AN		EQ 0.042% BASE	A211888	002	Apr 20, 2020	Apr	NEWA
	@ BAUSCH AND LOMB	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Feb	DISC
AN	! NEPHRON	EQ 0.5% BASE	A075664	001	Jun 26, 2001	Feb	CHRS

TABLET;ORAL									
ALBUTEROL SULFATE									
>A>	AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020	May	NEWA	
>A>	AB		EQ 4MG BASE	A213657	002	May 14, 2020	May	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
VOLMAX									
	+	@ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992	Mar	CRLD	
	+	@	EQ 8MG BASE	N019604	001	Dec 23, 1992	Mar	CRLD	
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>									
SOLUTION;INHALATION									
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE									
	@	WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007	Apr	DISC	
<u>ALOSETRON HYDROCHLORIDE</u>									
TABLET;ORAL									
ALOSETRON HYDROCHLORIDE									
	@	EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Apr	DISC	
	@		EQ 1MG BASE	A211621	002	Sep 16, 2019	Apr	DISC	
<u>ALPRAZOLAM</u>									
TABLET;ORAL									
ALPRAZOLAM									
	@	DAVA INTL INC	0.25MG	A074174	001	Oct 19, 1993	Feb	DISC	
	@		0.5MG	A074174	002	Oct 19, 1993	Feb	DISC	
	@		1MG	A074174	003	Oct 19, 1993	Feb	DISC	
	@		2MG	A074174	004	Oct 19, 1993	Feb	DISC	
XANAX									
AB	+	UPJOHN	0.25MG	N018276	001		Apr	CAHN	
AB	+		0.5MG	N018276	002		Apr	CAHN	
AB	+	!	1MG	N018276	003		Apr	CAHN	
AB	+		2MG	N018276	004	Nov 27, 1985	Apr	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
XANAX XR									
AB	+	UPJOHN	0.5MG	N021434	001	Jan 17, 2003	Apr	CAHN	
AB	+		1MG	N021434	002	Jan 17, 2003	Apr	CAHN	
AB	+		2MG	N021434	003	Jan 17, 2003	Apr	CAHN	
AB	+	!	3MG	N021434	004	Jan 17, 2003	Apr	CAHN	
<u>AMANTADINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
AMANTADINE HYDROCHLORIDE									
AB		INVATECH	100MG	A210129	001	Mar 02, 2020	Feb	NEWA	
>A>	AB	RUBICON	100MG	A212044	001	May 21, 2020	May	NEWA	
TABLET;ORAL									
AMANTADINE HYDROCHLORIDE									
AB		INVATECH	100MG	A210215	001	Mar 10, 2020	Feb	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
OSMOLEX ER									
	+	OSMOTICA PHARM	EQ 161MG BASE	N209410	004	Apr 22, 2020	Apr	NEWA	
<u>AMIKACIN SULFATE</u>									
INJECTABLE;INJECTION									
AMIKACIN SULFATE									
AP		TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993	Mar	CMFD	
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL</u>									
EMULSION;INTRAVENOUS									
PERIKABIVEN IN PLASTIC CONTAINER									
+	!	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014	Jan	CHRS	
<u>AMINOCAPROIC ACID</u>									
SYRUP;ORAL									
AMINOCAPROIC ACID									
AA		VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb	NEWA	

AMISULPRIDE

SOLUTION; INTRAVENOUS  
BARHEMSYS

+! ACACIA PHARMA LTD 5MG/2ML (2.5MG/ML) N209510 001 Feb 26, 2020 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL  
AMITRIPTYLINE HYDROCHLORIDE

AB		SANDOZ	10MG	A 085968	004			Jan	CMS1
AB	!		25MG	A 085968	002			Jan	CMS1
AB			75MG	A 085968	006			Jan	CMS1
AB			100MG	A 085968	003			Jan	CMS1
AB			150MG	A 085968	005			Jan	CMS1
>D>	AB	UPSHER SMITH LABS	25MG	A 212654	001	Apr 07, 2020		May	DISC
>A>		@	25MG	A 212654	001	Apr 07, 2020		May	DISC
AB			25MG	A 212654	001	Apr 07, 2020		Mar	NEWA

AMLODIPINE BENZOATE

SUSPENSION; ORAL  
KATERZIA

>A>	+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019		May	CAHN
>D>	+!	SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019		May	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL  
AMLODIPINE BESYLATE

	@	HIKMA	EQ 2.5MG BASE	A 077262	001	Jul 09, 2007		Feb	DISC
	@		EQ 5MG BASE	A 077262	002	Jul 09, 2007		Feb	DISC
	@		EQ 10MG BASE	A 077262	003	Jul 09, 2007		Feb	DISC
>D>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A 201380	001	Apr 13, 2012		May	DISC
>A>		@	EQ 5MG BASE	A 201380	001	Apr 13, 2012		May	DISC
>D>	AB		EQ 10MG BASE	A 201380	002	Apr 13, 2012		May	DISC
>A>		@	EQ 10MG BASE	A 201380	002	Apr 13, 2012		May	DISC
	@	WATSON LABS	EQ 2.5MG BASE	A 077671	001	Jul 19, 2007		Apr	DISC
	@		EQ 5MG BASE	A 077671	002	Jul 19, 2007		Apr	DISC
	@		EQ 10MG BASE	A 077671	003	Jul 19, 2007		Apr	DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL  
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A 207762	001	Jan 11, 2019		Feb	CMFD
AB			EQ 2.5MG BASE;EQ 20MG BASE	A 207762	002	Jan 11, 2019		Feb	CMFD
AB			EQ 2.5MG BASE;EQ 40MG BASE	A 207762	003	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 10MG BASE	A 207762	004	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 20MG BASE	A 207762	005	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 40MG BASE	A 207762	006	Jan 11, 2019		Feb	CMFD
AB			EQ 5MG BASE;EQ 80MG BASE	A 207762	007	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 10MG BASE	A 207762	008	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 20MG BASE	A 207762	009	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 40MG BASE	A 207762	010	Jan 11, 2019		Feb	CMFD
AB			EQ 10MG BASE;EQ 80MG BASE	A 207762	011	Jan 11, 2019		Feb	CMFD
		CADUET							
>D>	AB	+	PFIZER	EQ 2.5MG BASE;EQ 10MG BASE	N 021540	009	Jul 29, 2004	May	CAHN
>A>	AB	+		EQ 2.5MG BASE;EQ 10MG BASE	N 021540	009	Jul 29, 2004	May	CAHN
>D>	AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N 021540	010	Jul 29, 2004	May	CAHN
>A>	AB	+		EQ 2.5MG BASE;EQ 20MG BASE	N 021540	010	Jul 29, 2004	May	CAHN
>D>	AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N 021540	011	Jul 29, 2004	May	CAHN
>A>	AB	+		EQ 2.5MG BASE;EQ 40MG BASE	N 021540	011	Jul 29, 2004	May	CAHN
>D>	AB	+		EQ 5MG BASE;EQ 10MG BASE	N 021540	001	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 5MG BASE;EQ 10MG BASE	N 021540	001	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 5MG BASE;EQ 20MG BASE	N 021540	002	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 5MG BASE;EQ 20MG BASE	N 021540	002	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 5MG BASE;EQ 40MG BASE	N 021540	003	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 5MG BASE;EQ 40MG BASE	N 021540	003	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 5MG BASE;EQ 80MG BASE	N 021540	004	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 5MG BASE;EQ 80MG BASE	N 021540	004	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 10MG BASE;EQ 10MG BASE	N 021540	005	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 10MG BASE;EQ 10MG BASE	N 021540	005	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 10MG BASE;EQ 20MG BASE	N 021540	006	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 10MG BASE;EQ 20MG BASE	N 021540	006	Jan 30, 2004	May	CAHN
>D>	AB	+		EQ 10MG BASE;EQ 40MG BASE	N 021540	007	Jan 30, 2004	May	CAHN
>A>	AB	+		EQ 10MG BASE;EQ 40MG BASE	N 021540	007	Jan 30, 2004	May	CAHN

TABLET; ORAL  
CADUET

>D>	AB	+	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	May	CAHN
>A>	AB	+	EQ 10MG BASE;EQ 80MG BASE	N021540	008	Jan 30, 2004	May	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>D>	AB		EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	May	DISC
>A>		@	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	May	DISC
>D>	AB		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	May	DISC
>A>		@	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	May	DISC
>D>	AB		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	May	DISC
>A>		@	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	May	DISC
>D>	AB		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	May	DISC
>A>		@	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	May	DISC
>D>	AB		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	May	DISC
>A>		@	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	May	DISC
>D>	AB		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	May	DISC
>A>		@	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	May	DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB			EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017	Mar	CPOT
AB			EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017	Mar	CPOT
AB			EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017	Mar	CPOT
AB			EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017	Mar	CPOT
AB			EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017	Mar	CPOT
AB		LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015	Mar	CPOT
AB			EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015	Mar	CPOT
AB			EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015	Mar	CPOT
AB			EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015	Mar	CPOT
AB			EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015	Mar	CPOT
>D>	AB		EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	May	DISC
>A>		@	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	May	DISC
AB			EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Mar	CPOT
>D>	AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	May	DISC
>A>		@	EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	May	DISC
AB			EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Mar	CPOT
>D>	AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	May	DISC
>A>		@	EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	May	DISC
AB			EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Mar	CPOT
>D>	AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	May	DISC
>A>		@	EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	May	DISC
AB			EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Mar	CPOT
>D>	AB		EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	May	DISC
>A>		@	EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	May	DISC
AB			EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Mar	CPOT
		@ TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012	Mar	CPOT
		@	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012	Mar	CPOT
		@	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012	Mar	CPOT
		@	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012	Mar	CPOT
		@	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012	Mar	CPOT
		@ TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015	Mar	CPOT
		@	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015	Mar	CPOT
		@	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015	Mar	CPOT
		@	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015	Mar	CPOT
		@	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015	Mar	CPOT
		EXFORGE HCT						
AB	+	NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009	Mar	CPOT
AB	+		EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009	Mar	CPOT
AB	+		EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009	Mar	CPOT
AB	+		EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009	Mar	CPOT
AB	+		EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009	Mar	CPOT

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

>D>	AP		30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203700	001	Feb 25, 2013	May	CAHN
>A>	AP		30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203700	001	Feb 25, 2013	May	CAHN

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

@ WATSON LABS INC EQ 12% BASE A076829 001 Feb 07, 2006 Apr DISC

LOTION; TOPICAL

AMMONIUM LACTATE

@ WATSON LABS INC EQ 12% BASE A075575 001 Jun 11, 2002 Apr DISC

AMOXAPINE

TABLET; ORAL

AMOXAPINE

@ WATSON PHARMS TEVA 25MG A072418 001 Aug 01, 1989 Jan CMS1

@ 50MG A072419 001 Aug 01, 1989 Jan CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ANI PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019	Jan CAHN
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan CAHN
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan CAHN
AB		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan CAHN
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan CAHN
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan CAHN
>A>	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	May CAHN
>A>		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	May CAHN
>A>		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	May CAHN
>A>		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	May CAHN
>A>		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	May CAHN
>A>		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	May CAHN
	@ NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019	Jan DISC
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019	Jan DISC
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019	Jan DISC
	@	5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019	Jan DISC
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019	Jan DISC
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019	Jan DISC
AB	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Apr CMFD
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Apr CMFD
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Apr CMFD
AB		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Apr CMFD
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Apr CMFD
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Apr CMFD
>D>	SUNGEN PHARMA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	May CAHN
>D>		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	May CAHN
>D>		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	May CAHN
>D>		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	May CAHN
>D>		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	May CAHN
>D>		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	May CAHN
	@ TEVA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A077488	001	Apr 29, 2013	Apr DISC
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A077488	002	Apr 29, 2013	Apr DISC
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A077488	003	Apr 29, 2013	Apr DISC
	@	5MG; 5MG; 5MG; 5MG	A077488	004	Apr 29, 2013	Apr DISC
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A077488	005	Apr 29, 2013	Apr DISC
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A077488	006	Apr 29, 2013	Apr DISC
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	@ BARR LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076536	001	Feb 12, 2013	Apr DISC
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A076536	002	Feb 12, 2013	Apr DISC
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A076536	003	Feb 12, 2013	Apr DISC
	@	5MG; 5MG; 5MG; 5MG	A076536	004	Feb 12, 2013	Apr DISC
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A076536	005	Feb 12, 2013	Apr DISC
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A076536	006	Feb 12, 2013	Apr DISC
	TABLET; ORAL					
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	BIONPHARMA INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Mar NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Mar NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Mar NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Mar NEWA
AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Mar NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Mar NEWA
>A>	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211352	001	Dec 07, 2018	May CAHN
>A>		1.875MG; 1.875MG; 1.875MG; 1.875MG	A211352	002	Dec 07, 2018	May CAHN
>A>		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211352	003	Dec 07, 2018	May CAHN
>A>		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211352	004	Dec 07, 2018	May CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018	May CAHN
>A>	AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018	May CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018	May CAHN
>D>	AB	SUNGEN PHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018	May CAHN
>D>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018	May CAHN
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018	May CAHN
>D>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018	May CAHN
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018	May CAHN
>D>	AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018	May CAHN
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018	May CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA		CEROVENE INC	5MG	A212582	001	Feb 04, 2020	Jan NEWA
AA			10MG	A212582	002	Feb 04, 2020	Jan NEWA
>A>	AA	HAVIX	5MG	A212901	001	May 22, 2020	May NEWA
>A>	AA		10MG	A212901	002	May 22, 2020	May NEWA
AA		PRINSTON INC	5MG	A211861	001	Mar 11, 2020	Feb NEWA
AA			10MG	A211861	002	Mar 11, 2020	Feb NEWA

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!		XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Feb CAHN
---	--	-------------	-----------	---------	-----	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@		PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Jan CAHN
@			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Jan CAHN

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

@		DAVA PHARMS INC	EQ 500MG BASE	A062882	001	Feb 25, 1988	Mar DISC
!		SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995	Mar CHRS

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

@		BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Apr DISC
@			EQ 1MG BASE	A076530	002	Apr 18, 2005	Apr DISC

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

@		APOTEX INC	1MG	A200654	001	May 11, 2012	Feb DISC
@		MYLAN	1MG	A091051	001	Jun 28, 2010	Jan DISC

APIXABAN

TABLET;ORAL

APIXABAN

AB		BIONPHARMA INC	2.5MG	A210152	001	Apr 08, 2020	Mar NEWA
AB			5MG	A210152	002	Apr 08, 2020	Mar NEWA
		@ MYLAN	2.5MG	A210128	001	Dec 23, 2019	Jan DISC
		@	5MG	A210128	002	Dec 23, 2019	Jan DISC

APOMORPHINE HYDROCHLORIDE

>A>		FILM;SUBLINGUAL					
>A>		KYNMOBI					
>A>	+	SUNOVION PHARMS INC	10MG	N210875	001	May 21, 2020	May NEWA
>A>	+		15MG	N210875	002	May 21, 2020	May NEWA
>A>	+		20MG	N210875	003	May 21, 2020	May NEWA
>A>	+		25MG	N210875	004	May 21, 2020	May NEWA
>A>	+		30MG	N210875	005	May 21, 2020	May NEWA

ARGATROBAN

	INJECTABLE; INJECTION							
	ARGATROBAN							
AP	+!	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CHRS
AP	+		250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012	Mar	CRLD
	INJECTABLE; INTRAVENOUS							
	ARGATROBAN IN 0.9% SODIUM CHLORIDE							
	@	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Mar	DISC

>A> ARTESUNATE

>A>	POWDER; INTRAVENOUS							
>A>	ARTESUNATE							
>A>	+!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	May	NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

	INJECTABLE; INJECTION							
	SEPTOCAINE							
	+!	DEPROCO	4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)	N022010	001	Mar 30, 2006	Mar	CTEC
	+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001	Apr 03, 2000	Feb	CTEC
	ULTACAN							
	@	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017	Mar	DISC
	ULTACAN FORTE							
	@	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017	Feb	DISC

ASENAPINE MALEATE

	TABLET; SUBLINGUAL							
	SAPHRIS							
	+	ALLERGAN	EQ 2.5MG BASE	N022117	003	Mar 12, 2015	Jan	CMS1

ASPIRIN; BUTALBITAL; CAFFEINE

	TABLET; ORAL							
	BUTALBITAL, ASPIRIN AND CAFFEINE							
AA		STRIDES PHARMA	325MG; 50MG; 40MG	A204195	001	Sep 22, 2016	Mar	CAHN

>D> ASPIRIN; CARISOPRODOL

>D>	TABLET; ORAL							
>D>	CARISOPRODOL AND ASPIRIN							
>D>	AB	!	HERITAGE PHARMS INC	325MG; 200MG	A089594	001	Mar 31, 1989	May
>A>		@		325MG; 200MG	A089594	001	Mar 31, 1989	May
>D>	AB		NOVAST LABS	325MG; 200MG	A040832	001	Jan 07, 2010	May
>A>		@		325MG; 200MG	A040832	001	Jan 07, 2010	May
>D>	AB		SANDOZ	325MG; 200MG	A040116	001	Apr 25, 1996	May
>A>		@		325MG; 200MG	A040116	001	Apr 25, 1996	May

ASPIRIN; PRAVASTATIN SODIUM

	TABLET; ORAL							
	PRAVIGARD PAC (COPACKAGED)							
>A>	@	BRISTOL MYERS SQUIBB	81MG; 20MG	N021387	001	Jun 24, 2003	May	CPOT
>A>	@		81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003	May	CDFR
>A>	@		81MG; 40MG	N021387	002	Jun 24, 2003	May	CPOT
>A>	@		81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003	May	CDFR
>A>	@		81MG; 80MG	N021387	003	Jun 24, 2003	May	CPOT
>A>	@		81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003	May	CDFR
>A>	@		325MG; 20MG	N021387	004	Jun 24, 2003	May	CPOT
>A>	@		325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003	May	CDFR
>A>	@		325MG; 40MG	N021387	005	Jun 24, 2003	May	CPOT
>A>	@		325MG, N/A; N/A, 40MG	N021387	005	Jun 24, 2003	May	CDFR
>A>	@		325MG; 80MG	N021387	006	Jun 24, 2003	May	CPOT
>A>	@		325MG, N/A; N/A, 80MG	N021387	006	Jun 24, 2003	May	CDFR
	TABLET, TABLET; ORAL							
	PRAVIGARD PAC (COPACKAGED)							
>D>	@	BRISTOL MYERS SQUIBB	325MG, N/A; N/A, 80MG	N021387	006	Jun 24, 2003	May	CDFR
	TABLET, TABLET; ORAL							
	PRAVIGARD PAC (COPACKAGED)							
>D>	@	BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387	001	Jun 24, 2003	May	CDFR
>D>	@		81MG, N/A; N/A, 40MG	N021387	002	Jun 24, 2003	May	CDFR
>D>	@		81MG, N/A; N/A, 80MG	N021387	003	Jun 24, 2003	May	CDFR
>D>	@		325MG, N/A; N/A, 20MG	N021387	004	Jun 24, 2003	May	CDFR

TABLET, TABLET, TABLET;ORAL  
PRAVIGARD PAC (COPACKAGED)

>D> @ 325MG,N/A;N/A,40MG N021387 005 Jun 24, 2003 May CDFR

ATAZANAVIR SULFATE

CAPSULE;ORAL  
ATAZANAVIR SULFATE

>A> AB AMNEAL EQ 100MG BASE A209717 001 Jun 01, 2020 May NEWA  
 >A> AB EQ 150MG BASE A209717 002 Jun 01, 2020 May NEWA  
 >A> AB EQ 200MG BASE A209717 003 Jun 01, 2020 May NEWA  
 >A> AB EQ 300MG BASE A209717 004 Jun 01, 2020 May NEWA  
 @ MYLAN EQ 150MG BASE A208177 001 Sep 24, 2018 Feb DISC  
 @ EQ 200MG BASE A208177 002 Sep 24, 2018 Feb DISC  
 @ EQ 300MG BASE A208177 003 Sep 24, 2018 Feb DISC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL  
ATENOLOL AND CHLORTHALIDONE

>D> AB MYLAN 50MG;25MG A074203 001 Oct 31, 1993 May DISC  
 >A> @ 50MG;25MG A074203 001 Oct 31, 1993 May DISC  
 >D> AB 100MG;25MG A074203 002 Oct 31, 1993 May DISC  
 >A> @ 100MG;25MG A074203 002 Oct 31, 1993 May DISC

ATORVASTATIN CALCIUM

TABLET;ORAL  
ATORVASTATIN CALCIUM

AB LUPIN LTD EQ 10MG BASE A204991 001 Mar 06, 2019 Jan CMFD  
 AB EQ 20MG BASE A204991 002 Mar 06, 2019 Jan CMFD  
 AB EQ 40MG BASE A204991 003 Mar 06, 2019 Jan CMFD  
 AB EQ 80MG BASE A204991 004 Mar 06, 2019 Jan CMFD

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL  
EZETIMIBE AND ATORVASTATIN CALCIUM

@ SCOV3 EQ 10MG BASE;10MG A206084 001 Apr 26, 2017 Apr DISC  
 EQ 10MG BASE;10MG A206084 001 Apr 26, 2017 Mar CAHN  
 @ EQ 20MG BASE;10MG A206084 002 Apr 26, 2017 Apr DISC  
 EQ 20MG BASE;10MG A206084 002 Apr 26, 2017 Mar CAHN  
 @ EQ 40MG BASE;10MG A206084 003 Apr 26, 2017 Apr DISC  
 EQ 40MG BASE;10MG A206084 003 Apr 26, 2017 Mar CAHN  
 @ EQ 80MG BASE;10MG A206084 004 Apr 26, 2017 Apr DISC  
 ! EQ 80MG BASE;10MG A206084 004 Apr 26, 2017 Mar CAHN

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC  
ISOPTO ATROPINE

+! ALCON LABS INC 1% N208151 001 Dec 01, 2016 Feb CRLD  
 ! 1% N208151 001 Dec 01, 2016 Feb CHRS

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA LEADING PHARMA LLC 0.025MG;2.5MG A213413 001 Feb 20, 2020 Feb NEWA  
 >A> AA MAYNE PHARMA INC 0.025MG;2.5MG A210789 001 Jun 03, 2020 May NEWA  
 >D> AA PAR PHARM 0.025MG;2.5MG A040357 001 May 02, 2000 May DISC  
 >A> @ 0.025MG;2.5MG A040357 001 May 02, 2000 May DISC

AVAPRITINIB

TABLET;ORAL  
AYVAKIT

+ BLUEPRINT MEDICINES 100MG N212608 001 Jan 09, 2020 Jan NEWA  
 + 200MG N212608 002 Jan 09, 2020 Jan NEWA  
 +! 300MG N212608 003 Jan 09, 2020 Jan NEWA

AZATHIOPRINE

TABLET;ORAL  
AZATHIOPRINE

AB ALKEM LABS LTD 25MG A208687 001 Mar 27, 2020 Mar NEWA  
 AB 50MG A208687 002 Mar 27, 2020 Mar NEWA  
 AB 75MG A208687 003 Mar 27, 2020 Mar NEWA  
 AB 100MG A208687 004 Mar 27, 2020 Mar NEWA  
 >D> AB MYLAN 50MG A075568 001 Dec 13, 1999 May CAHN

	TABLET;ORAL						
	AZATHIOPRINE						
>A>	AB	RISING	50MG	A075568	001	Dec 13, 1999	May CAHN
	<u>AZELASTINE HYDROCHLORIDE</u>						
	SOLUTION/DROPS;OPHTHALMIC						
	AZELASTINE HYDROCHLORIDE						
AT		GLAND PHARMA LTD	0.05%	A210092	001	Feb 25, 2020	Feb NEWA
	SPRAY, METERED;NASAL						
	AZELASTINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY	A212289	001	May 08, 2020	Apr NEWA
	<u>AZITHROMYCIN</u>						
	FOR SUSPENSION;ORAL						
	AZITHROMYCIN						
>D>	AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	May DISC
>A>		@	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	May DISC
		@ TEVA PHARMS	EQ 100MG BASE/5ML	A065419	001	Jun 24, 2008	Apr DISC
		@	EQ 200MG BASE/5ML	A065419	002	Jun 24, 2008	Apr DISC
	INJECTABLE;INJECTION						
	AZITHROMYCIN						
		@ HIKMA	EQ 500MG BASE/VIAL	A065265	001	Jan 18, 2007	Mar CAHN
		@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204732	001	Jan 26, 2017	Mar DISC
	TABLET;ORAL						
	AZITHROMYCIN						
AB		ALEMBIC PHARMS LTD	EQ 250MG BASE	A211791	001	Jan 28, 2020	Jan NEWA
AB			EQ 500MG BASE	A211792	001	Jan 28, 2020	Jan NEWA
AB			EQ 600MG BASE	A211793	001	Jan 27, 2020	Jan NEWA
		@ MYLAN	EQ 600MG BASE	A065360	001	Jan 08, 2007	Jan DISC
	<u>BACITRACIN</u>						
	INJECTABLE;INJECTION						
	BACIIM						
		@ X GEN PHARMS	50,000 UNITS/VIAL	A064153	001	May 09, 1997	Mar DISC
	BACITRACIN						
		@ AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017	Mar DISC
		@ FRESENIUS KABI USA	50,000 UNITS/VIAL	A065116	001	Dec 03, 2002	Mar DISC
	<u>BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>						
	OINTMENT;OPHTHALMIC						
	LUMI-SPORYN						
>A>							
>A>	AT	+ CASPER PHARMA LLC	EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM	N050417	001		May CTNA
>D>		NEOSPORIN					
>D>	AT	+ CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		May CTNA
	<u>BACLOFEN</u>						
	INJECTABLE;INTRATHECAL						
	BACLOFEN						
		@ MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Mar DISC
		@	2MG/ML	A210048	002	Sep 11, 2019	Mar DISC
	TABLET;ORAL						
	BACLOFEN						
		@ MYLAN	20MG	A077121	002	Jul 29, 2005	Jan DISC
		@ MYLAN PHARMS INC	10MG	A090334	001	Feb 18, 2010	Apr DISC
		@	20MG	A090334	002	Feb 18, 2010	Apr DISC
AB		RUBICON	5MG	A209102	001	Nov 28, 2017	Apr CTEC
AB		ZYDUS	5MG	A211659	003	Apr 17, 2020	Apr NEWA
	<u>BEDAQUILINE FUMARATE</u>						
	TABLET;ORAL						
	SIRTURO						
>A>		+ JANSSEN THERAP	EQ 20MG BASE	N204384	002	May 27, 2020	May NEWA
	<u>BEMPEDOIC ACID</u>						
	TABLET;ORAL						
	NEXLETOL						
		+! ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020	Feb NEWA

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL  
NEXLIZET

+! ESPERION THERAPS INC 180MG;10MG N211617 001 Feb 26, 2020 Feb NEWA

BENZAEPRIIL HYDROCHLORIDE

TABLET;ORAL  
BENZAEPRIIL HYDROCHLORIDE

AB COREPHARMA 5MG A077128 001 Mar 08, 2006 Feb CAHN  
 AB 10MG A077128 002 Mar 08, 2006 Feb CAHN  
 AB 20MG A077128 003 Mar 08, 2006 Feb CAHN  
 AB 40MG A077128 004 Mar 08, 2006 Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC  
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+! BAUSCH 0.4%;0.3% N211039 001 Mar 09, 2020 Mar NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL  
BENZPHETAMINE HYDROCHLORIDE

@ EMCURE PHARMS LTD 50MG A202061 001 Jan 27, 2012 Mar DISC  
 @ SPECGX LLC 50MG A040773 001 Apr 25, 2007 Apr DISC  
 @ TWI PHARMS 50MG A040578 001 Apr 17, 2006 Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC  
BEPOTASTINE BESILATE

@ MYLAN 1.5% A206220 001 Mar 18, 2019 Feb DISC  
 BEPREVE  
 +! BAUSCH AND LOMB INC 1.5% N022288 001 Sep 08, 2009 Feb CTEC

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL  
BETAMETHASONE DIPROPIONATE

AB ! GLENMARK GENERICS EQ 0.05% BASE A078930 001 Sep 23, 2008 Feb CHRS  
 DIPROLENE AF  
 + @ MERCK SHARP DOHME EQ 0.05% BASE N019555 001 Apr 27, 1987 Feb DISC  
 LOTION;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 @ ACTAVIS MID ATLANTIC EQ 0.05% BASE A070281 001 Jul 31, 1985 Apr DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL  
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB TOLMAR 0.064%;0.005% A210765 001 May 11, 2020 Apr NFTG  
 TACLONEX  
 AB +! LEO PHARMA AS 0.064%;0.005% N022185 001 May 09, 2008 Apr CFTG

BETHANECHOL CHLORIDE

TABLET;ORAL  
BETHANECHOL CHLORIDE

AA ! AMNEAL PHARM 5MG A040855 001 Nov 21, 2007 Jan CHRS  
 AA ! 10MG A040855 002 Nov 21, 2007 Jan CHRS  
 AA ! 25MG A040855 003 Nov 21, 2007 Jan CHRS  
 @ IMPAX LABS 25MG A040721 003 Nov 01, 2006 Jan CMS1  
 URECHOLINE  
 @ ODYSSEY PHARMS 5MG A089095 001 Dec 19, 1985 Jan DISC  
 @ 10MG A088440 001 May 29, 1984 Jan DISC  
 @ 25MG A088441 001 May 29, 1984 Jan DISC

BEXAROTENE

CAPSULE;ORAL  
BEXAROTENE

AB ANI PHARMS INC 75MG A209861 001 May 08, 2018 Jan CAHN

<u>BICALUTAMIDE</u>							
TABLET; ORAL							
BICALUTAMIDE							
	@ MYLAN	50MG	A079185	001	Jul 06, 2009	Jan	DISC
<u>BIMATOPROST</u>							
IMPLANT; OPHTHALMIC							
DURYSTA							
	+! ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020	Mar	NEWA
SOLUTION/DROPS; TOPICAL							
BIMATOPROST							
AT	ALEMBIC PHARMS LTD	0.03%	A210515	001	Jan 21, 2020	Jan	NEWA
<u>BISOPROLOL FUMARATE</u>							
TABLET; ORAL							
BISOPROLOL FUMARATE							
	@ TEVA PHARMS	5MG	A075644	001	Jun 26, 2001	Apr	DISC
	@	10MG	A075644	002	Jun 26, 2001	Apr	DISC
<u>BIVALIRUDIN</u>							
INJECTABLE; INTRAVENOUS							
BIVALIRUDIN							
	@ APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017	Feb	DISC
<u>BOSENTAN</u>							
TABLET; ORAL							
BOSENTAN							
AB	ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Jan	NEWA
AB		125MG	A211461	002	Jan 23, 2020	Jan	NEWA
	@ MYLAN	62.5MG	A205173	001	Jan 15, 2020	Jan	DISC
	@	125MG	A205173	002	Jan 15, 2020	Jan	DISC
<u>BROMFENAC SODIUM</u>							
SOLUTION/DROPS; OPHTHALMIC							
BROMFENAC SODIUM							
AT2	GLAND PHARMA LTD	EQ 0.09% ACID	A211029	001	Mar 17, 2020	Mar	NEWA
<u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>							
SYRUP; ORAL							
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE							
AA	LANNETT CO INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A213125	001	Apr 17, 2020	Apr	NEWA
<u>BUDESONIDE</u>							
AEROSOL, FOAM; RECTAL							
UCERIS							
	+! SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Feb	CAHN
<u>BUMETANIDE</u>							
TABLET; ORAL							
BUMETANIDE							
AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jan	CAHN
AB		1MG	A212019	002	Dec 12, 2019	Jan	CAHN
AB		2MG	A212019	003	Dec 12, 2019	Jan	CAHN
<u>BUPRENORPHINE</u>							
FILM, EXTENDED RELEASE; TRANSDERMAL							
BUPRENORPHINE							
AB	AMNEAL PHARMS LLC	5MCG/HR	A211586	001	Apr 14, 2020	Mar	NEWA
AB		7.5MCG/HR	A211586	002	Apr 14, 2020	Mar	NFTG
AB		10MCG/HR	A211586	003	Apr 14, 2020	Mar	NEWA
AB		15MCG/HR	A211586	004	Apr 14, 2020	Mar	NEWA
AB		20MCG/HR	A211586	005	Apr 14, 2020	Mar	NEWA
BUTRANS							
AB	+ PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Mar	CFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB	MYLAN TECHNOLOGIES	EQ 2MG BASE;EQ 0.5MG BASE	A211785	001	Apr 17, 2020	Apr	NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A211785	002	Apr 17, 2020	Apr	NEWA

TABLET;SUBLINGUAL

	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB	RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Mar	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Mar	NEWA

BUPROPION HYDROCHLORIDE

TABLET;ORAL

	BUPROPION HYDROCHLORIDE						
AB	CADILA PHARMS LTD	75MG	A208606	001	Jan 16, 2020	Jan	NEWA
AB		100MG	A208606	002	Jan 16, 2020	Jan	NEWA
AB	MICRO LABS	75MG	A207403	001	Apr 17, 2020	Apr	NEWA
AB		100MG	A207403	002	Apr 17, 2020	Apr	NEWA

TABLET, EXTENDED RELEASE;ORAL

	BUPROPION HYDROCHLORIDE						
	@ JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Feb	DISC
	@	150MG	A202774	002	Oct 11, 2013	Feb	DISC
	@	150MG	A202775	001	Oct 11, 2013	Feb	DISC
	@	150MG	A207459	001	Jun 30, 2017	Feb	DISC
	@	200MG	A202774	003	Oct 11, 2013	Feb	DISC
	@	300MG	A207459	002	Jun 30, 2017	Feb	DISC
	@ WATSON LABS INC	100MG	A077455	001	Jul 19, 2010	Apr	DISC
	@	150MG	A077455	002	Mar 12, 2008	Apr	DISC
	@	200MG	A077455	003	Jul 19, 2010	Apr	DISC

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

	CONTRAVE						
	+! NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014	Jan	CAHN

BUSULFAN

INJECTABLE;INJECTION

	BUSULFAN						
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Apr	CTNA
	@ MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018	Feb	DISC

>D> BUTABARBITAL SODIUM

>D> TABLET;ORAL

>D> BUTISOL SODIUM

>D>	+! MYLAN SPECIALITY LP	30MG	N000793	004		May	DISC
>A>	+ @	30MG	N000793	004		May	DISC

CABERGOLINE

TABLET;ORAL

	CABERGOLINE						
	@ MYLAN	0.5MG	A202947	001	Dec 02, 2013	Jan	DISC

CALCITRIOL

CAPSULE;ORAL

	CALCITRIOL						
AB	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Mar	CMFD
AB		0.5MCG	A204556	002	Feb 21, 2019	Mar	CMFD

INJECTABLE;INJECTION

	CALCITRIOL						
AP	! AKORN	0.001MG/ML	A078066	001	Jan 29, 2008	Jan	CTEC
AP	GLAND PHARMA LTD	0.001MG/ML	A211030	001	Feb 03, 2020	Jan	NEWA

CALCIUM ACETATE

CAPSULE;ORAL

	CALCIUM ACETATE						
	@ LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016	Jan	DISC

CAPECITABINE

TABLET;ORAL  
CAPECITABINE

AB	RELIANCE LIFE	150MG	A211724	001	Apr 27, 2020	Apr	NEWA
AB		500MG	A211724	002	Apr 27, 2020	Apr	NEWA

>A> CAPMATINIB HYDROCHLORIDE

>A> TABLET;ORAL  
>A> TABRECTA

>A>	+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020	May	NEWA
>A>	+	!	EQ 200MG BASE	N213591	002	May 06, 2020	May	NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION  
CAPREOMYCIN SULFATE

@	HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796	001	Oct 18, 2018	Mar	DISC
---	----------------------	------------------	---------	-----	--------------	-----	------

CAPTOPRIL

TABLET;ORAL  
CAPTOPRIL

@	COREPHARMA	12.5MG	A074737	001	Oct 28, 1998	Feb	CAHN
@		25MG	A074737	002	Oct 28, 1998	Feb	CAHN
@		50MG	A074737	003	Oct 28, 1998	Feb	CAHN
@		100MG	A074737	004	Oct 28, 1998	Feb	CAHN
>D> AB	SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	May	DISC
>A>	@	12.5MG	A212223	001	Oct 30, 2019	May	DISC
>D> AB		25MG	A212223	002	Oct 30, 2019	May	DISC
>A>	@	25MG	A212223	002	Oct 30, 2019	May	DISC
>D> AB		50MG	A212223	003	Oct 30, 2019	May	DISC
>A>	@	50MG	A212223	003	Oct 30, 2019	May	DISC
>D> AB		100MG	A212223	004	Oct 30, 2019	May	DISC
>A>	@	100MG	A212223	004	Oct 30, 2019	May	DISC
@	TEVA	12.5MG	A074322	001	Feb 13, 1996	Apr	DISC
@		25MG	A074322	002	Feb 13, 1996	Apr	DISC
@		50MG	A074322	003	Feb 13, 1996	Apr	DISC
@		100MG	A074322	004	Feb 13, 1996	Apr	DISC
@	WATSON LABS	12.5MG	A074386	001	May 23, 1996	Apr	DISC
@		25MG	A074386	002	May 23, 1996	Apr	DISC
@		50MG	A074386	003	May 23, 1996	Apr	DISC
@		100MG	A074386	004	May 23, 1996	Apr	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL  
CARBAMAZEPINE

>D>	@	NOSTRUM LABS INC	100MG	A076697	001	May 20, 2011	May	CMFD
>A> AB			100MG	A076697	001	May 20, 2011	May	CMFD
>D>	@		200MG	A076697	002	May 20, 2011	May	CMFD
>A> AB			200MG	A076697	002	May 20, 2011	May	CMFD
>D>	@		300MG	A076697	003	May 20, 2011	May	CMFD
>A> AB			300MG	A076697	003	May 20, 2011	May	CMFD

TABLET;ORAL  
CARBAMAZEPINE

AB	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005	Mar	CTEC
AB	UMEDICA LABS PVT LTD	100MG	A207798	001	Apr 15, 2020	Mar	NEWA
AB		200MG	A207798	002	Apr 15, 2020	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL  
CARBAMAZEPINE

AB	UNIQUE PHARM	100MG	A211623	001	Apr 24, 2020	Apr	NEWA
AB		200MG	A211623	002	Apr 24, 2020	Apr	NEWA
AB		400MG	A211623	003	Apr 24, 2020	Apr	NEWA

CARBIDOPA

TABLET;ORAL  
CARBIDOPA

AB	ANI PHARMS INC	25MG	A203261	001	Mar 10, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL  
SINEMET CR

+ @ MERCK SHARP DOHME 25MG;100MG N019856 002 Dec 24, 1992 Jan DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

	@	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar DISC	
	@		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar DISC	
	@		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar DISC	
	@	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	Apr DISC	
	@		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	Apr DISC	
	@		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	Apr DISC	
	@		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	Apr DISC	
>D>	AP	!	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May DISC
>A>		@		50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May DISC
>D>	AP	!		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May DISC
>A>		@		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May DISC
>D>	AP	!		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May DISC
>A>		@		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May DISC
>D>	AP	!		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May DISC
>A>		@		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May DISC

CARFILZOMIB

POWDER; INTRAVENOUS  
CARFILZOMIB

AP		APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020	Mar NFTG
AP			60MG/VIAL	A209425	001	Mar 16, 2020	Mar NEWA
AP	+	ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Mar CFTG

CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL

AA		@	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Feb DISC
		@	OXFORD PHARMS	350MG	A040188	001	Mar 07, 1997	Apr CMFD

CEFIXIME

FOR SUSPENSION; ORAL  
SUPRAX

@ LUPIN PHARMS 100MG/5ML A065129 001 Feb 23, 2004 Jan DISC

TABLET; ORAL  
SUPRAX

@ LUPIN PHARMS 400MG A065130 001 Feb 12, 2004 Jan DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION  
MEFOXIN IN PLASTIC CONTAINER

@ MYLAN INSTITUTIONAL EQ 20MG BASE/ML A063182 001 Jan 25, 1993 Mar DISC  
@ EQ 40MG BASE/ML A063182 002 Jan 25, 1993 Mar DISC

CEFPROZIL

FOR SUSPENSION; ORAL  
CEFPROZIL

@ TEVA PHARMS 125MG/5ML A065236 001 Dec 08, 2005 Apr DISC  
@ 250MG/5ML A065236 002 Dec 08, 2005 Apr DISC

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION  
CEFTRIAXONE

@ HOSPIRA INC EQ 10GM BASE/VIAL A065232 001 Aug 02, 2005 Jan DISC

CELECOXIB

CAPSULE; ORAL  
CELECOXIB

AB		NANJING	200MG	A213598	001	May 13, 2020	Apr NEWA	
>D>	AB		QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	May DISC
>A>		@		50MG	A208856	001	Aug 07, 2019	May DISC
>D>	AB			100MG	A208856	002	Aug 07, 2019	May DISC
>A>		@		100MG	A208856	002	Aug 07, 2019	May DISC

CAPSULE;ORAL  
CELECOXIB

>D>	AB		200MG	A208856	003	Aug 07, 2019	May	DISC
>A>	@		200MG	A208856	003	Aug 07, 2019	May	DISC
>D>	AB		400MG	A208856	004	Aug 07, 2019	May	DISC
>A>	@		400MG	A208856	004	Aug 07, 2019	May	DISC
	AB	TIANJIN TIANYAO	50MG	A207872	001	Feb 25, 2020	Feb	NEWA
	AB		100MG	A207872	002	Feb 25, 2020	Feb	NEWA
	AB		200MG	A207872	003	Feb 25, 2020	Feb	NEWA
	AB		400MG	A207872	004	Feb 25, 2020	Feb	NEWA
	AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Jan	CDFR
	AB		100MG	A210628	002	Nov 27, 2019	Jan	CDFR
	AB		200MG	A210628	003	Nov 27, 2019	Jan	CDFR
	AB		400MG	A210628	004	Nov 27, 2019	Jan	CDFR
	AB	YILING PHARM LTD	50MG	A211412	001	Mar 06, 2020	Feb	NEWA
	AB		100MG	A211412	002	Mar 06, 2020	Feb	NEWA
	AB		200MG	A211412	003	Mar 06, 2020	Feb	NEWA
	AB		400MG	A211412	004	Mar 06, 2020	Feb	NEWA
>A>		SOLUTION;ORAL						
>A>		ELYXYB						
>A>	+!	DR REDDYS	25MG/ML	N212157	001	May 05, 2020	May	NEWA

CENOBAMATE

TABLET;ORAL  
XCOPRI

+	SK LIFE		12.5MG	N212839	001	Mar 10, 2020	Mar	NEWA
+			25MG	N212839	002	Mar 10, 2020	Mar	NEWA
+			50MG	N212839	003	Mar 10, 2020	Mar	NEWA
+			100MG	N212839	004	Mar 10, 2020	Mar	NEWA
+			150MG	N212839	005	Mar 10, 2020	Mar	NEWA
+	!		200MG	N212839	006	Mar 10, 2020	Mar	NEWA

CHLOROQUINE PHOSPHATE

TABLET;ORAL  
ARALEN

+	@	SANOFI AVENTIS US	500MG	N006002	001		Apr	CPOT
		CHLOROQUINE PHOSPHATE						
	@	HIKMA PHARMS	EQ 150MG BASE	A083082	001		Feb	DISC
	@		250MG	A083082	001		Apr	CPOT
AA			500MG	A083082	002	Sep 17, 1999	Apr	CPOT
	@	IMPAX LABS	250MG	A080880	001		Apr	CPOT
	@		500MG	A040516	001	Aug 29, 2003	Apr	CPOT
AA		IPCA LABS LTD	250MG	A090610	001	Dec 03, 2009	Apr	CPOT
AA			500MG	A090249	001	Dec 03, 2009	Apr	CPOT
	@	MD PHARM	250MG	A087228	001		Apr	CPOT
AA	!	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Feb	CHRS
AA	!		250MG	A091621	001	Jan 21, 2011	Apr	CPOT
AA	!		500MG	A090612	001	Jan 21, 2011	Apr	CPOT
	@	PUREPAC PHARM	250MG	A080886	001		Apr	CPOT
	@	TEVA	250MG	A087504	001	Jan 13, 1982	Apr	CPOT
	@	WATSON LABS	250MG	A087979	001	Dec 21, 1982	Apr	CPOT
	@		500MG	A088030	001	Dec 21, 1982	Apr	CPOT

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL  
CHLORPROMAZINE HYDROCHLORIDE

AB		ZYDUS	10MG	A213368	001	Jan 17, 2020	Jan	NEWA
AB			25MG	A213368	002	Jan 17, 2020	Jan	NEWA
AB			50MG	A213368	003	Jan 17, 2020	Jan	NEWA
AB			100MG	A213368	004	Jan 17, 2020	Jan	NEWA
AB			200MG	A213368	005	Jan 17, 2020	Jan	NEWA

CHLORTHALIDONE

TABLET;ORAL  
CHLORTHALIDONE

AB		ALKEM LABS LTD	25MG	A213412	001	Feb 11, 2020	Jan	NEWA
AB			50MG	A213412	002	Feb 11, 2020	Jan	NEWA
AB		VISTAPHARM	25MG	A211063	001	Feb 26, 2019	Feb	CAHN
AB			50MG	A211063	002	Feb 26, 2019	Feb	CAHN

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

>A>	AB	GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020	May NEWA
>A>	AB		750MG	A212185	002	May 26, 2020	May NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	EQ 4GM RESIN/PACKET	A211119	001	Apr 06, 2020	Mar NEWA
AB			EQ 4GM RESIN/SCOOPFUL	A211119	002	Apr 06, 2020	Mar NEWA
		LOCHOLEST					
		@ ALLIED	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Feb CAHN
		@ INVATECH	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996	Jan CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996	Jan CAHN
		LOCHOLEST LIGHT					
		@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Feb CAHN
		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Feb CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar CMFD
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar CMFD

CIMETIDINE HYDROCHLORIDE

>D> INJECTABLE;INJECTION

>D> CIMETIDINE HYDROCHLORIDE

>D>		DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May DISC
>A>		@	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996	May DISC

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	EQ 30MG BASE	A211892	001	May 15, 2020	May NEWA
>A>	AB		EQ 60MG BASE	A211892	002	May 15, 2020	May NEWA
>A>	AB		EQ 90MG BASE	A211892	003	May 15, 2020	May NEWA
>A>	AB	ACME LABS	EQ 30MG BASE	A213325	001	May 18, 2020	May NEWA
>A>	AB		EQ 60MG BASE	A213325	002	May 18, 2020	May NEWA
>A>	AB		EQ 90MG BASE	A213325	003	May 18, 2020	May NEWA
		@ LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jan DISC
		@	EQ 60MG BASE	A210548	002	Jun 28, 2019	Jan DISC
		@	EQ 90MG BASE	A210548	003	Jun 28, 2019	Jan DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Apr NEWA
AP		HOSPIRA INC	EQ 2MG BASE/ML	A203238	001	Mar 30, 2018	Jan CMFD
AP		PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020	Apr NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

		@ JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015	Mar DISC
		@	EQ 20MG BASE	A205407	002	Dec 23, 2015	Mar DISC
		@	EQ 40MG BASE	A205407	003	Dec 23, 2015	Mar DISC

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

>A>		PHEXXI					
>A>		+! EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020	May NEWA

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	AT	TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020	May DISC
>A>		@	1%	A210004	001	Mar 11, 2020	May DISC
	AT		1%	A210004	001	Mar 11, 2020	Feb NEWA

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB	HETERO LABS LTD III	2.5MG/ML	A209796	001	Feb 24, 2020	Feb	NEWA
AB	LANNETT CO INC	2.5MG/ML	A213110	001	Apr 24, 2020	Apr	NEWA
	@ TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020	Apr	DISC
AB		2.5MG/ML	A211032	001	Jan 31, 2020	Jan	NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A213291	001	Jan 27, 2020	Jan	NEWA
-----	----------------------	-------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE (EMOLLIENT)

>A>	AB2	INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	May	CAHN
>D>	AB2	NOVAST LABS	0.05%	A075733	001	Aug 22, 2001	May	CAHN

LOTION;TOPICAL

IMPEKLO

>A>	+!	MYLAN LABS INC	0.05%	N213691	001	May 19, 2020	May	NEWA
-----	----	----------------	-------	---------	-----	--------------	-----	------

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	ALEOR DERMACEUTICALS	0.05%	A213290	001	May 18, 2020	May	NEWA
-----	----	----------------------	-------	---------	-----	--------------	-----	------

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

@ ALEOR DERMACEUTICALS 0.05%

A211191	001	Oct 02, 2019	Jan	DISC
---------	-----	--------------	-----	------

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

AB	TARO	0.1%	A206370	001	Apr 21, 2020	Apr	NFTG
----	------	------	---------	-----	--------------	-----	------

CLODERM

AB	+!	EPI HLTH	0.1%	N017765	001		Apr	CFTG
----	----	----------	------	---------	-----	--	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	LEADING PHARMA LLC	25MG	A211364	001	Feb 07, 2020	Jan	NEWA
AB		50MG	A211364	002	Feb 07, 2020	Jan	NEWA
AB		75MG	A211364	003	Feb 07, 2020	Jan	NEWA
AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Jan	CMFD
AB		50MG	A211767	002	Apr 08, 2019	Jan	CMFD
AB		75MG	A211767	003	Apr 08, 2019	Jan	CMFD
	@ TEVA	25MG	A074958	001	Aug 26, 1997	Feb	DISC
	@	50MG	A074958	002	Aug 26, 1997	Feb	DISC
	@	75MG	A074958	003	Aug 26, 1997	Feb	DISC
AB	TULEX PHARMS INC	25MG	A210653	001	Apr 03, 2020	Mar	NEWA
AB		50MG	A210653	002	Apr 03, 2020	Mar	NEWA
AB		75MG	A210653	003	Apr 03, 2020	Mar	NEWA

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

>D>	AB	MYLAN	0.5MG	A075150	001	Oct 05, 1998	May	DISC
>A>	@		0.5MG	A075150	001	Oct 05, 1998	May	DISC
>D>	AB		2MG	A075150	003	Oct 05, 1998	May	DISC
>A>	@		2MG	A075150	003	Oct 05, 1998	May	DISC

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP	XGEN PHARMS	1MG/10ML (0.1MG/ML)	A203167	001	Oct 29, 2013	Feb	CAHN
AP		5MG/10ML (0.5MG/ML)	A203167	002	Oct 29, 2013	Feb	CAHN

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

>A>	@	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May	CAHN
>A>	@		0.2MG	A070886	001	Aug 31, 1988	May	CAHN
>A>	@		0.3MG	A070886	003	Aug 31, 1988	May	CAHN
>D>	@	AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	May	CAHN
>D>	@		0.2MG	A070886	001	Aug 31, 1988	May	CAHN
>D>	@		0.3MG	A070886	003	Aug 31, 1988	May	CAHN

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

AB1 UPSHER SMITH LABS 0.1MG A211433 001 Oct 12, 2018 Feb CMFD

CLOPIDOGREL BISULFATE

TABLET;ORAL  
CLOPIDOGREL BISULFATE

>D> AB APOTEX INC EQ 300MG BASE A076274 002 Mar 04, 2014 May CHRS  
>A> AB ! EQ 300MG BASE A076274 002 Mar 04, 2014 May CHRS  
AB GRAVITI PHARMS EQ 75MG BASE A204359 001 Feb 02, 2017 Apr CAHN  
PLAVIX  
>D> AB +! SANOFI AVENTIS US EQ 300MG BASE N020839 002 Sep 20, 2007 May CHRS  
>A> AB + EQ 300MG BASE N020839 002 Sep 20, 2007 May CHRS

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL  
CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG A072112 002 Aug 26, 1988 Feb CMS1  
@ 7.5MG A072112 003 Aug 26, 1988 Feb CMS1

COCAINE HYDROCHLORIDE

SOLUTION;NASAL  
NUMBRINO

CODY LABS INC 4% N209575 001 Jan 10, 2020 Jan NEWA

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL  
PROMETHAZINE WITH CODEINE

@ VINTAGE 10MG/5ML;6.25MG/5ML A040650 001 Jan 31, 2006 Apr DISC

COLCHICINE

TABLET;ORAL  
COLCHICINE

AB AMNEAL PHARMS 0.6MG A204711 001 Sep 28, 2016 Jan CMFD  
AB GRANULES PHARMS 0.6MG A210425 001 Feb 05, 2020 Jan NEWA

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL  
COLESEVELAM HYDROCHLORIDE

AB INVAGEN PHARMS 625MG A212602 001 Apr 20, 2020 Apr NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION  
COLISTIMETHATE SODIUM

AP XGEN PHARMS EQ 150MG BASE/VIAL A064216 001 Feb 26, 1999 Feb CAHN

CYCLOPHOSPHAMIDE

CAPSULE;ORAL  
CYCLOPHOSPHAMIDE

AB ANI PHARMS INC 25MG A207014 001 Mar 19, 2018 Jan CAHN  
AB 50MG A207014 002 Mar 19, 2018 Jan CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL  
CYPROHEPTADINE HYDROCHLORIDE

AA APPCO 4MG A206553 001 Nov 29, 2016 Mar CAHN  
>D> AA PAR PHARM 4MG A087129 001 May DISC  
>A> @ 4MG A087129 001 May DISC

CYSTEAMINE BITARTRATE

GRANULE;ORAL  
PROCYSBI

+ HORIZON PHARMA USA EQ 75MG BASE/PACKET N213491 001 Feb 14, 2020 Feb NEWA  
+! EQ 300MG BASE/PACKET N213491 002 Feb 14, 2020 Feb NEWA

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
NOURESS

>D> AVADEL LEGACY 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019 May DISC  
>A> + @ 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019 May CRLD  
>A> @ 500MG/10ML (50MG/ML) N212535 001 Dec 13, 2019 May DISC

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALKEM LABS LTD	EQ 75MG BASE	A208040	001	Mar 11, 2020	Feb	NFTG
AB		EQ 150MG BASE	A208040	002	Mar 11, 2020	Feb	NFTG
AB	HETERO LABS LTD III	EQ 75MG BASE	A207961	001	May 06, 2020	Apr	NEWA
AB		EQ 150MG BASE	A207961	002	May 06, 2020	Apr	NEWA
PRADAXA							
AB	+ BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010	Feb	CFTG
AB	+!	EQ 150MG BASE	N022512	002	Oct 19, 2010	Feb	CFTG

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AP	XGEN PHARMS	0.5MG/VIAL	A203999	001	May 20, 2019	Feb	CAHN
----	-------------	------------	---------	-----	--------------	-----	------

DAPSONE

GEL; TOPICAL

DAPSONE

AB	TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Feb	NEWA
----	-------------	------	---------	-----	--------------	-----	------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

@	ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Apr	DISC
@		EQ 15MG BASE	A209571	001	Oct 22, 2019	Apr	DISC
@	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Feb	DISC
@		EQ 15MG BASE	A091190	002	Mar 13, 2015	Feb	DISC

DEFERASIROX

TABLET; ORAL

DEFERASIROX

AB	ALKEM LABS LTD	90MG	A210555	001	Mar 30, 2020	Mar	NEWA
AB		360MG	A210555	002	Mar 30, 2020	Mar	NEWA
AB	AMNEAL	90MG	A210727	001	Dec 27, 2019	Feb	CAHN
AB		360MG	A210727	002	Dec 27, 2019	Feb	CAHN
AB	CIPLA	90MG	A211852	001	Feb 11, 2020	Jan	NEWA
AB		360MG	A211852	002	Feb 11, 2020	Jan	NEWA
AB	TEVA PHARMS USA	180MG	A209223	003	Apr 24, 2020	Apr	NEWA

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB	ZYDUS PHARMS	125MG	A208882	001	May 05, 2020	Apr	NEWA
AB		250MG	A208882	002	May 05, 2020	Apr	NEWA
AB		500MG	A208882	003	May 05, 2020	Apr	NEWA

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+	CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Mar	CAHN
+	!	100MG/ML	N208030	001	Sep 09, 2015	Mar	CAHN

TABLET; ORAL

FERRIPROX

+	!	CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CAHN
+			1GM	N021825	002	Jul 25, 2019	Mar	CAHN
>A>	+	!	1GM	N212269	001	May 19, 2020	May	NEWA

DELAVIRDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+	@	VIIV HLTHCARE	200MG	N020705	002	Jul 14, 1999	Mar	DISC
---	---	---------------	-------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

AP	UBI	0.004MG/ML	A210218	001	Feb 14, 2020	Feb	NEWA
----	-----	------------	---------	-----	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		EMOQUETTE							
	@ VINTAGE PHARMS LLC	0.15MG; 0.03MG		A076675	001	Feb 25, 2011	Apr	DISC	
	SIMLIYA								
AB	AUROBINDO PHARMA LTD	0.15MG, N/A; 0.02MG, 0.01MG		A206853	001	Mar 22, 2017	Mar	CTNA	

DESONIDE

GEL; TOPICAL		DESONATE							
AB	+! LEO PHARMA AS	0.05%		N021844	001	Oct 20, 2006	Apr	CFTG	
	DESONIDE								
AB	TERESINA	0.05%		A202470	001	May 11, 2020	Apr	NFTG	

DESOXIMETASONE

CREAM; TOPICAL		DESOXIMETASONE							
AB	CADILA	0.25%		A205620	001	Sep 28, 2018	Mar	CMFD	
AB	COSETTE	0.25%		A209595	001	Mar 04, 2020	Feb	NEWA	

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL		DESVENLAFAXINE SUCCINATE							
	@ MYLAN	EQ 50MG BASE		A204095	001	Jun 29, 2015	Feb	DISC	

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC		TOBRADEX ST							
	+! EYEVANCE	0.05%; 0.3%		N050818	001	Feb 13, 2009	Feb	CAHN	

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION		DEXMEDETOMIDINE							
AP	JIANGSU HENGRUI MED	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)		A209065	001	Sep 19, 2017	Jan	CTNA	
	DEXMEDETOMIDINE HYDROCHLORIDE								
>A>	AP	AMNEAL PHARMS CO	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A207551	001	May 20, 2020	May	NEWA	
>A>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A207551	002	May 20, 2020	May	NEWA	
>A>	AP	GLAND PHARMA LTD	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A209307	001	Jun 03, 2020	May	NEWA	
>A>	AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A209307	002	Jun 03, 2020	May	NEWA	
AP		HIKMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	Jan	NEWA	
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	Jan	NEWA	

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL		DEXMETHYLPHENIDATE HYDROCHLORIDE							
AB	BIONPHARMA INC	5MG		A209754	001	Mar 24, 2020	Mar	NEWA	
AB		10MG		A209754	002	Mar 24, 2020	Mar	NEWA	

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL		DEXTROAMPHETAMINE SULFATE							
	@ PII	5MG		A205077	001	Jun 21, 2019	Jan	DISC	
	@	10MG		A205077	002	Jun 21, 2019	Jan	DISC	
	@	15MG		A205077	003	Jun 21, 2019	Jan	DISC	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETHAZINE DM							
AA	! SLATE	15MG/5ML; 6.25MG/5ML		A040649	001	Feb 14, 2006	Mar	CMFD	
	@	15MG/5ML; 6.25MG/5ML		A040649	001	Feb 14, 2006	Feb	CAHN	
	PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE								
AA	AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML		A090575	001	Feb 08, 2011	Mar	CMFD	
	@ HI TECH PHARMA	15MG/5ML; 6.25MG/5ML		A040027	001	Jul 31, 1996	Mar	DISC	

DIAZEPAM

SPRAY;NASAL  
VALTOCO

+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020	Jan	NEWA
+		7.5MG/SPRAY	N211635	002	Jan 10, 2020	Jan	NEWA
+	!	10MG/SPRAY	N211635	003	Jan 10, 2020	Jan	NEWA

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL  
FLECTOR

+	!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	Feb	CDFR
+	!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Apr	CHRS
+			1.3%	N206976	001	Dec 19, 2018	Apr	CMFD

DICLOFENAC POTASSIUM

TABLET;ORAL  
CATAFLAM

+	@	NOVARTIS	50MG	N020142	002	Nov 24, 1993	Jan	CRLD
---	---	----------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL  
DICLOFENAC SODIUM

AB		ENCUBE	1%	A210986	001	Jan 27, 2020	Jan	NEWA
		TABLET, DELAYED RELEASE;ORAL						
		DICLOFENAC SODIUM						
	@	MICRO LABS USA	50MG	A074986	001	Feb 26, 1999	Mar	CAHN
	@		75MG	A074986	002	Feb 26, 1999	Mar	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL  
DICLOFENAC SODIUM AND MISOPROSTOL

AB		YUNG SHIN PHARM	50MG;0.2MG	A205143	001	Feb 19, 2020	Feb	NEWA
AB			75MG;0.2MG	A205143	002	Feb 19, 2020	Feb	NEWA

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL  
DICYCLOMINE HYDROCHLORIDE

>D>	!	GENERICS	10MG/5ML	A040169	001	Mar 24, 2005	May	CTEC
>A>	AA	!	10MG/5ML	A040169	001	Mar 24, 2005	May	CTEC
>A>	AA	HIKMA	10MG/5ML	A212286	001	May 22, 2020	May	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL  
TENUATE

+	@	NOSTRUM LABS INC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		TENUATE DOSPAN						
+	@	NOSTRUM LABS INC	75MG	N012546	001		Mar	CAHN

DIHYDROERGOTAMINE MESYLATE

SPRAY, METERED;NASAL  
DIHYDROERGOTAMINE MESYLATE

>A>	AB	CIPLA	0.5MG/SPRAY	A212907	001	May 20, 2020	May	NEWA		
	AB	CUSTOPHARM INC	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Feb	NFTG		
		MIGRANAL								
	AB	+	!	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Feb	CFTG

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DILTIAZEM HYDROCHLORIDE

AB2		ACCORD HLTHCARE	120MG	A206997	001	Apr 28, 2020	Apr	NEWA
AB2			180MG	A206997	002	Apr 28, 2020	Apr	NEWA
AB2			240MG	A206997	003	Apr 28, 2020	Apr	NEWA
AB2		APOTEX	120MG	A074943	003	Dec 19, 2000	Apr	CTEC
		DILTZAC						
	@	APOTEX	120MG	A076395	001	Feb 01, 2006	Apr	DISC
	@		180MG	A076395	002	Feb 01, 2006	Apr	DISC
	@		240MG	A076395	003	Feb 01, 2006	Apr	DISC
	@		300MG	A076395	004	Feb 01, 2006	Apr	DISC
	@		360MG	A076395	005	Feb 01, 2006	Apr	DISC

DISULFIRAM

TABLET; ORAL  
DISULFIRAM  
@ HIKMA 250MG  
@ 500MG

A202652 001 Feb 05, 2014 Feb DISC  
A202652 002 Feb 05, 2014 Feb DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL  
DIVALPROEX SODIUM  
AB AJANTA PHARMA LTD EQ 125MG VALPROIC ACID  
@ MYLAN EQ 125MG VALPROIC ACID

A213181 001 Mar 02, 2020 Feb NEWA  
A090407 001 Mar 28, 2011 Jan DISC

TABLET, DELAYED RELEASE; ORAL  
DIVALPROEX SODIUM  
@ MYLAN EQ 125MG VALPROIC ACID  
@ EQ 250MG VALPROIC ACID  
@ EQ 500MG VALPROIC ACID

A090062 001 Mar 17, 2009 Jan DISC  
A090062 002 Mar 17, 2009 Jan DISC  
A090062 003 Mar 17, 2009 Jan DISC

TABLET, EXTENDED RELEASE; ORAL  
DIVALPROEX SODIUM  
@ LUPIN LTD EQ 250MG VALPROIC ACID  
@ EQ 500MG VALPROIC ACID

A209286 001 Oct 18, 2019 Apr DISC  
A209286 002 Oct 18, 2019 Apr DISC

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

AP SHILPA MEDICARE LTD 20MG/ML (20MG/ML)  
AP 80MG/4ML (20MG/ML)  
AP 160MG/8ML (20MG/ML)

A210327 001 May 16, 2019 Jan CMFD  
A210327 002 May 16, 2019 Jan CMFD  
A210327 003 May 16, 2019 Jan CMFD

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

AB MSN 0.125MG  
AB 0.25MG  
AB 0.5MG

A213220 001 Jan 29, 2020 Jan NEWA  
A213220 002 Jan 29, 2020 Jan NEWA  
A213220 003 Jan 29, 2020 Jan NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL  
DONEPEZIL HYDROCHLORIDE

AB GRAVITI PHARMS 5MG  
AB 10MG  
@ MYLAN PHARMS INC 5MG  
@ 10MG

A202114 001 Jul 05, 2013 Apr CAHN  
A202114 002 Jul 05, 2013 Apr CAHN  
A090521 001 May 31, 2011 Mar DISC  
A090521 002 May 31, 2011 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A> AT MICRO LABS EQ 2.0% BASE; EQ 0.5% BASE

A204777 001 May 28, 2020 May NEWA

DOXAZOSIN MESYLATE

TABLET; ORAL  
DOXAZOSIN MESYLATE

@ ANI PHARMS INC EQ 1MG BASE  
@ EQ 2MG BASE  
@ EQ 4MG BASE  
@ EQ 8MG BASE

A075432 001 Oct 18, 2000 Jan DISC  
A075432 002 Oct 18, 2000 Jan DISC  
A075432 003 Oct 18, 2000 Jan DISC  
A075432 004 Oct 18, 2000 Jan DISC

DOXEPIIN HYDROCHLORIDE

CONCENTRATE; ORAL  
DOXEPIIN HYDROCHLORIDE

>D> AA LANNETT CO INC EQ 10MG BASE/ML  
>A> AA ! EQ 10MG BASE/ML  
>D> AA ! TEVA PHARMS EQ 10MG BASE/ML  
>A> @ EQ 10MG BASE/ML

A074721 001 Dec 29, 1998 May CHRS  
A074721 001 Dec 29, 1998 May CHRS  
A071609 001 Nov 09, 1987 May DISC  
A071609 001 Nov 09, 1987 May DISC

DOXERCALCIFEROL

INJECTABLE; INJECTION  
DOXERCALCIFEROL

AP MEITHEAL 4MCG/2ML (2MCG/ML)  
AP NANJING KING-FRIEND 4MCG/2ML (2MCG/ML)

A211670 001 Feb 07, 2020 Feb CAHN  
A211670 001 Feb 07, 2020 Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL  
DOXYCYCLINE

@ MYLAN PHARMS INC EQ 150MG BASE A202778 001 Jun 08, 2012 Jan DISC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL  
DOXYCYCLINE HYCLATE

AB ZHEJIANG YONGTAI EQ 50MG BASE A212610 001 Mar 31, 2020 Mar NEWA  
AB EQ 100MG BASE A212610 002 Mar 31, 2020 Mar NEWA

TABLET;ORAL  
DOXYCYCLINE HYCLATE

>A> AB AJANTA PHARMA LTD EQ 75MG BASE A211584 001 Jun 01, 2020 May NEWA  
>A> AB EQ 150MG BASE A211584 002 Jun 01, 2020 May NEWA  
AB ALEMBIC PHARMS LTD EQ 20MG BASE A210537 001 Mar 03, 2020 Feb NEWA  
>A> AB EQ 100MG BASE A210536 001 May 14, 2020 May NEWA  
AB OAKLOCK LLC EQ 100MG BASE A210664 001 Mar 16, 2020 Mar NEWA

TABLET, DELAYED RELEASE;ORAL  
DORYX

+ MAYNE PHARMA EQ 80MG BASE N050795 004 Apr 11, 2013 Mar CMFD  
DOXYCYCLINE HYCLATE  
AB PRINSTON INC EQ 50MG BASE A207494 003 Feb 19, 2019 Feb NEWA

DRONABINOL

CAPSULE;ORAL  
DRONABINOL

AB ASCENT PHARMS INC 2.5MG A207421 001 Feb 07, 2020 Jan NEWA  
AB 5MG A207421 002 Feb 07, 2020 Jan NEWA  
AB 10MG A207421 003 Feb 07, 2020 Jan NEWA

MARINOL

AB + ALKEM LABS LTD 2.5MG N018651 001 May 31, 1985 Jan CAHN  
AB +! 5MG N018651 002 May 31, 1985 Jan CAHN  
AB + 10MG N018651 003 May 31, 1985 Jan CAHN

SOLUTION;ORAL  
SYNDROS

+! BENUVIA 5MG/ML N205525 001 Mar 23, 2017 Feb CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL  
DROSPIRENONE AND ETHINYL ESTRADIOL

AB ALLIED 3MG;0.02MG A203291 001 Jul 18, 2017 Jan CAHN

TABLET;ORAL-28  
DROSPIRENONE AND ETHINYL ESTRADIOL

AB HETERO LABS LTD 3MG;0.03MG A213034 001 Jan 24, 2020 Jan NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

>D> AB QINGDAO BAHEAL PHARM EQ 20MG BASE A210599 001 Apr 17, 2019 May DISC  
>A> @ EQ 20MG BASE A210599 001 Apr 17, 2019 May DISC  
>D> AB EQ 30MG BASE A210599 002 Apr 17, 2019 May DISC  
>A> @ EQ 30MG BASE A210599 002 Apr 17, 2019 May DISC  
>D> AB EQ 60MG BASE A210599 003 Apr 17, 2019 May DISC  
>A> @ EQ 60MG BASE A210599 003 Apr 17, 2019 May DISC  
@ YAOPHARMA CO LTD EQ 20MG BASE A207219 001 Aug 16, 2019 Mar DISC  
@ EQ 30MG BASE A207219 002 Aug 16, 2019 Mar DISC  
@ EQ 60MG BASE A207219 003 Aug 16, 2019 Mar DISC

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

@ ACTAVIS LABS FL INC 0.5MG A202808 001 Nov 20, 2015 Jan DISC  
@ APOTEX INC 0.5MG A204292 001 Nov 24, 2015 Feb DISC  
>A> AB AUROBINDO PHARMA LTD 0.5MG A202660 001 Nov 20, 2015 May CAHN  
>D> AB AUROLIFE PHARMA LLC 0.5MG A202660 001 Nov 20, 2015 May CAHN  
@ HIKMA 0.5MG A202204 001 Nov 23, 2015 Feb DISC  
@ STRIDES PHARMA 0.5MG A208227 001 Jun 22, 2018 Mar CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

		TABLET; ORAL					
>A>		EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
>A>	AB	LAURUS LABS LTD	400MG;300MG;300MG	A213038	001	May 14, 2020	May NFTG
>A>	AB		600MG;300MG;300MG	A212786	001	May 14, 2020	May NFTG
		SYMFI					
>D>	+!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	May CFTG
>A>	AB	+!	600MG;300MG;300MG	N022142	001	Mar 22, 2018	May CFTG
		SYMFI LO					
>D>	+!	MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018	May CFTG
>A>	AB	+!	400MG;300MG;300MG	N208255	001	Feb 05, 2018	May CFTG

ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM

		CAPSULE; ORAL					
>A>		ORIAHNN (COPACKAGED)					
>A>	+!	ABBVIE INC	EQ 300MG BASE, 1MG, 0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 TRIJARDY XR

+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020	Jan NEWA
+		10MG;5MG;1GM	N212614	002	Jan 27, 2020	Jan NEWA
+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020	Jan NEWA
+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020	Jan NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	May NEWA
		@ MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb DISC
	AB	ZYDUS PHARMS	200MG;300MG	A212689	001	Feb 28, 2020	Feb NEWA

ENALAPRIL MALEATE

SOLUTION; ORAL  
 EPANED

>A>	+!	AZURITY	1MG/ML	N208686	001	Sep 20, 2016	May CAHN
>D>	+!	SILVERGATE PHARMS	1MG/ML	N208686	001	Sep 20, 2016	May CAHN

ENTECAVIR

TABLET; ORAL  
 ENTECAVIR

		@ MYLAN	0.5MG	A206226	001	Mar 26, 2019	Jan DISC
		@	1MG	A206226	002	Mar 26, 2019	Jan DISC
>A>	AB	SUNSHINE LAKE	0.5MG	A211978	001	May 20, 2020	May NEWA
>A>	AB		1MG	A211978	002	May 20, 2020	May NEWA
		@ YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Apr DISC
		@	1MG	A212201	002	Nov 04, 2019	Apr DISC

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS  
 EMERPHED

+!	NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Apr NEWA
----	--------------	--------------------	---------	-----	--------------	----------

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
 ADRENALIN

AP	+!	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Apr CFTG
AP		INTL MEDICATION SYS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A211880	001	Apr 24, 2020	Apr NFTG

EPLERENONE

TABLET; ORAL  
 EPLERENONE

AB		COREPHARMA	25MG	A078482	001	Jul 30, 2008	Feb CAHN
AB			50MG	A078482	002	Jul 30, 2008	Feb CAHN

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

@ MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011	Apr	DISC
@	EQ 600MG BASE	A202012	002	Nov 16, 2011	Apr	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP	HYBIO	2MG/ML	A207864	001	Mar 20, 2020	Mar	NEWA
AP		75MG/100ML	A207864	002	Mar 20, 2020	Mar	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	ZYDUS PHARMS	EQ 25MG BASE	A213065	001	Apr 16, 2020	Apr	NEWA
AB		EQ 100MG BASE	A213065	002	Apr 16, 2020	Apr	NEWA
AB		EQ 150MG BASE	A213065	003	Apr 16, 2020	Apr	NEWA

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Jan	CAHN
AA	! HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	Apr	CHRS

LEXAPRO

+ @ ALLERGAN

EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Apr	DISC
-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

>D>	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210	001	Sep 11, 2012	May	DISC
>A>		@	EQ 5MG BASE	A202210	001	Sep 11, 2012	May	DISC
>D>	AB		EQ 10MG BASE	A202210	002	Sep 11, 2012	May	DISC
>A>		@	EQ 10MG BASE	A202210	002	Sep 11, 2012	May	DISC
>D>	AB		EQ 20MG BASE	A202210	003	Sep 11, 2012	May	DISC
>A>		@	EQ 20MG BASE	A202210	003	Sep 11, 2012	May	DISC

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	HETERO LABS LTD III	EQ 20MG BASE	A211977	001	Jun 02, 2020	May	NEWA
>A>	AB		EQ 40MG BASE	A211977	002	Jun 02, 2020	May	NEWA

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AB	CIPLA	EQ 10MG BASE/PACKET	A211752	001	Mar 23, 2020	Mar	NFTG
AB		EQ 20MG BASE/PACKET	A211751	001	Mar 23, 2020	Mar	NFTG
AB		EQ 40MG BASE/PACKET	A211751	002	Mar 23, 2020	Mar	NFTG

NEXIUM

AB	+ ASTRAZENECA PHARMS	EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Mar	CFTG
AB	+	EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Mar	CFTG
AB	+!	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Mar	CFTG

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A204206	001	Feb 18, 2020	Feb	NEWA
AB		EQ 20MG BASE; 500MG	A204206	002	Feb 18, 2020	Feb	NEWA

VIMOVO

AB	+ HORIZON	EQ 20MG BASE; 375MG	N022511	002	Apr 30, 2010	Feb	CTEC
AB	+!	EQ 20MG BASE; 500MG	N022511	001	Apr 30, 2010	Feb	CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	Mar	NEWA
AP		EQ 40MG BASE/VIAL	A203349	002	Apr 01, 2020	Mar	NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL  
ESOMEPRAZOLE STRONTIUM

	+ @ BELCHER	24.65MG	N202342	001	Aug 06, 2013	Mar	CAHN
	+ @	49.3MG	N202342	002	Aug 06, 2013	Mar	CAHN

ESTRADIOL VALERATE

INJECTABLE; INJECTION  
DELESTROGEN

AO	+!	PAR STERILE PRODUCTS	10MG/ML	N009402	002		Apr	CTEC
AO		HIKMA	10MG/ML	A203723	001	Apr 21, 2020	Apr	NEWA
AO			20MG/ML	A203723	002	Apr 21, 2020	Apr	NEWA
AO			40MG/ML	A203723	003	Apr 21, 2020	Apr	NEWA

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL  
ESTRADIOL AND NORETHINDRONE ACETATE  
@ TEVA PHARMS USA 0.5MG;0.1MG

A200747	001	Mar 08, 2012	Jan	DISC
---------	-----	--------------	-----	------

ESTROPIPATE

TABLET;ORAL  
ESTROPIPATE

@ MYLAN	0.75MG	A040359	001	Aug 26, 1999	Jan	DISC
@	1.5MG	A040359	002	Aug 26, 1999	Jan	DISC

ESZOPICLONE

TABLET;ORAL  
ESZOPICLONE

@ HIKMA	1MG	A091153	001	Apr 15, 2014	Feb	DISC
@	2MG	A091153	002	Apr 15, 2014	Feb	DISC
@	3MG	A091153	003	Apr 15, 2014	Feb	DISC

ETHACRYNIC ACID

TABLET;ORAL  
ETHACRYNIC ACID

AB		UPSHER SMITH LABS	25MG	A212417	001	Feb 19, 2020	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM; TRANSDERMAL  
TWIRLA

+!	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020	Feb	NEWA
----	-------	-------------------------	---------	-----	--------------	-----	------

TABLET;ORAL  
BALCOLTRA

+!	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan	CHRS
+		0.02MG;0.1MG	N208612	001	Jan 09, 2018	Jan	CRLD

FAYOSIM

@ LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	DISC
-------------	---	---------	-----	--------------	-----	------

TABLET;ORAL-28

ELIFEMME

@ XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Mar	DISC
-----------	---	---------	-----	--------------	-----	------

LEVONORGESTREL AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Feb	DISC
------------------	---	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL  
LOESTRIN 24 FE

AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan	CAHN
----	---	--------------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL-21

LOESTRIN 21 1.5/30

AB	+	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jan	CAHN
----	---	--------------------	--------------	---------	-----	--	-----	------

LOESTRIN 21 1/20

AB	+	TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jan	CAHN
----	---	--------------------	------------	---------	-----	--	-----	------

LOESTRIN FE 1.5/30

AB	+!	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jan	CAHN
----	----	--------------------	--------------	---------	-----	--	-----	------

TABLET;ORAL-28

	CHABELINA FE								
AB	NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Mar	NEWA		
	LOESTRIN FE 1/20								
AB	+ TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jan	CAHN		
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL								
	@ MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb	DISC		
	TABLET, CHEWABLE;ORAL								
	FINZALA								
AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Mar	NEWA		

ETHOSUXIMIDE

	CAPSULE;ORAL								
	ETHOSUXIMIDE								
AB	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Mar	NEWA		

ETODOLAC

	TABLET;ORAL								
	ETODOLAC								
	@ TEVA	400MG	A075009	001	Nov 26, 1997	Feb	DISC		
	@	500MG	A075009	002	Dec 28, 1999	Feb	DISC		

ETOMIDATE

	INJECTABLE;INJECTION								
	ETOMIDATE								
	@ MYLAN LABS LTD	2MG/ML	A078289	001	Jan 02, 2009	Feb	DISC		

EXEMESTANE

	TABLET;ORAL								
	EXEMESTANE								
	@ MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jan	DISC		
AB	QILU	25MG	A213547	001	Apr 13, 2020	Mar	NEWA		

EZETIMIBE

	TABLET;ORAL								
	EZETIMIBE								
	@ MYLAN	10MG	A201790	001	Apr 26, 2019	Feb	DISC		
	@ TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017	Mar	DISC		

FAMOTIDINE

	TABLET;ORAL								
	FAMOTIDINE								
AB	! AUROBINDO PHARMA LTD	40MG	A206530	002	Dec 22, 2015	Jan	CHRS		
	@ MYLAN	20MG	A075704	001	Apr 16, 2001	Feb	DISC		
	@ TEVA	20MG	A075311	001	Apr 16, 2001	Mar	DISC		
	@	40MG	A075311	002	Apr 16, 2001	Mar	DISC		
	PEPCID								
	+ @ VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Jan	DISC		
	+ @	40MG	N019462	002	Oct 15, 1986	Jan	DISC		

FEBUXOSTAT

	TABLET;ORAL								
	FEBUXOSTAT								
>A>	AB	SUNSHINE LAKE	40MG	A213069	001	Jun 02, 2020	May	NEWA	
>A>	AB		80MG	A213069	002	Jun 02, 2020	May	NEWA	

FENOFIBRATE

	CAPSULE;ORAL								
	FENOFIBRATE (MICRONIZED)								
AB	ANI PHARMS INC	67MG	A209504	001	Apr 30, 2018	Jan	CAHN		
AB		134MG	A209504	002	Apr 30, 2018	Jan	CAHN		
AB		200MG	A209504	003	Apr 30, 2018	Jan	CAHN		
	@ MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013	Mar	DISC		
	@	130MG	A202579	002	Jan 10, 2013	Mar	DISC		
	TABLET;ORAL								
	FENOFIBRATE								
AB	ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020	Jan	NEWA		
AB		160MG	A213252	002	Jan 17, 2020	Jan	NEWA		
AB	APPCO	54MG	A210670	001	Sep 06, 2019	Jan	CAHN		
AB		160MG	A210670	002	Sep 06, 2019	Jan	CAHN		
AB	GRAVITI PHARMS	48MG	A211122	001	Mar 18, 2020	Mar	NEWA		
AB		54MG	A210606	001	Aug 17, 2018	Jan	CMFD		

TABLET;ORAL					
FENOFIBRATE					
AB	145MG	A211122	002	Mar 18, 2020	Mar NEWA
AB	160MG	A210606	002	Aug 17, 2018	Jan CMFD
<u>FENTANYL CITRATE</u>					
INJECTABLE;INJECTION					
FENTANYL CITRATE PRESERVATIVE FREE					
AP	+! HIKMA EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
<u>FERRIC DERISOMALTOSE</u>					
SOLUTION;INTRAVENOUS					
MONOFERRIC					
+!	PHARMACOSMOS AS 1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020	Jan NEWA
<u>FERRIC PYROPHOSPHATE CITRATE</u>					
SOLUTION;INTRAVENOUS					
TRIFERIC AVNU					
+!	ROCKWELL MEDICAL INC 6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020	Mar NEWA
<u>FESOTERODINE FUMARATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
FESOTERODINE FUMARATE					
@	DR REDDYS LABS LTD 4MG	A204975	001	Aug 13, 2019	Feb DISC
@	8MG	A204975	002	Aug 13, 2019	Feb DISC
<u>FEXOFENADINE HYDROCHLORIDE</u>					
TABLET;ORAL					
FEXOFENADINE HYDROCHLORIDE					
@	BARR 30MG	A076191	001	Aug 31, 2005	Mar DISC
@	60MG	A076191	002	Aug 31, 2005	Mar DISC
@	180MG	A076191	003	Aug 31, 2005	Mar DISC
<u>FIDAXOMICIN</u>					
FOR SUSPENSION;ORAL					
DIFICID					
+!	CUBIST PHARMS LLC 40MG/ML	N213138	001	Jan 24, 2020	Jan NEWA
<u>FINASTERIDE</u>					
TABLET;ORAL					
FINASTERIDE					
@	TEVA 1MG	A076905	001	Nov 05, 2013	Mar DISC
<u>FINGOLIMOD HYDROCHLORIDE</u>					
CAPSULE;ORAL					
FINGOLIMOD HYDROCHLORIDE					
>A> AB	HETERO LABS LTD V EQ 0.5MG BASE	A207933	001	May 18, 2020	May NEWA
<u>FLORTAUCIPIR F-18</u>					
SOLUTION;INTRAVENOUS					
TAUVID					
>A>	+! AVID RADIOPHARMS INC 30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	May NEWA
>A>	+! 50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	May NEWA
<u>FLUCONAZOLE</u>					
FOR SUSPENSION;ORAL					
FLUCONAZOLE					
@	HIKMA 50MG/5ML	A076246	001	Jul 29, 2004	Feb DISC
@	200MG/5ML	A076246	002	Jul 29, 2004	Feb DISC
INJECTABLE;INJECTION					
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER					
@	HIKMA FARMACEUTICA 200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012	Mar DISC
@	400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012	Mar DISC
@	HOSPIRA 200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004	Mar DISC
@	400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004	Mar DISC
@	WOODWARD 200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Mar DISC
@	400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Mar DISC
TABLET;ORAL					
FLUCONAZOLE					
@	MYLAN 50MG	A076351	001	Jul 29, 2004	Jan DISC
@	100MG	A076351	002	Jul 29, 2004	Jan DISC

TABLET;ORAL  
FLUCONAZOLE

@		150MG	A 076351	003	Jul 29, 2004	Jan	DISC
@		200MG	A 076351	004	Jul 29, 2004	Jan	DISC
@	TEVA	50MG	A 074681	001	Jul 29, 2004	Mar	DISC
@		100MG	A 074681	002	Jul 29, 2004	Mar	DISC
@		150MG	A 074681	003	Jul 29, 2004	Mar	DISC
@		200MG	A 074681	004	Jul 29, 2004	Mar	DISC

FLUCYTOSINE

CAPSULE;ORAL  
FLUCYTOSINE

AB	AUROBINDO PHARMA LTD	250MG	A 213665	001	May 01, 2020	Apr	NEWA
AB		500MG	A 213665	002	May 01, 2020	Apr	NEWA
AB	STRIDES PHARMA	250MG	A 212632	001	Apr 17, 2020	Apr	NEWA
AB		500MG	A 212632	002	Apr 17, 2020	Apr	NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS  
FLUDEOXYGLUCOSE F18

>D>	AP	UNIV TX SW MEDCTR	20-200mCi/ML	A 210265	001	Feb 06, 2020	May	DISC
>A>	@		20-200mCi/ML	A 210265	001	Feb 06, 2020	May	DISC
	AP		20-200mCi/ML	A 210265	001	Feb 06, 2020	Jan	NEWA

FLUNISOLIDE

SPRAY, METERED;NASAL  
FLUNISOLIDE

!	APOTEX	0.029MG/SPRAY	A 077436	001	Aug 09, 2007	Mar	CHRS
		0.029MG/SPRAY	A 077436	001	Aug 09, 2007	Mar	CMFD

FLUOCINONIDE

CREAM;TOPICAL  
FLUOCINONIDE

AB1	AMNEAL PHARMS LLC	0.05%	A 210554	001	Aug 21, 2018	Apr	CMFD
AB	CADILA	0.1%	A 208989	001	Feb 10, 2020	Feb	CAHN
AB	ZYDUS PHARMS	0.1%	A 208989	001	Feb 10, 2020	Jan	NEWA

SOLUTION;TOPICAL  
FLUOCINONIDE

@	TEVA	0.05%	A 072511	001	Feb 07, 1989	Mar	DISC
---	------	-------	----------	-----	--------------	-----	------

>A> FLUOROESTRADIOL F-18

>A> SOLUTION;INTRAVENOUS  
>A> CERIANNA

>A>	+	ZIONEXA	50ML (4-100mCi/ML)	N 212155	001	May 20, 2020	May	NEWA
-----	---	---------	--------------------	----------	-----	--------------	-----	------

FLUOROURACIL

INJECTABLE;INJECTION  
FLUOROURACIL

@	INGENUS PHARMS LLC	500MG/10ML (50MG/ML)	A 209219	001	Dec 12, 2019	Apr	DISC
@		500MG/10ML (50MG/ML)	A 209271	001	Dec 11, 2019	Apr	DISC
@		1GM/20ML (50MG/ML)	A 209219	002	Dec 12, 2019	Apr	DISC
@		2.5GM/50ML (50MG/ML)	A 209271	002	Dec 11, 2019	Apr	DISC

SOLUTION;TOPICAL  
FLUOROURACIL

AT	!	TARO	5%	A 076526	002	Nov 05, 2003	Mar	CHRS
----	---	------	----	----------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL  
FLUOXETINE HYDROCHLORIDE

@	BARR	EQ 10MG BASE	A 074803	002	Jan 30, 2002	Mar	DISC	
@		EQ 20MG BASE	A 074803	001	Aug 02, 2001	Mar	DISC	
>D>	AB1	SPECGX LLC	EQ 10MG BASE	A 075658	001	Jan 29, 2002	May	DISC
>A>	@		EQ 10MG BASE	A 075658	001	Jan 29, 2002	May	DISC
>D>	AB1		EQ 20MG BASE	A 075658	002	Jan 29, 2002	May	DISC
>A>	@		EQ 20MG BASE	A 075658	002	Jan 29, 2002	May	DISC

SOLUTION;ORAL  
FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/5ML	A 079209	001	Mar 20, 2009	Mar	CMFD	
>D>	AA	SPECGX LLC	EQ 20MG BASE/5ML	A 075920	001	Jan 29, 2002	May	DISC
>A>	@		EQ 20MG BASE/5ML	A 075920	001	Jan 29, 2002	May	DISC

TABLET;ORAL

		FLUOXETINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020	Mar	NEWA
AB		EQ 20MG BASE	A213286	002	Apr 08, 2020	Mar	NEWA
	@ G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Mar	DISC
SARAFEM							
+	APIL	EQ 15MG BASE	N021860	002	May 19, 2006	Apr	CTEC
SELFEMRA							
	@ TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Apr	DISC
	@	EQ 15MG BASE	A200151	002	Feb 03, 2014	Apr	DISC
	@	EQ 20MG BASE	A200151	003	Feb 03, 2014	Apr	DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

		FLUPHENAZINE HYDROCHLORIDE					
	@ SANDOZ	1MG	A089586	002	Oct 16, 1987	Mar	DISC
	@	2.5MG	A089586	003	Oct 16, 1987	Mar	DISC
	@	5MG	A089586	004	Oct 16, 1987	Mar	DISC
	@	10MG	A089586	001	Oct 16, 1987	Mar	DISC

FLUTICASONE PROPIONATE

POWDER;INHALATION

		ARMONAIR DIGIHALER					
+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Mar	NEWA
+		0.113MG/INH	N208798	005	Feb 20, 2020	Mar	NEWA
+	!	0.232MG/INH	N208798	006	Feb 20, 2020	Mar	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

		FLUVOXAMINE MALEATE					
AB	BIONPHARMA INC	150MG	A212182	001	May 11, 2020	Apr	NEWA
TABLET;ORAL							
FLUVOXAMINE MALEATE							
	@ TEVA	25MG	A075893	001	Sep 10, 2002	Mar	DISC
	@	50MG	A075893	002	Sep 10, 2002	Mar	DISC
	@	100MG	A075893	003	Sep 10, 2002	Mar	DISC

FOLIC ACID

INJECTABLE;INJECTION

		FOLIC ACID					
AP	X-GEN PHARMS INC	5MG/ML	A202522	001	Nov 06, 2019	Jan	CAHN
AP	XGEN PHARMS	5MG/ML	A202522	001	Nov 06, 2019	Feb	CAHN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB	!	AUROBINDO PHARMA	20MG;12.5MG	A079245	002	Jul 09, 2009	Apr	CHRS
	@	EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Apr	DISC
	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Apr	DISC

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

		AKYNZEO						
>D>	+	HELSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018	May	CMS1
>A>	+		EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018	May	CMS1
SOLUTION;INTRAVENOUS								
AKYNZEO								
>A>	+	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020	May	NEWA

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

		FULVESTRANT					
AO	CHIA TAI TIANQING	50MG/ML	A211422	001	Feb 07, 2020	Jan	NEWA

FUROSEMIDE

TABLET; ORAL  
 FUROSEMIDE  
 @ AVET 20MG  
 @ 40MG

N018413 001 Nov 30, 1983 Jan DISC  
 N018413 002 Nov 30, 1983 Jan DISC

GABAPENTIN

CAPSULE; ORAL  
 GABAPENTIN

AB CSPC OUYI 100MG  
 AB 300MG  
 AB 400MG  
 >D> AB JIANGSU HENGRUI MED 100MG  
 >A> @ 100MG  
 >D> AB 300MG  
 >A> @ 300MG  
 >D> AB 400MG  
 >A> @ 400MG  
 @ TEVA PHARMS 100MG  
 @ 300MG  
 @ 400MG

A075477 001 Mar 23, 2005 Jan CMFD  
 A075477 002 Mar 23, 2005 Jan CMFD  
 A075477 003 Mar 23, 2005 Jan CMFD  
 A091008 001 Oct 26, 2017 May DISC  
 A091008 001 Oct 26, 2017 May DISC  
 A091008 002 Oct 26, 2017 May DISC  
 A091008 002 Oct 26, 2017 May DISC  
 A091008 003 Oct 26, 2017 May DISC  
 A091008 003 Oct 26, 2017 May DISC  
 A075435 001 Oct 08, 2004 Mar DISC  
 A075435 002 Oct 08, 2004 Mar DISC  
 A075435 003 Oct 08, 2004 Mar DISC

SOLUTION; ORAL  
 GABAPENTIN

>D> AA VISTAPHARM 250MG/5ML  
 >A> @ 250MG/5ML

A211330 001 Dec 03, 2019 May DISC  
 A211330 001 Dec 03, 2019 May DISC

TABLET; ORAL  
 GABAPENTIN

@ MYLAN PHARMS INC 600MG  
 @ 800MG  
 @ TEVA PHARMS USA 600MG  
 @ 800MG  
 GRALISE  
 BX +! ALMATICA 300MG  
 BX +! 600MG

A090335 001 Jun 01, 2010 Mar DISC  
 A090335 002 Jun 01, 2010 Mar DISC  
 A205807 001 Mar 10, 2017 Mar DISC  
 A205807 002 Mar 10, 2017 Mar DISC  
 N022544 001 Jan 28, 2011 Jan CAHN  
 N022544 002 Jan 28, 2011 Jan CAHN

GALANTAMINE HYDROBROMIDE

TABLET; ORAL  
 GALANTAMINE HYDROBROMIDE

@ HIKMA EQ 4MG BASE  
 @ EQ 8MG BASE  
 @ EQ 12MG BASE

A077608 001 Feb 11, 2009 Feb DISC  
 A077608 002 Feb 11, 2009 Feb DISC  
 A077608 003 Feb 11, 2009 Feb DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 GEMCITABINE HYDROCHLORIDE

@ APOTEX 200MG/5.26ML (38MG/ML)  
 @ 1GM/26.3ML (38MG/ML)  
 @ 2GM/52.6ML (38MG/ML)  
 >D> AP MYLAN LABS LTD EQ 1GM BASE/VIAL  
 >A> @ EQ 1GM BASE/VIAL  
 @ EQ 2GM BASE/VIAL  
 AP SHILPA MEDICARE LTD EQ 200MG BASE/VIAL  
 AP EQ 1GM BASE/VIAL  
 @ TEVA PHARMS EQ 200MG BASE/VIAL  
 @ EQ 1GM BASE/VIAL

A206776 001 May 23, 2017 Feb DISC  
 A206776 002 May 23, 2017 Feb DISC  
 A206776 003 May 23, 2017 Feb DISC  
 A200145 002 Jul 25, 2011 May DISC  
 A200145 002 Jul 25, 2011 May DISC  
 A200145 003 Jul 25, 2011 Mar DISC  
 A207575 001 Feb 22, 2019 Jan CMFD  
 A207575 002 Feb 22, 2019 Jan CMFD  
 A077983 002 Jan 25, 2011 Mar DISC  
 A077983 001 Jan 25, 2011 Mar DISC

GEMFIBROZIL

TABLET; ORAL  
 GEMFIBROZIL

AB CADILA 600MG  
 @ TEVA 600MG

A204189 001 Aug 28, 2018 Feb CAHN  
 A074256 001 Oct 31, 1993 Feb DISC

GENTAMICIN SULFATE

INJECTABLE; INJECTION  
 GENTAMICIN SULFATE

@ HOSPIRA EQ 10MG BASE/ML

A062612 004 Feb 20, 1986 Mar DISC

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ MYLAN	1MG	A 077624	001	Nov 28, 2005	Apr	DISC
@	2MG	A 077624	002	Nov 28, 2005	Apr	DISC
@	4MG	A 077624	003	Nov 28, 2005	Apr	DISC

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>D>	@ ORIENT PHARMA CO LTD	1.25MG	A 206483	001	Feb 22, 2019	May	CMFD
>A>	AB1	1.25MG	A 206483	001	Feb 22, 2019	May	CMFD
>D>	@	2.5MG	A 206483	002	Feb 22, 2019	May	CMFD
>A>	AB1	2.5MG	A 206483	002	Feb 22, 2019	May	CMFD
>D>	@	5MG	A 206483	003	Feb 22, 2019	May	CMFD
>A>	AB1	5MG	A 206483	003	Feb 22, 2019	May	CMFD

GLYBURIDE (MICRONIZED)

@ MYLAN	1.5MG	A 074792	001	Jun 26, 1998	Jan	DISC
@	3MG	A 074792	002	Jun 26, 1998	Jan	DISC
@	6MG	A 074792	003	Aug 17, 1999	Jan	DISC

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	RICONPHARMA LLC	0.2MG/ML	A 210083	001	Feb 21, 2020	Feb	NEWA
----	-----------------	----------	----------	-----	--------------	-----	------

POWDER; INHALATION

SEEBRI

+ @	NOVARTIS	15.6MCG/INH	N 207923	001	Oct 29, 2015	Mar	CAHN
+ @	SUNOVION PHARMS INC	15.6MCG/INH	N 207923	001	Oct 29, 2015	Mar	DISC

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

EXELA PHARMA SCS LLC	1MG/5ML (0.2MG/ML)	N 210997	003	Apr 09, 2020	Apr	NEWA
----------------------	--------------------	----------	-----	--------------	-----	------

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+ @	NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N 207930	001	Oct 29, 2015	Mar	CAHN
+ @	SUNOVION PHARMS INC	15.6MCG/INH; 27.5MCG/INH	N 207930	001	Oct 29, 2015	Mar	DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>D>	AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078262	001	Dec 31, 2007	May	CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078258	001	Jun 30, 2008	May	CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078258	002	Jun 30, 2008	May	CAHN
		@ MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 203454	001	Apr 04, 2017	Apr	DISC
		@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 203454	002	Apr 04, 2017	Apr	DISC
		@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 203453	001	Jan 31, 2017	Mar	DISC
>A>	AP	PUNISKA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 078262	001	Dec 31, 2007	May	CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A 078258	001	Jun 30, 2008	May	CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A 078258	002	Jun 30, 2008	May	CAHN
		@ YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 202647	001	Mar 06, 2020	Apr	DISC
	AP		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A 202647	001	Mar 06, 2020	Feb	NEWA

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

@ MYLAN	EQ 1MG BASE	A 078725	001	Jan 30, 2008	Jan	DISC
---------	-------------	----------	-----	--------------	-----	------

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

>A>	AB	COSETTE	125MG/5ML	A 065438	001	Oct 08, 2010	May	CAHN
>D>	AB	VINTAGE PHARMS	125MG/5ML	A 065438	001	Oct 08, 2010	May	CAHN

HALCINONIDESOLUTION;TOPICAL  
HALOG

! SUN PHARM INDS INC 0.1% N017823 001 Mar CMFD

HALOBETASOL PROPIONATELOTION;TOPICAL  
HALOBETASOL PROPIONATE

>A> AB PERRIGO ISRAEL 0.05% A211464 001 Jun 03, 2020 May NFTG  
ULTRAVATE

>D> +! SUN PHARM INDUSTRIES 0.05% N208183 001 Nov 06, 2015 May CFTG  
>A> AB +! 0.05% N208183 001 Nov 06, 2015 May CFTG

HALOPERIDOL LACTATEINJECTABLE;INJECTION  
HALOPERIDOL

@ TEVA PHARMS USA EQ 5MG BASE/ML A076035 001 Aug 29, 2001 Mar DISC

HEPARIN SODIUMINJECTABLE;INJECTION  
HEPARIN SODIUM

AP GLAND PHARMA LTD 1,000 UNITS/ML A205323 002 Nov 18, 2019 Apr NEWA  
AP NANJING KING-FRIEND 20,000 UNITS/ML A211004 001 Feb 24, 2020 Feb NEWA  
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
BAXTER HLTHCARE 2,000 UNITS/1000ML N018609 004 Apr 23, 2020 Apr NEWA  
HEPARIN SODIUM PRESERVATIVE FREE  
AP +! FRESENIUS KABI USA 10,000 UNITS/ML N017029 019 Nov 22, 2010 Mar CTEC  
AP NANJING KING-FRIEND 10,000 UNITS/ML A212060 001 Apr 02, 2020 Mar NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATESYRUP;ORAL  
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE  
@ NOSTRUM LABS INC 1.5MG/5ML;5MG/5ML A210663 001 Jun 11, 2019 Apr CAHNTABLET;ORAL  
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA ! NOVEL LABS INC 1.5MG;5MG A091528 001 Apr 20, 2011 Jan CHRS  
TUSSIGON  
@ KING PHARMS 1.5MG;5MG A088508 001 Jul 30, 1985 Jan DISC

HYDRALAZINE HYDROCHLORIDEINJECTABLE;INJECTION  
HYDRALAZINE HYDROCHLORIDE

AP XGEN PHARMS 20MG/ML A203110 001 Jun 29, 2015 Feb CAHN

TABLET;ORAL  
HYDRALAZINE HYDROCHLORIDE  
@ STRIDES PHARMA 10MG A200770 004 Jun 25, 2019 Jan DISCHYDROCHLOROTHIAZIDECAPSULE;ORAL  
HYDROCHLOROTHIAZIDE

@ IVAX SUB TEVA PHARMS 12.5MG A077005 001 Jul 13, 2005 Mar DISC

TABLET;ORAL  
HYDROCHLOROTHIAZIDE

@ MYLAN PHARMS INC 25MG A040735 002 Jan 23, 2007 Jan DISC  
@ 50MG A040735 003 Jan 23, 2007 Jan DISC

HYDROCHLOROTHIAZIDE; LISINAPRILTABLET;ORAL  
LISINAPRIL AND HYDROCHLOROTHIAZIDE

@ COREPHARMA 12.5MG;10MG A076674 001 Oct 05, 2004 Feb CAHN  
@ 12.5MG;20MG A076674 002 Oct 05, 2004 Feb CAHN  
@ 25MG;20MG A076674 003 Oct 05, 2004 Feb CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDETABLET;ORAL  
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMS INC 12.5MG;7.5MG A202150 001 Mar 07, 2014 Apr DISC  
@ 12.5MG;15MG A202150 002 Mar 07, 2014 Apr DISC  
@ 25MG;15MG A202150 003 Mar 07, 2014 Apr DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>D>	@	UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	May	CMFD
>A>	AB		12.5MG;20MG	A208847	001	Sep 17, 2019	May	CMFD
	@		12.5MG;20MG	A208847	001	Sep 17, 2019	Mar	DISC
>D>	@		12.5MG;40MG	A208847	003	Sep 17, 2019	May	CMFD
>A>	AB		12.5MG;40MG	A208847	003	Sep 17, 2019	May	CMFD
	@		12.5MG;40MG	A208847	003	Sep 17, 2019	Mar	DISC
>D>	@		25MG;40MG	A208847	002	Sep 17, 2019	May	CMFD
>A>	AB		25MG;40MG	A208847	002	Sep 17, 2019	May	CMFD
	@		25MG;40MG	A208847	002	Sep 17, 2019	Mar	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

## TABLET; ORAL

## TELMISARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	MACLEODS PHARMS LTD	12.5MG;40MG	A204169	001	Nov 02, 2015	May	DISC
>A>	@		12.5MG;40MG	A204169	001	Nov 02, 2015	May	DISC
>D>	AB		12.5MG;80MG	A204169	002	Nov 02, 2015	May	DISC
>A>	@		12.5MG;80MG	A204169	002	Nov 02, 2015	May	DISC
>D>	AB		25MG;80MG	A204169	003	Nov 02, 2015	May	DISC
>A>	@		25MG;80MG	A204169	003	Nov 02, 2015	May	DISC
	@	MYLAN	12.5MG;40MG	A091648	001	Feb 25, 2014	Apr	DISC
	@		12.5MG;80MG	A091648	002	Feb 25, 2014	Apr	DISC
	@		25MG;80MG	A091648	003	Feb 25, 2014	Apr	DISC

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE; ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	25MG;37.5MG	A208358	001	Feb 11, 2019	Feb	CAHN
	@	DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999	Mar	DISC

## TABLET; ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@	PLIVA	25MG;37.5MG	A074026	001	Apr 26, 1996	Mar	DISC
--	---	-------	-------------	---------	-----	--------------	-----	------

HYDROCODONE BITARTRATE

## CAPSULE, EXTENDED RELEASE; ORAL

## HYDROCODONE BITARTRATE

AB		ALVOGEN	10MG	A206986	001	Jan 21, 2020	Jan	NFTG
AB			15MG	A206986	002	Jan 21, 2020	Jan	NFTG
AB			20MG	A206986	003	Jan 21, 2020	Jan	NFTG
AB			30MG	A206986	004	Jan 21, 2020	Jan	NFTG
AB			40MG	A206986	005	Jan 21, 2020	Jan	NFTG
AB			50MG	A206986	006	Jan 21, 2020	Jan	NFTG
		ZOHYDRO ER						
AB	+	PERSION	10MG	N202880	001	Oct 25, 2013	Jan	CFTG
AB	+		15MG	N202880	002	Oct 25, 2013	Jan	CFTG
AB	+		20MG	N202880	003	Oct 25, 2013	Jan	CFTG
AB	+		30MG	N202880	004	Oct 25, 2013	Jan	CFTG
AB	+		40MG	N202880	005	Oct 25, 2013	Jan	CFTG
AB	+		50MG	N202880	006	Oct 25, 2013	Jan	CFTG

HYDROCORTISONE

## ENEMA; RECTAL

## HYDROCORTISONE

	@	TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994	Mar	DISC
--	---	-------------	------------	---------	-----	--------------	-----	------

## LOTION; TOPICAL

## HYDROCORTISONE

	@	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Apr	DISC
--	---	----------------	------	---------	-----	--------------	-----	------

## STIE-CORT

AT	!	PERRIGO CO	2.5%	A089074	001	Nov 26, 1985	Apr	CHRS
----	---	------------	------	---------	-----	--------------	-----	------

## OINTMENT; TOPICAL

## HYDROCORTISONE

	@	ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982	Mar	DISC
--	---	----------------------	----	---------	-----	--------------	-----	------

## TABLET; ORAL

## HYDROCORTISONE

AB		STRIDES PHARMA	5MG	A207029	001	Apr 27, 2017	Feb	CAHN
AB			10MG	A207029	002	Apr 27, 2017	Feb	CAHN
AB			20MG	A207029	003	Apr 27, 2017	Feb	CAHN

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL  
HYDROCORTISONE VALERATE

AB	COSETTE	0.2%	A211764	001	Mar 04, 2020	Feb	NEWA
----	---------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION  
DILAUDID

+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	Jan	NEWA
----	--------------------	----------	---------	-----	--------------	-----	------

	HYDROMORPHONE HYDROCHLORIDE						
	@ BARR	10MG/ML	A076444	001	Apr 25, 2003	Mar	DISC

SOLUTION; ORAL  
HYDROMORPHONE HYDROCHLORIDE

AA	LANNETT CO INC	5MG/5ML	A207108	001	Apr 22, 2020	Apr	NEWA
----	----------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL  
HYDROMORPHONE HYDROCHLORIDE

AB	NOSTRUM LABS INC	8MG	A076723	001	Oct 18, 2005	Feb	CAHN
----	------------------	-----	---------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL  
HYDROXYCHLOROQUINE SULFATE

AB	ACCORD HLTHCARE	200MG	A213342	001	Apr 07, 2020	Mar	NEWA
AB	APPCO	200MG	A210441	001	May 01, 2018	Mar	CAHN
>A>	HAVIX	200MG	A212902	001	May 14, 2020	May	NEWA
AB	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Mar	CMFD
AB	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Mar	CMFD

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR  
HYDROXYPROGESTERONE CAPROATE

	@ AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Feb	DISC
AP1		1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jan	CMS1

HYDROXYUREA

CAPSULE; ORAL  
HYDROXYUREA

AB	LEADING PHARMA LLC	500MG	A213438	001	Apr 08, 2020	Mar	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL  
HYDROXYZINE HYDROCHLORIDE

>D>	AA	!	VINTAGE PHARMS	10MG/5ML	A040391	001	Apr 10, 2002	May	DISC
>A>		@		10MG/5ML	A040391	001	Apr 10, 2002	May	DISC

TABLET; ORAL  
HYDROXYZINE HYDROCHLORIDE

>A>	@	AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May	CAHN
>A>	@		25MG	A087871	003	Dec 20, 1982	May	CAHN
>A>	@		50MG	A087871	001	Dec 20, 1982	May	CAHN
>D>	@	AUROLIFE PHARMA LLC	10MG	A087871	002	Dec 20, 1982	May	CAHN
>D>	@		25MG	A087871	003	Dec 20, 1982	May	CAHN
>D>	@		50MG	A087871	001	Dec 20, 1982	May	CAHN

IBUPROFEN

TABLET; ORAL  
IBUPROFEN

AB	AUROBINDO PHARMA LTD	400MG	A213794	001	May 08, 2020	Apr	NEWA
AB		600MG	A213794	002	May 08, 2020	Apr	NEWA
AB		800MG	A213794	003	May 08, 2020	Apr	NEWA

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS  
IBUPROFEN LYSINE

AP	XGEN PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Feb	CAHN
----	-------------	------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL  
COMBUNOX  
+ @ FOREST LABS 400MG; 5MG  
OXYCODONE HYDROCHLORIDE AND IBUPROFEN  
ACTAVIS ELIZABETH 400MG; 5MG

N021378	001	Nov 26, 2004	Apr	CRLD
A078769	001	Jan 04, 2008	Apr	CTEC

## TABLET;ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN  
@ BARR LABS INC 400MG;5MG

A078316 001 Nov 29, 2007 Apr DISC

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS  
ICATIBANT ACETATE

AP JIANGSU HANSOH PHARM EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A211021 001 Mar 09, 2020 Feb NEWA

ICOSAPENT ETHYL

CAPSULE;ORAL

&gt;A&gt; ICOSAPENT ETHYL

>A> AB HIKMA 1GM A209457 001 May 21, 2020 May NFTG

VASCEPA

>D> +! AMARIN PHARMS 1GM N202057 001 Jul 26, 2012 May CFTG

>A> AB +! 1GM N202057 001 Jul 26, 2012 May CFTG

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB ZYDUS PHARMS EQ 100MG BASE A210658 001 Apr 08, 2020 Mar NEWA

AB EQ 400MG BASE A210658 002 Apr 08, 2020 Mar NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB OXFORD PHARMS 10MG A040751 003 Feb 28, 2008 Apr CMFD

AB 25MG A040751 002 Feb 28, 2008 Apr CMFD

AB 50MG A040751 001 Feb 28, 2008 Apr CMFD

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

+ @ NOVARTIS EQ 75MCG BASE N022383 001 Jul 01, 2011 Mar CAHN

+ @ SUNOVION PHARMS INC EQ 75MCG BASE N022383 001 Jul 01, 2011 Mar DISC

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB ANI PHARMS INC 1.25MG A075201 001 Dec 04, 1998 Jan CAHN

AB 2.5MG A075201 002 Dec 04, 1998 Jan CAHN

INDINAVIR SULFATE

CAPSULE;ORAL

CRIXIVAN

+ @ MERCK SHARP DOHME EQ 200MG BASE N020685 003 Mar 13, 1996 Mar DISC

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

AB HERITAGE 25MG N018851 001 May 18, 1984 Jan CAHN

AB 50MG N018851 002 May 18, 1984 Jan CAHN

@ HERITAGE PHARMA 25MG A070719 001 Feb 12, 1986 Apr DISC

@ 50MG A070756 001 Feb 12, 1986 Mar DISC

CAPSULE, EXTENDED RELEASE;ORAL

INDOMETHACIN

>D> AB MYLAN 75MG A202139 001 Mar 20, 2014 May DISC

>A> @ 75MG A202139 001 Mar 20, 2014 May DISC

IPRATROPIUM BROMIDE

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

@ WATSON LABS 0.02% A076291 001 May 09, 2005 Apr DISC

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB APOTEX INC 0.021MG/SPRAY A076156 001 Apr 18, 2003 Jan CMFD

IRBESARTAN

TABLET; ORAL  
IRBESARTAN  
@ HIKMA  
@  
@

75MG  
150MG  
300MG

A090201 001 Oct 15, 2012 Feb DISC  
A090201 002 Oct 15, 2012 Feb DISC  
A090201 003 Oct 15, 2012 Feb DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

@ CIPLA LTD  
@  
@ PLIVA LACHEMA  
@

40MG/2ML (20MG/ML)  
100MG/5ML (20MG/ML)  
40MG/2ML (20MG/ML)  
100MG/5ML (20MG/ML)

A077219 001 Feb 20, 2008 Apr DISC  
A077219 002 Feb 20, 2008 Apr DISC  
A078122 001 Oct 31, 2008 Apr DISC  
A078122 002 Oct 31, 2008 Apr DISC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE MONONITRATE

@ HIKMA INTL PHARMS  
@

30MG  
60MG

A076813 002 Mar 30, 2006 Feb DISC  
A076813 001 Jan 07, 2005 Feb DISC

ITRACONAZOLE

SOLUTION; ORAL  
ITRACONAZOLE

@ APOTEX

10MG/ML

A208481 001 Aug 02, 2019 Feb DISC

IVERMECTIN

CREAM; TOPICAL  
IVERMECTIN

AB PERRIGO UK FINCO

1%

A210225 001 Apr 13, 2020 Mar NEWA

LOTION; TOPICAL  
IVERMECTIN

AB TARO  
SKLICE

0.5%

A210720 001 May 06, 2020 Apr NFTG

AB +! ARBOR PHARMS LLC

0.5%

N202736 001 Feb 07, 2012 Apr CFTG

KETOCONAZOLE

TABLET; ORAL  
KETOCONAZOLE

AB HAVIX

200MG

A075912 001 Jan 10, 2002 Apr CMFD

KETOROLAC TROMETHAMINE

TABLET; ORAL  
KETOROLAC TROMETHAMINE

AB MYLAN  
@ PLIVA  
AB ! TEVA

10MG  
10MG  
10MG

A074761 001 May 16, 1997 Feb CHRS  
A075284 001 Jun 23, 1999 Apr DISC  
A074754 001 May 16, 1997 Feb CHRS

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION  
NORMODYNE

+ @ SCHERING

5MG/ML

N018686 001 Aug 01, 1984 Jan CRLD

TABLET; ORAL  
LABETALOL HYDROCHLORIDE

AB HERITAGE PHARMA  
AB

100MG  
200MG

A074787 001 Aug 03, 1998 Feb CMFD  
A074787 002 Aug 03, 1998 Feb CMFD

LACTITOL

FOR SOLUTION; ORAL  
PIZENSY

+! BRAINTREE LABS  
+

10GM  
10GM/PACKET

N211281 001 Feb 12, 2020 Feb NEWA  
N211281 001 Feb 12, 2020 Feb NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
TEMIXYS

>D> CELLTRION  
>A> +!  
>A> +

300MG; 300MG  
300MG; 300MG  
300MG; 300MG

N211284 001 Nov 16, 2018 May CRLD  
N211284 001 Nov 16, 2018 May CHRS  
N211284 001 Nov 16, 2018 May CRLD

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

@ MYLAN LABS LTD 150MG;300MG A079079 001 Aug 12, 2019 Apr CAHN

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

@ MYLAN 25MG A077420 001 Jan 27, 2009 Mar DISC

@ 100MG A077420 002 Jan 27, 2009 Mar DISC

@ 150MG A077420 003 Jan 27, 2009 Mar DISC

@ 200MG A077420 004 Jan 27, 2009 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB DR REDDYS LABS LTD 250MG A202383 006 Sep 06, 2018 Mar NEWA

AB ZYDUS PHARMS 25MG A207763 001 Apr 01, 2020 Mar NEWA

AB 50MG A207763 002 Apr 01, 2020 Mar NEWA

AB 100MG A207763 003 Apr 01, 2020 Mar NEWA

AB 200MG A207763 004 Apr 01, 2020 Mar NEWA

AB 250MG A207763 005 Apr 01, 2020 Mar NEWA

AB 300MG A207763 006 Apr 01, 2020 Mar NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

>A> AB HETERO LABS LTD III 15MG A203083 001 May 18, 2020 May NEWA

>A> AB 30MG A203083 002 May 18, 2020 May NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+ ELI LILLY AND CO 50MG N211280 001 Jan 31, 2020 Jan NEWA

+! 100MG N211280 002 Jan 31, 2020 Jan NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

@ AUROBINDO PHARMA LTD 0.005% A206519 001 Sep 03, 2019 Mar DISC

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

@ BARR 10MG A077083 001 Sep 13, 2005 Apr DISC

@ 20MG A077083 002 Sep 13, 2005 Apr DISC

AB LUPIN LTD 10MG A211863 001 Feb 04, 2020 Jan NEWA

AB 20MG A211863 002 Feb 04, 2020 Jan NEWA

@ TEVA PHARMS 10MG A077084 001 Sep 13, 2005 Apr DISC

@ 20MG A077084 002 Sep 13, 2005 Apr DISC

LEMBOREXANT

TABLET;ORAL

DAYVIGO

+ EISAI INC 5MG N212028 001 Apr 07, 2020 Apr NEWA

+! 10MG N212028 002 Apr 07, 2020 Apr NEWA

LETROZOLE

TABLET;ORAL

LETROZOLE

>D> AB JIANGSU HENGRUI MED 2.5MG A202716 001 May 16, 2013 May DISC

>A> @ 2.5MG A202716 001 May 16, 2013 May DISC

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

AB EPIC PHARMA LLC EQ 5MG BASE A074544 001 Aug 28, 1997 Mar CMFD

AB EQ 25MG BASE A074544 002 Aug 28, 1997 Mar CMFD

LEUPROLIDE ACETATE

## INJECTABLE; INJECTION

## LUPRON DEPOT-PED

>D>	+ @	ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CTNA
>D>	+ @		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CTNA
>D>	+	!	7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CTNA
>D>	+	!	11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CTNA
>D>	+	!	11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CTNA
>D>	+	!	15MG/VIAL	N020263	006	Jan 21, 1994	May	CTNA
>D>	+	!	30MG/VIAL	N020263	008	Aug 15, 2011	May	CTNA
>A>			LUPRON DEPOT-PED KIT					
>A>	+ @	ABBVIE ENDOCRINE INC	3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CTNA
>A>	+ @		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CTNA
>A>	+	!	7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CTNA
>A>	+	!	11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CTNA
>A>	+	!	11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CTNA
>A>	+	!	15MG/VIAL	N020263	006	Jan 21, 1994	May	CTNA
>A>	+	!	30MG/VIAL	N020263	008	Aug 15, 2011	May	CTNA

## INJECTABLE; SUBCUTANEOUS

## ELIGARD

>D>	+	!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CTNA
>D>	+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CTNA
>D>	+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May	CTNA
>D>	+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May	CTNA
>A>			ELIGARD KIT						
>A>	+	!	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CTNA
>A>	+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CTNA
>A>	+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May	CTNA
>A>	+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May	CTNA

## POWDER; INTRAMUSCULAR

## LUPRON DEPOT-PED KIT

>A>	+ @	ABBVIE ENDOCRINE INC	3.75MG, 7.5MG	N020263	003	Apr 16, 1993	May	CPOT
>A>	+ @		3.75MG/VIAL, 7.5MG/VIAL	N020263	003	Apr 16, 1993	May	CDFR
>A>	+	!	7.5MG	N020263	002	Apr 16, 1993	May	CPOT
>A>	+	!	7.5MG/VIAL	N020263	002	Apr 16, 1993	May	CDFR
>A>	+ @		7.5MG, 7.5MG	N020263	004	Apr 16, 1993	May	CPOT
>A>	+ @		7.5MG/VIAL, 7.5MG/VIAL	N020263	004	Apr 16, 1993	May	CDFR
>A>	+	!	11.25MG	N020263	005	Jan 21, 1994	May	CPOT
>A>	+	!	11.25MG/VIAL	N020263	005	Jan 21, 1994	May	CDFR
>A>	+	!	11.25MG	N020263	007	Aug 15, 2011	May	CPOT
>A>	+	!	11.25MG/VIAL	N020263	007	Aug 15, 2011	May	CDFR
>A>	+	!	15MG	N020263	006	Jan 21, 1994	May	CPOT
>A>	+	!	15MG/VIAL	N020263	006	Jan 21, 1994	May	CDFR
>A>	+	!	30MG	N020263	008	Aug 15, 2011	May	CPOT
>A>	+	!	30MG/VIAL	N020263	008	Aug 15, 2011	May	CDFR

## POWDER; SUBCUTANEOUS

## ELIGARD KIT

>A>	+	!	TOLMAR THERAP	7.5MG	N021343	001	Jan 23, 2002	May	CPOT
>A>	+	!		7.5MG/VIAL	N021343	001	Jan 23, 2002	May	CDFR
>A>	+	!		22.5MG	N021379	001	Jul 24, 2002	May	CPOT
>A>	+	!		22.5MG/VIAL	N021379	001	Jul 24, 2002	May	CDFR
>A>	+	!		30MG	N021488	001	Feb 13, 2003	May	CPOT
>A>	+	!		30MG/VIAL	N021488	001	Feb 13, 2003	May	CDFR
>A>	+	!		45MG	N021731	001	Dec 14, 2004	May	CPOT
>A>	+	!		45MG/VIAL	N021731	001	Dec 14, 2004	May	CDFR
>A>			FENSOLVI KIT						
>A>	+	!	TOLMAR	45MG	N213150	001	May 01, 2020	May	NEWA

LEVAMLODIPINE MALEATE

## TABLET; ORAL

## CONJUPRI

>D>	+		CSPC OUYI	EQ 1.25MG BASE	N212895	001	Dec 19, 2019	May	DISC
>A>	+	@		EQ 1.25MG BASE	N212895	001	Dec 19, 2019	May	DISC

LEVETIRACETAM

## INJECTABLE; INTRAVENOUS

## LEVETIRACETAM

AP			XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
----	--	--	-------------	----------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## LEVETIRACETAM

## @ TEVA PHARMS

				250MG	A078101	001	Jan 15, 2009	Apr	DISC
--	--	--	--	-------	---------	-----	--------------	-----	------

<u>TABLET;ORAL</u>							
LEVETIRACETAM							
	@	500MG		A078101	002	Jan 15, 2009	Apr DISC
	@	750MG		A078101	003	Jan 15, 2009	Apr DISC
	@	1GM		A078101	004	Jan 15, 2009	Apr DISC
AB	VIWIT PHARM	250MG		A078869	001	Mar 13, 2009	Mar CAHN
AB		250MG		A078869	001	Mar 13, 2009	Mar CAHN
AB		500MG		A078869	002	Mar 13, 2009	Mar CAHN
AB		500MG		A078869	002	Mar 13, 2009	Mar CAHN
AB		750MG		A078869	003	Mar 13, 2009	Mar CAHN
AB		750MG		A078869	003	Mar 13, 2009	Mar CAHN
AB		1GM		A078869	004	Mar 13, 2009	Mar CAHN
AB		1GM		A078869	004	Mar 13, 2009	Mar CAHN
<u>TABLET, EXTENDED RELEASE;ORAL</u>							
LEVETIRACETAM							
	@ ACTAVIS ELIZABETH	500MG		A091557	001	Sep 12, 2011	Apr DISC
	@	750MG		A091557	002	Sep 12, 2011	Apr DISC
	@ TEVA PHARMS	500MG		A091430	001	Sep 12, 2011	Apr DISC
	@	750MG		A091430	002	Sep 12, 2011	Apr DISC
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
<u>SOLUTION;ORAL</u>							
LEVOCETIRIZINE DIHYDROCHLORIDE							
	@ APOTEX	2.5MG/5ML		A202915	001	Aug 21, 2014	Feb DISC
<u>TABLET;ORAL</u>							
LEVOCETIRIZINE DIHYDROCHLORIDE							
	@ APOTEX	5MG		A203027	001	Feb 13, 2015	Feb DISC
<u>LEVOFLOXACIN</u>							
<u>INJECTABLE;INJECTION</u>							
LEVOFLOXACIN							
AP	GLAND PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)		A205540	001	Apr 22, 2020	Apr NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)		A205540	002	Apr 22, 2020	Apr NEWA
<u>LEVOLEUCOVORIN CALCIUM</u>							
<u>SOLUTION;INTRAVENOUS</u>							
LEVOLEUCOVORIN CALCIUM							
AP	! INGENUS PHARMS LLC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		A210623	001	May 03, 2018	Apr CHRS
AP	!	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A210623	002	May 03, 2018	Apr CHRS
	@ SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		A203563	002	Mar 09, 2015	Apr DISC
<u>LEVOTHYROXINE SODIUM</u>							
<u>POWDER;INTRAVENOUS</u>							
LEVOTHYROXINE SODIUM							
AP	DR REDDYS	100MCG/VIAL		A208837	001	Mar 27, 2020	Mar NEWA
<u>LEVOTHYROXINE SODIUM **</u>							
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium							
<u>TABLET;ORAL</u>							
THYRO-TABS							
AB2, AB4	+ ALVOGEN	0.3MG		N021116	009	Oct 24, 2002	Jan CHRS
<u>LIDOCAINE</u>							
<u>OINTMENT;TOPICAL</u>							
LIDOCAINE							
AT	MACLEODS PHARMS LTD	5%		A211697	001	Mar 16, 2020	Mar NEWA
	@ SUNGEN PHARMA	5%		A212486	001	Oct 17, 2019	Mar DISC
AT		5%		A212486	001	Oct 17, 2019	Mar CPOT
	@ TEVA PHARMS USA	5%		A210256	001	Jan 16, 2018	Apr DISC
<u>PATCH;TOPICAL</u>							
LIDOCAINE							
AB	RHODES PHARMS	5%		A209190	001	Apr 30, 2020	Apr NEWA

LIDOCAINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	LIDOCAINE HYDROCHLORIDE						
AP	HUONS	1%	A212821	001	May 07, 2020	Apr	NEWA
AP	WEST-WARD PHARMS INT	1%	A080407	001		Mar	CMFD
AP		2%	A080407	002		Mar	CMFD
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	WEST-WARD PHARMS INT	1%	A084625	001		Mar	CMFD
AP		2%	A084625	002		Mar	CMFD

LINCOMYCIN HYDROCHLORIDE

	INJECTABLE; INJECTION						
	LINCOMYCIN						
AP	XGEN PHARMS	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	Feb	CAHN

LINEZOLID

	TABLET; ORAL						
	LINEZOLID						
	@ GATE PHARMS	600MG	A091210	001	Feb 05, 2016	Apr	DISC
>D>	AB	TEVA PHARMS USA	A078061	001	May 18, 2015	May	DISC
>A>		@	A078061	001	May 18, 2015	May	DISC

LIOTHYRONINE SODIUM

	INJECTABLE; INJECTION						
	LIOTHYRONINE SODIUM						
AP	XGEN PHARMS	EQ 0.01MG BASE/ML	A076923	001	Aug 17, 2005	Feb	CAHN
	TABLET; ORAL						
	LIOTHYRONINE SODIUM						
AB	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jan	CMFD
AB		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jan	CMFD
AB		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jan	CMFD

LISINOPRIL

	SOLUTION; ORAL							
	QBRELIS							
>A>	+	! AZURITY	1MG/ML	N208401	001	Jul 29, 2016	May	CAHN
>D>	+	! SILVERGATE PHARMS	1MG/ML	N208401	001	Jul 29, 2016	May	CAHN
	TABLET; ORAL							
	LISINOPRIL							
AB	COREPHARMA	2.5MG	A076102	001	Sep 30, 2002	Feb	CAHN	
AB		5MG	A076102	002	Sep 30, 2002	Feb	CAHN	
AB		10MG	A076102	003	Sep 30, 2002	Feb	CAHN	
AB		20MG	A076102	004	Sep 30, 2002	Feb	CAHN	
AB		30MG	A076102	005	Sep 30, 2002	Feb	CAHN	
AB		40MG	A076102	006	Sep 30, 2002	Feb	CAHN	

LITHIUM CARBONATE

	CAPSULE; ORAL							
	LITHIUM CARBONATE							
AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Jan	CAHN
AB	+		300MG	N017812	001		Jan	CAHN
AB	+	!	600MG	N017812	003	Jan 28, 1987	Jan	CAHN
		@ MYLAN	150MG	A076243	002	Feb 24, 2003	Jan	DISC
		@	300MG	A076243	001	Jun 27, 2002	Jan	DISC

LITHIUM CITRATE

	SYRUP; ORAL							
	LITHIUM CITRATE							
AA	+	! HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Jan	CAHN

LOMITAPIDE MESYLATE

	CAPSULE; ORAL							
	JUXTAPID							
>D>	+	AEGERION	EQ 5MG BASE	N203858	001	Dec 21, 2012	May	CAHN
>D>	+		EQ 10MG BASE	N203858	002	Dec 21, 2012	May	CAHN
>D>	+		EQ 20MG BASE	N203858	003	Dec 21, 2012	May	CAHN
>D>	+		EQ 30MG BASE	N203858	004	Apr 23, 2015	May	CAHN
>D>	+		EQ 40MG BASE	N203858	005	Apr 23, 2015	May	CAHN
>D>	+	!	EQ 60MG BASE	N203858	006	Apr 23, 2015	May	CAHN
>A>	+	AMRYT	EQ 5MG BASE	N203858	001	Dec 21, 2012	May	CAHN
>A>	+		EQ 10MG BASE	N203858	002	Dec 21, 2012	May	CAHN

CAPSULE;ORAL  
 JUXTAPID

>A>	+	EQ 20MG BASE	N203858	003	Dec 21, 2012	May CAHN
>A>	+	EQ 30MG BASE	N203858	004	Apr 23, 2015	May CAHN
>A>	+	EQ 40MG BASE	N203858	005	Apr 23, 2015	May CAHN
>A>	+	EQ 60MG BASE	N203858	006	Apr 23, 2015	May CAHN

LORAZEPAM

TABLET;ORAL  
 LORAZEPAM

@ MYLAN	0.5MG	A077657	001	Mar 16, 2006	Mar DISC
@	1MG	A077657	002	Mar 16, 2006	Mar DISC
@	2MG	A077657	003	Mar 16, 2006	Mar DISC

LORCASERIN HYDROCHLORIDE

TABLET;ORAL  
 BELVIQ

+ @ EISAI INC	10MG	N022529	001	Jun 27, 2012	Feb DISC
---------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL  
 BELVIQ XR

+ @ EISAI INC	20MG	N208524	001	Jul 15, 2016	Feb DISC
---------------	------	---------	-----	--------------	----------

LOSARTAN POTASSIUM

TABLET;ORAL  
 LOSARTAN POTASSIUM

@ HIKMA	25MG	A077459	001	Oct 06, 2010	Feb DISC
@	50MG	A077459	002	Oct 06, 2010	Feb DISC
@	100MG	A077459	003	Oct 06, 2010	Feb DISC

LOVASTATIN

TABLET;ORAL  
 LOVASTATIN

AB COREPHARMA	10MG	A077748	001	Feb 28, 2007	Feb CAHN
AB	20MG	A077748	002	Feb 28, 2007	Feb CAHN
AB	40MG	A077748	003	Feb 28, 2007	Feb CAHN

MAFENIDE ACETATE

CREAM;TOPICAL  
 SULFAMYLON

>D>	+	MYLAN INSTITUTIONAL	EQ 85MG BASE/GM	N016763	001	May CAHN
>A>	+	RISING	EQ 85MG BASE/GM	N016763	001	May CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION  
 MAGNESIUM SULFATE IN PLASTIC CONTAINER

>A> AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	May NEWA
>A> AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	May NEWA
>A> AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	May NEWA

MAZINDOL

TABLET;ORAL  
 SANOREX

+ @ NOVARTIS	1MG	N017247	001		Jan CAHN
+ @	2MG	N017247	002		Jan CAHN

MECLIZINE HYDROCHLORIDE

TABLET;ORAL  
 MECLIZINE HYDROCHLORIDE

@ MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Jan DISC
@	25MG	A202640	002	Sep 17, 2012	Jan DISC

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL  
 MEFLOQUINE HYDROCHLORIDE

!	BARR	250MG	A076392	001	Dec 29, 2003	Feb CTEC
@	HIKMA	250MG	A076523	001	Oct 01, 2004	Feb DISC

MEGESTROL ACETATE

	SUSPENSION;ORAL						
	MEGESTROL ACETATE						
	@	HIKMA	40MG/ML	A 075997	001	Feb 15, 2002	Feb DISC
AB	!	PAR PHARM	40MG/ML	A 075671	001	Jul 25, 2001	Feb CHRS
	@	TEVA PHARMS	40MG/ML	A 075681	001	May 05, 2003	Apr DISC

MELOXICAM

	CAPSULE;ORAL						
>A>	MELOXICAM						
>A>	AB	LUPIN LTD	5MG	A 209487	001	Jun 01, 2020	May NFTG
>A>	AB		10MG	A 209487	002	Jun 01, 2020	May NFTG
	VIVLODEX						
>D>	+	ZYLA	5MG	N 207233	001	Oct 22, 2015	May CFTG
>A>	AB		5MG	N 207233	001	Oct 22, 2015	May CFTG
>D>		+	10MG	N 207233	002	Oct 22, 2015	May CFTG
>A>	AB	+	10MG	N 207233	002	Oct 22, 2015	May CFTG
	SOLUTION;INTRAVENOUS						
	ANJESO						
	+	BAUDAX	30MG/ML (30MG/ML)	N 210583	001	Feb 20, 2020	Feb NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL						
	QMIIZ ODT						
	+	@ TERSERA THERAPS LLC	7.5MG	N 211210	001	Oct 19, 2018	Apr DISC
	+	@	15MG	N 211210	002	Oct 19, 2018	Apr DISC

MELPHALAN HYDROCHLORIDE

	INJECTABLE;INJECTION						
	MELPHALAN HYDROCHLORIDE						
>D>	AP	ALVOGEN INC	EQ 50MG BASE/VIAL	A 204817	001	May 17, 2019	May DISC
>A>		@	EQ 50MG BASE/VIAL	A 204817	001	May 17, 2019	May DISC
	AP	BPI LABS LLC	EQ 50MG BASE/VIAL	A 209197	001	May 08, 2020	Apr NEWA
	AP	INGENUS PHARMS LLC	EQ 50MG BASE/VIAL	A 210947	001	Feb 18, 2020	Feb NEWA
		@ PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A 204773	001	Aug 22, 2016	Feb DISC
		@ TWI PHARMS	EQ 50MG BASE/VIAL	A 211463	001	Sep 13, 2019	Jan DISC
	POWDER;INTRAVENOUS						
	EVOMELA						
	+	ACROTECH	EQ 50MG BASE/VIAL	N 207155	001	Mar 10, 2016	Mar CTEC
AP	+		EQ 50MG BASE/VIAL	N 207155	001	Mar 10, 2016	Feb CFTG
	MELPHALAN HYDROCHLORIDE						
		@ ACTAVIS LLC	EQ 50MG BASE/VIAL	A 209323	001	Mar 06, 2020	Mar DISC
AP			EQ 50MG BASE/VIAL	A 209323	001	Mar 06, 2020	Feb NFTG

MEMANTINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	MEMANTINE HYDROCHLORIDE						
AB		ANI PHARMS INC	7MG	A 205365	001	Feb 28, 2020	Feb NEWA
AB			14MG	A 205365	002	Feb 28, 2020	Feb NEWA
AB			21MG	A 205365	003	Feb 28, 2020	Feb NEWA
AB			28MG	A 205365	004	Feb 28, 2020	Feb NEWA
	TABLET;ORAL						
	MEMANTINE HYDROCHLORIDE						
	@	CHARTWELL	5MG	A 090244	001	Jul 11, 2018	Mar CAHN
	@		10MG	A 090244	002	Jul 11, 2018	Mar CAHN
AB		HIKMA PHARMS	5MG	A 208173	001	Feb 28, 2020	Feb NEWA
AB			10MG	A 208173	002	Feb 28, 2020	Feb NEWA
AB		NINGBO	5MG	A 212947	001	Apr 03, 2020	Apr CAHN
AB			5MG	A 212947	001	Apr 03, 2020	Mar NEWA
AB			10MG	A 212947	002	Apr 03, 2020	Apr CAHN
AB			10MG	A 212947	002	Apr 03, 2020	Mar NEWA
	@	TEVA PHARMS	5MG	A 090052	001	Oct 25, 2011	Apr DISC
	@		10MG	A 090052	002	Oct 25, 2011	Apr DISC

MEPERIDINE HYDROCHLORIDE

	TABLET;ORAL						
	MEPERIDINE HYDROCHLORIDE						
AA	!	EPIC PHARMA	50MG	A 040331	001	May 28, 1999	Feb CHRS
AA	!		100MG	A 040331	002	May 28, 1999	Feb CHRS
	@	HIKMA	50MG	A 040110	001	Mar 12, 1997	Feb DISC
	@		100MG	A 040110	002	Mar 12, 1997	Feb DISC

MESALAMINE

SUPPOSITORY;RECTAL  
MESALAMINE

AB	ANNORA PHARMA	1GM	A213377	001	Mar 19, 2020	Mar	NEWA
AB	ZYDUS PHARMS	1GM	A208953	001	Feb 12, 2020	Jan	NEWA

METAXALONE

TABLET;ORAL  
METAXALONE

AB	MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Mar	CTEC
AB	SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020	Mar	NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL  
METFORMIN HYDROCHLORIDE

AB	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020	Feb	NFTG
AB	+! RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003	Feb	CFTG
	+!	500MG/5ML	N021591	001	Sep 11, 2003	Jan	CAHN

TABLET;ORAL  
METFORMIN HYDROCHLORIDE

	@ HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Mar	DISC
	@	850MG	A075978	002	Jan 25, 2002	Mar	DISC
	@	1GM	A075978	003	Nov 05, 2002	Mar	DISC
>D>	AB MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	May	DISC
>A>	@	500MG	A205330	001	Oct 31, 2017	May	DISC
>D>	AB	850MG	A205330	002	Oct 31, 2017	May	DISC
>A>	@	850MG	A205330	002	Oct 31, 2017	May	DISC
>D>	AB	1GM	A205330	003	Oct 31, 2017	May	DISC
>A>	@	1GM	A205330	003	Oct 31, 2017	May	DISC
	@ MYLAN	500MG	A075976	001	Jan 24, 2002	Jan	DISC
	@	850MG	A075976	002	Jan 24, 2002	Jan	DISC
	@	1GM	A075976	003	Jan 24, 2002	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL  
METFORMIN HYDROCHLORIDE

AB2	AJANTA PHARMA LTD	500MG	A213651	001	Apr 09, 2020	Mar	NEWA
AB2		1GM	A213651	002	Apr 09, 2020	Mar	NEWA
>D>	AB APOTEX	750MG	A076706	002	Dec 29, 2005	May	DISC
>A>	@	750MG	A076706	002	Dec 29, 2005	May	DISC
	@ BARR	750MG	A076863	001	Oct 14, 2004	Apr	DISC
>D>	AB1 MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	May	DISC
>A>	@	500MG	A206955	001	Dec 07, 2016	May	DISC
>D>	AB	750MG	A206955	002	Dec 07, 2016	May	DISC
>A>	@	750MG	A206955	002	Dec 07, 2016	May	DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL  
METHADONE HYDROCHLORIDE

>D>	AA PHARM ASSOC	10MG/ML	A207368	001	Aug 22, 2019	May	CAHN
>A>	AA SPECGX LLC	10MG/ML	A207368	001	Aug 22, 2019	May	CAHN

SOLUTION;ORAL  
METHADONE HYDROCHLORIDE

>D>	AA PHARM ASSOC	5MG/5ML	A207537	001	Oct 02, 2019	May	CAHN
>D>	AA	10MG/5ML	A207537	002	Oct 01, 2019	May	CAHN
>A>	AA SPECGX LLC	5MG/5ML	A207537	001	Oct 02, 2019	May	CAHN
>A>	AA	10MG/5ML	A207537	002	Oct 01, 2019	May	CAHN

TABLET;ORAL  
METHADONE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Mar	CAHN
AA		5MG	A210484	001	Aug 02, 2018	Mar	CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar	CAHN
AA		10MG	A210484	002	Aug 02, 2018	Mar	CAHN
>D>	@ ROXANE	5MG	A088108	001	Mar 08, 1983	May	CMFD
>A>	AA	5MG	A088108	001	Mar 08, 1983	May	CMFD
>D>	@	10MG	A088109	001	Mar 08, 1983	May	CMFD
>A>	AA	10MG	A088109	001	Mar 08, 1983	May	CMFD
AA	VISTAPHARM	10MG	A204166	001	Mar 16, 2020	Mar	NEWA
	METHADOSE						
>D>	AA SPECGX LLC	5MG	A040050	001	Apr 15, 1993	May	DISC
>A>	@	5MG	A040050	001	Apr 15, 1993	May	DISC
>D>	AA	10MG	A040050	002	Apr 15, 1993	May	DISC

	TABLET;ORAL								
	METHADOSE								
>A>	@	10MG		A040050	002	Apr 15, 1993		May	DISC
	<u>METHOCARBAMOL</u>								
	TABLET;ORAL								
	METHOCARBAMOL								
	@ HIKMA INTL PHARMS	500MG		A085159	001			Feb	DISC
	@	750MG		A085123	001			Feb	DISC
	<u>METHOTREXATE SODIUM</u>								
	INJECTABLE;INJECTION								
	METHOTREXATE SODIUM PRESERVATIVE FREE								
	@ MYLAN LABS LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)		A201529	001	Mar 29, 2012		Jan	DISC
	@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)		A201529	002	Mar 29, 2012		Jan	DISC
	@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)		A201529	003	Mar 29, 2012		Jan	DISC
	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)		A040843	003	Feb 27, 2012		Jan	CTEC
	SOLUTION;ORAL								
	XATMEP								
>A>	+! AZURITY	EQ 2MG BASE/ML		N208400	001	Apr 25, 2017		May	CAHN
>D>	+! SILVERGATE PHARMS	EQ 2MG BASE/ML		N208400	001	Apr 25, 2017		May	CAHN
	TABLET;ORAL								
	METHOTREXATE SODIUM								
AB	! ACCORD HLTHCARE	EQ 2.5MG BASE		A213343	001	Jan 24, 2020		Jan	NEWA
	+ @ DAVA PHARMS INC	EQ 2.5MG BASE		N008085	002			Mar	DISC
AB	! EUGIA PHARMA	EQ 2.5MG BASE		A210454	001	Jan 30, 2020		Jan	NEWA
AB	! HIKMA	EQ 2.5MG BASE		A040054	001	Aug 01, 1994		Mar	CHRS
	<u>METHSCOPOLAMINE BROMIDE</u>								
	TABLET;ORAL								
	METHSCOPOLAMINE BROMIDE								
AA	! BAYSHORE PHARMS LLC	2.5MG		A200602	001	Sep 24, 2012		Apr	CTEC
AA	!	5MG		A200602	002	Sep 24, 2012		Apr	CTEC
AA	BRECKENRIDGE PHARM	2.5MG		A040642	001	Dec 06, 2011		Apr	CMFD
AA		5MG		A040642	002	Dec 06, 2011		Apr	CMFD
	<u>METHYLDOPA</u>								
	TABLET;ORAL								
	METHYLDOPA								
	@ HERITAGE PHARMA	250MG		A070098	001	Feb 20, 1986		Apr	DISC
	@	500MG		A070343	001	Feb 20, 1986		Apr	DISC
	@ WATSON LABS	500MG		A070625	001	Jun 06, 1986		Apr	DISC
	<u>METHYLERGONOVINE MALEATE</u>								
	TABLET;ORAL								
	METHYLERGONOVINE MALEATE								
AB	TULEX PHARMS INC	0.2MG		A212233	001	May 01, 2020		Apr	NEWA
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
	@ BARR LABS INC	10MG		A079031	004	Oct 15, 2014		Apr	DISC
	@	20MG		A079031	001	Jul 13, 2012		Apr	DISC
	@	30MG		A079031	002	Jul 13, 2012		Apr	DISC
	@	40MG		A079031	003	Jul 13, 2012		Apr	DISC
	SOLUTION;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
AA	ALKEM LABS LTD	5MG/5ML		A211647	001	Mar 30, 2020		Mar	NEWA
AA		10MG/5ML		A211647	002	Mar 30, 2020		Mar	NEWA
AA	PATRIN PHARMA INC	5MG/5ML		A210764	001	Apr 10, 2020		Mar	NEWA
AA		10MG/5ML		A210764	002	Apr 10, 2020		Mar	NEWA
	TABLET;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
	@ WATSON LABS	5MG		A040220	001	Aug 29, 1997		Apr	DISC
	@	10MG		A040220	002	Aug 29, 1997		Apr	DISC
	@	20MG		A040220	003	Aug 29, 1997		Apr	DISC
	TABLET, EXTENDED RELEASE;ORAL								
	METHYLPHENIDATE HYDROCHLORIDE								
	@ ACTAVIS LABS FL	18MG		A076772	001	Mar 22, 2018		Mar	DISC

## TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	27MG	A076772	002	Mar 22, 2018	Mar DISC
@	36MG	A076772	003	Mar 22, 2018	Mar DISC
@	54MG	A076655	001	Mar 21, 2018	Mar DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

@	DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984	Mar DISC
---	---------------------	-----	---------	-----	--------------	----------

METOLAZONE

TABLET;ORAL

METOLAZONE

>A>	@ ANI PHARMS INC	2.5MG	A075543	001	Jan 06, 2004	May CMS1
>A>	@	5MG	A075543	002	Mar 01, 2004	May CMS1

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

@	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Mar DISC
@		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Mar DISC
@		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Mar DISC
@		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Mar DISC
@	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Jan DISC
@		EQ 100MG TARTRATE	A077298	001	Apr 15, 2010	Jan DISC
@		EQ 200MG TARTRATE	A077298	002	Apr 15, 2010	Jan DISC
AB	PHARMADAX INC	EQ 25MG TARTRATE	A203028	001	Mar 31, 2020	Mar NEWA
AB		EQ 50MG TARTRATE	A203028	002	Mar 31, 2020	Mar NEWA
AB		EQ 100MG TARTRATE	A203699	001	Mar 30, 2020	Mar NEWA
AB		EQ 200MG TARTRATE	A203699	002	Mar 30, 2020	Mar NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@	HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Feb DISC
@		100MG	A074141	002	Jan 31, 1995	Feb DISC
AB	YOUNGTECH PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan NEWA
AB		50MG	A208955	002	Feb 05, 2020	Jan NEWA
AB		100MG	A208955	003	Feb 05, 2020	Jan NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@	MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan DISC
@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan DISC

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Apr CAHN
AP	NANJING KING-FRIEND	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020	Mar NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

ZILXI

>A>	+!	FOAMIX	EQ 1.5% BASE	N213690	001	May 28, 2020	May NEWA
-----	----	--------	--------------	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012	Feb CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Feb CAHN
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Feb CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Feb CAHN
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Feb CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 50MG BASE	A213662	001	May 01, 2020	Apr NEWA
AB		EQ 75MG BASE	A213662	002	May 01, 2020	Apr NEWA
AB		EQ 100MG BASE	A213662	003	May 01, 2020	Apr NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

@ SAWAI USA 25MG A209446 001 Dec 27, 2019 Jan DISC

MYRBETRIQ

+! APGDI 25MG N202611 001 Jun 28, 2012 Jan CTEC

MITOMYCIN

POWDER;PYELOALYCEAL

JELMYTO

+! UROGEN PHARMA 40MG/VIAL N211728 001 Apr 15, 2020 Apr NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB AMNEAL PHARMS 0.05MG/SPRAY A207989 001 Apr 03, 2017 Mar CPOT

AB APOTEX INC 0.05MG/SPRAY A091161 001 Mar 22, 2016 Mar CPOT

NASONEX

AB +! MERCK SHARP DOHME 0.05MG/SPRAY N020762 001 Oct 01, 1997 Mar CPOT

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

+! BANNER LIFE SCIENCES 95MG N210296 001 Apr 28, 2020 Apr NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB AUROBINDO PHARMA LTD EQ 4MG BASE/PACKET A213471 001 Feb 18, 2020 Feb NEWA

TABLET;ORAL

MONTELUKAST SODIUM

>D> AB CSPC OUYI EQ 10MG BASE A209012 001 Apr 24, 2017 May CAHN

>A> AB GRAVITI PHARMS EQ 10MG BASE A209012 001 Apr 24, 2017 May CAHN

@ HIKMA EQ 10MG BASE A090655 001 Aug 03, 2012 Feb DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB GRAVITI PHARMS EQ 4MG BASE A209011 001 Apr 18, 2017 Apr CAHN

AB EQ 5MG BASE A209011 002 Apr 18, 2017 Apr CAHN

@ JUBILANT GENERICS EQ 4MG BASE A203795 001 Feb 27, 2015 Jan DISC

@ EQ 5MG BASE A203795 002 Feb 27, 2015 Jan DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

+ ALLERGAN 70MG N020616 010 Jul 09, 2012 Apr CTEC

MORPHINE SULFATE

@ TEVA PHARMS USA 20MG A202718 001 Dec 29, 2014 Apr DISC

@ 30MG A202718 002 Dec 29, 2014 Apr DISC

@ 40MG A202718 007 Jun 03, 2015 Apr DISC

@ 50MG A202718 003 Dec 29, 2014 Apr DISC

@ 60MG A202718 004 Dec 29, 2014 Apr DISC

@ 70MG A202718 008 Jun 03, 2015 Apr DISC

@ 80MG A202718 005 Dec 29, 2014 Apr DISC

@ 100MG A202718 006 Dec 29, 2014 Apr DISC

INJECTABLE;INJECTION

DURAMORPH PF

AP +! HIKMA 0.5MG/ML N018565 001 Sep 18, 1984 Feb CAHN

AP +! 1MG/ML N018565 002 Sep 18, 1984 Feb CAHN

INFUMORPH

AP +! HIKMA 10MG/ML N018565 003 Jul 19, 1991 Feb CAHN

AP +! 25MG/ML N018565 004 Jul 19, 1991 Feb CAHN

MORPHINE SULFATE

AP HIKMA 4MG/ML A205758 001 May 21, 2015 Feb CAHN

AP 8MG/ML A205758 002 May 21, 2015 Feb CAHN

AP 10MG/ML A205758 003 May 21, 2015 Feb CAHN

>D> AP HOSPIRA 1MG/ML A071850 001 May 11, 1988 May DISC

>A> @ 1MG/ML A071850 001 May 11, 1988 May DISC

>D> AP +! ICU MEDICAL INC 1MG/ML N019916 001 Oct 30, 1992 May DISC

>A> + @ 1MG/ML N019916 001 Oct 30, 1992 May DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	@ NESHER PHARMS	15MG	A076733	001	May 19, 2004	Mar	DISC
	@	100MG	A077855	001	Sep 27, 2007	Mar	DISC
	@	200MG	A077855	002	Sep 27, 2007	Mar	DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1	GLAND PHARMA LTD	EQ 0.5% BASE	A208778	001	Mar 30, 2020	Mar	NEWA
AT1	MYLAN	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Mar	NEWA

TABLET;ORAL

AVELOX

+ @ BAYER HLTHCARE EQ 400MG BASE  
MOXIFLOXACIN HYDROCHLORIDE

N021085	001	Dec 10, 1999	Apr	DISC
---------	-----	--------------	-----	------

AB	!	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Apr	CHRS
----	---	--------------------	---------------	---------	-----	--------------	-----	------

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB	!	GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CTEC
AB		TARO	EQ 2% BASE	A207116	001	Apr 27, 2020	Apr	NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

	@ TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014	Mar	DISC
	@	360MG	A202720	002	Oct 30, 2014	Mar	DISC

NABILONE

CAPSULE;ORAL

CESAMET

+!	BAUSCH	1MG	N018677	001	Dec 26, 1985	Mar	CAHN
----	--------	-----	---------	-----	--------------	-----	------

NADOLOL

TABLET;ORAL

NADOLOL

	@ VGYAAN	20MG	A212856	001	Sep 13, 2019	Mar	DISC
	@	40MG	A212856	002	Sep 13, 2019	Mar	DISC
	@	80MG	A212856	003	Sep 13, 2019	Mar	DISC

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

>A>	AP	FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	May	NEWA
-----	----	-----------	-------------------	---------	-----	--------------	-----	------

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

	@ MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Feb	DISC
	@	10MG/ML	A207595	001	Jan 11, 2019	Feb	DISC
	@	20MG/ML	A206506	002	Feb 06, 2019	Feb	DISC
	@	20MG/ML	A207595	002	Jan 11, 2019	Feb	DISC

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP		DR REDDYS	1MG/ML	A213209	001	Mar 16, 2020	Mar	NEWA
AP	!	INTL MEDICATION	1MG/ML	A072076	001	Mar 24, 1988	Mar	CTEC
AP		PAR STERILE PRODUCTS	0.4MG/ML	A211286	001	Jan 17, 2020	Jan	NEWA

NAPROXEN

TABLET;ORAL

NAPROXEN

	@ MYLAN	250MG	A074121	001	Dec 21, 1993	Jan	DISC	
	@	375MG	A074121	002	Dec 21, 1993	Jan	DISC	
	@	500MG	A074121	003	Dec 21, 1993	Jan	DISC	
AB		SCIEGEN PHARMS INC	250MG	A212517	001	Feb 21, 2020	Feb	NEWA
AB			375MG	A212517	002	Feb 21, 2020	Feb	NEWA
AB			500MG	A212517	003	Feb 21, 2020	Feb	NEWA

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

@ PLIVA 375MG A075337 001 May 26, 1999 Mar DISC  
 @ 500MG A075337 002 May 26, 1999 Mar DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ TEVA EQ 250MG BASE A074198 001 Dec 21, 1993 Mar DISC  
 @ EQ 500MG BASE A074198 002 Dec 21, 1993 Mar DISC

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

@ ALVOGEN 60MG A205055 001 Dec 11, 2015 Mar DISC  
 @ 120MG A205055 002 Dec 11, 2015 Mar DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA @ BRECKENRIDGE 500MG A065468 001 Mar 29, 2010 Apr DISC  
 XGEN PHARMS 500MG A065220 001 Jul 28, 2006 Feb CAHN

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT WATSON LABS EQ 40MG BASE/ML;200,000 UNITS/ML A062664 001 Apr 08, 1986 Mar CMFD  
 AT XGEN PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML A065106 001 Jan 31, 2006 Feb CAHN  
 AT EQ 40MG BASE/ML;200,000 UNITS/ML A065108 001 Jan 31, 2006 Feb CAHN

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

+! AERIE PHARMS INC EQ 0.02% BASE N208254 001 Dec 18, 2017 Feb CAIN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

@ MYLAN 500MG A203742 001 Feb 22, 2019 Jan DISC  
 @ 750MG A203742 002 Feb 22, 2019 Jan DISC  
 @ 1GM A203742 003 Feb 22, 2019 Jan DISC

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

>D> @ AM REGENT 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 May CMFD  
 >A> 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 May CMFD

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>D> @ EXELA PHARMA SCIENCE 20MG/200ML (0.1MG/ML) N022276 002 Apr 07, 2016 May CMFD  
 >A> 20MG/200ML (0.1MG/ML) N022276 002 Apr 07, 2016 May CMFD  
 >D> @ 40MG/200ML (0.2MG/ML) N022276 003 Apr 07, 2016 May CMFD  
 >A> 40MG/200ML (0.2MG/ML) N022276 003 Apr 07, 2016 May CMFD

NIMODIPINE

SOLUTION;ORAL

NYMALIZE

+ @ ARBOR PHARMS LLC 3MG/ML N203340 001 May 10, 2013 Apr DISC  
 +! 3MG/ML N203340 001 May 10, 2013 Apr CPOT  
 +! 6MG/ML N203340 002 Apr 08, 2020 Apr NEWA

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+! GLAXOSMITHKLINE EQ 100MG BASE N208447 001 Mar 27, 2017 Jan CAHN

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL  
NITRO-DUR

BX	+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Mar	CTEC
BX	+			0.2MG/HR	N020145	002	Apr 04, 1995	Mar	CTEC
BX	+			0.4MG/HR	N020145	004	Apr 04, 1995	Mar	CTEC
BX	+			0.6MG/HR	N020145	005	Apr 04, 1995	Mar	CTEC

TABLET;SUBLINGUAL  
NITROGLYCERIN

	@		ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017	Mar	DISC
	@			0.4MG	A203693	002	Oct 16, 2017	Mar	DISC
	@			0.6MG	A203693	003	Oct 16, 2017	Mar	DISC

NIZATIDINECAPSULE;ORAL  
NIZATIDINE

>D>	AB		MYLAN PHARMS INC	150MG	A075806	001	Jul 05, 2002	May	DISC
>A>		@		150MG	A075806	001	Jul 05, 2002	May	DISC
>D>	AB	!		300MG	A075806	002	Jul 05, 2002	May	DISC
>A>		@		300MG	A075806	002	Jul 05, 2002	May	DISC
>D>	AB		WATSON LABS	300MG	A075616	002	Jul 09, 2002	May	CHRS
>A>	AB	!		300MG	A075616	002	Jul 09, 2002	May	CHRS

NORETHINDRONETABLET;ORAL-28  
NOR-QD

AB1	+	!	TEVA BRANDED PHARM	0.35MG	N017060	001		Jan	CAHN
-----	---	---	--------------------	--------	---------	-----	--	-----	------

NYSTATINPOWDER;TOPICAL  
NYSTATIN

AT			XGEN PHARMS	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Feb	CAHN
----	--	--	-------------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL  
NYSTATIN

>D>		@	SOCORRO	100,000 UNITS/ML	A062832	001	Dec 27, 1991	May	CMFD
>A>	AA			100,000 UNITS/ML	A062832	001	Dec 27, 1991	May	CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDEOINTMENT;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

>D>	AT		VITRUVIAS THERAP	100000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	DISC
>A>		@		100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	CPOT
>A>		@		100000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	May	DISC
AT			ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar	CMFD

OCTREOTIDE ACETATEINJECTABLE;INJECTION  
OCTREOTIDE ACETATE

	@		HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Feb	DISC
	@			EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Feb	DISC
	@			EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Feb	DISC

SANDOSTATIN

>D>	AP	+	!	NOVARTIS	EQ 0.2MG BASE/ML	N019667	004	Jun 12, 1991	May	DISC
>A>		+	@		EQ 0.2MG BASE/ML	N019667	004	Jun 12, 1991	May	DISC
>D>	AP	+	!		EQ 1MG BASE/ML	N019667	005	Jun 12, 1991	May	DISC
>A>		+	@		EQ 1MG BASE/ML	N019667	005	Jun 12, 1991	May	DISC

SOLUTION;SUBCUTANEOUS  
BYNFEZIA PEN

	+	!	SUN PHARM	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N213224	001	Jan 28, 2020	Jan	NEWA
--	---	---	-----------	-------------------------------------	---------	-----	--------------	-----	------

OLANZAPINETABLET;ORAL  
OLANZAPINE

	@		IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Mar	DISC
>D>	AB		JIANGSU HANSON PHARM	2.5MG	A209399	001	Sep 24, 2018	May	DISC
>A>		@		2.5MG	A209399	001	Sep 24, 2018	May	DISC
>D>	AB			5MG	A209399	002	Sep 24, 2018	May	DISC
>A>		@		5MG	A209399	002	Sep 24, 2018	May	DISC
>D>	AB			10MG	A209399	003	Sep 24, 2018	May	DISC
>A>		@		10MG	A209399	003	Sep 24, 2018	May	DISC

TABLET;ORAL

OLANZAPINE

@	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011	Jan	DISC
@		5MG	A076000	002	Oct 24, 2011	Jan	DISC
@		7.5MG	A076000	003	Oct 24, 2011	Jan	DISC
@		10MG	A076000	004	Oct 24, 2011	Jan	DISC
@		15MG	A076000	005	Oct 24, 2011	Jan	DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>A>	AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	NEWA
>A>	AB		20MG	A208659	002	May 18, 2020	May	NEWA
>A>	AB		40MG	A208659	003	May 18, 2020	May	NEWA
	@	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Feb	DISC
	@		20MG	A205482	002	Apr 24, 2017	Feb	DISC
	@		40MG	A205482	003	Apr 24, 2017	Feb	DISC
	AB	SANDOZ INC	5MG	A090237	001	Apr 13, 2020	Mar	NEWA
	AB		20MG	A090237	002	Apr 13, 2020	Mar	NEWA
	AB		40MG	A090237	003	Apr 13, 2020	Mar	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	@	CIPLA	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Mar	DISC
	@		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	DISC
	@	WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020	Mar	DISC
AT			EQ 0.7% BASE	A208637	001	Feb 19, 2020	Feb	NFTG

PAZEO

+	!	NOVARTIS	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Mar	CTEC
AT	+	!	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Feb	CFTG

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan	NEWA
----	--	-------------------	---------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB		CSPC NBP PHARM CO	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211979	001	May 12, 2020	Apr	NEWA
AB		SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Feb	CMFD

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

	@	MYLAN	10MG	A205070	001	Jun 29, 2018	Feb	DISC
	@		20MG	A075876	002	May 29, 2003	Jan	DISC
	@		20MG	A205070	002	Jun 29, 2018	Feb	DISC
	@		40MG	A205070	003	Jun 29, 2018	Feb	DISC
>D>	AB	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017	May	DISC
>A>	@		40MG	A204661	002	Jun 13, 2017	May	DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		GUARDIAN DRUG	20MG;1.1GM	A212587	001	Apr 30, 2020	Apr	NEWA
AB			40MG;1.1GM	A212587	002	Apr 30, 2020	Apr	NEWA

ONDANSETRON

FILM;ORAL

ZUPLENZ

>A>	+	FORTOVIA	4MG	N022524	001	Jul 02, 2010	May	CAHN
>A>	+	!	8MG	N022524	002	Jul 02, 2010	May	CAHN
>D>	+	MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	May	CAHN
>D>	+	!	8MG	N022524	002	Jul 02, 2010	May	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@	BARR	4MG	A076693	001	Jun 25, 2007	Mar	DISC
@		8MG	A076693	002	Jun 25, 2007	Mar	DISC
@	TEVA	4MG	A076810	001	Jun 25, 2007	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
ONDANSETRON

@ 8MG A076810 002 Jun 25, 2007 Mar DISC

ONDANSETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE

>D> AP @ BAXTER HLTHCARE CORP EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Mar DISC  
>A> AP @ EMCURE PHARMS EQ 2MG BASE/ML A090424 001 Apr 16, 2010 May DISC  
>A> AP @ EQ 2MG BASE/ML A090424 001 Apr 16, 2010 May DISC  
AP ! QILU EQ 2MG BASE/ML A203711 001 Sep 08, 2014 Mar CHRS

## TABLET;ORAL

## ONDANSETRON HYDROCHLORIDE

@ MYLAN EQ 4MG BASE A076930 001 Jun 25, 2007 Jan DISC  
@ EQ 8MG BASE A076930 002 Jun 25, 2007 Jan DISC  
@ PLIVA HRVATSKA DOO EQ 4MG BASE A077112 001 Jun 25, 2007 Mar DISC  
@ EQ 8MG BASE A077112 002 Jun 25, 2007 Mar DISC  
@ EQ 24MG BASE A077112 003 Jun 25, 2007 Mar DISC

OPICAPONE

## CAPSULE;ORAL

## ONGENTYS

+ NEUROCRINE 25MG N212489 001 Apr 24, 2020 Apr NEWA  
+! 50MG N212489 002 Apr 24, 2020 Apr NEWA

OSELTAMIVIR PHOSPHATE

## CAPSULE;ORAL

## OSELTAMIVIR PHOSPHATE

>A> AB MSN EQ 30MG BASE A212544 001 May 20, 2020 May NEWA  
>A> AB EQ 45MG BASE A212544 002 May 20, 2020 May NEWA  
>A> AB EQ 75MG BASE A212544 003 May 20, 2020 May NEWA  
AB SUNSHINE LAKE EQ 30MG BASE A212739 001 Mar 04, 2020 Feb NEWA  
AB EQ 45MG BASE A212739 002 Mar 04, 2020 Feb NEWA  
AB EQ 75MG BASE A212739 003 Mar 04, 2020 Feb NEWA

## FOR SUSPENSION;ORAL

## OSELTAMIVIR PHOSPHATE

>A> AB AJANTA PHARMA LTD EQ 6MG BASE/ML A212784 001 May 27, 2020 May NEWA

OSILODROSTAT PHOSPHATE

## TABLET;ORAL

## ISTURISA

+ RECORDATI RARE EQ 1MG BASE N212801 001 Mar 06, 2020 Mar NEWA  
+ EQ 5MG BASE N212801 002 Mar 06, 2020 Mar NEWA  
+! EQ 10MG BASE N212801 003 Mar 06, 2020 Mar NEWA

OXAPROZIN

## TABLET;ORAL

## OXAPROZIN

AB CHARTWELL 600MG A075987 001 Sep 02, 2004 Mar CAHN  
@ IVAX SUB TEVA PHARMS 600MG A075846 001 May 13, 2002 Mar DISC

OXAZEPAM

## CAPSULE;ORAL

## OXAZEPAM

AB FRONTIDA BIOPHARM 10MG A071026 002 Aug 10, 1987 Mar CMFD  
AB 15MG A071026 003 Aug 10, 1987 Mar CMFD  
AB 30MG A071026 001 Aug 10, 1987 Mar CMFD

OXCARBAZEPINE

## TABLET;ORAL

## OXCARBAZEPINE

@ HIKMA 150MG A077795 001 Oct 09, 2007 Feb DISC  
@ 300MG A077795 002 Oct 09, 2007 Feb DISC  
@ 600MG A077795 003 Oct 09, 2007 Feb DISC

OXYBUTYNIN CHLORIDE

## TABLET;ORAL

## OXYBUTYNIN CHLORIDE

AB LEADING PHARMA LLC 5MG A212798 001 Apr 06, 2020 Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

	@ MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006	Jan	DISC
	@	15MG	A076644	002	May 10, 2007	Jan	DISC

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	@ ANI PHARMS INC	100MG/5ML	A203447	001	Aug 30, 2017	Jan	DISC
AA	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020	Jan	NEWA
AA		100MG/5ML	A212429	002	Jan 27, 2020	Jan	NEWA
	@ HIKMA	100MG/5ML	A203208	001	Jul 12, 2013	Feb	DISC
AA	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020	Apr	NEWA

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

	@ NESHER PHARMS	5MG	A077290	001	Dec 08, 2005	Mar	DISC
	@	10MG	A077290	002	Dec 08, 2005	Mar	DISC
	@	15MG	A077290	003	Dec 08, 2005	Mar	DISC
	@	20MG	A077290	004	Dec 08, 2005	Mar	DISC
	@	30MG	A077290	005	Dec 08, 2005	Mar	DISC

ROXYBOND

>D>	@ INSPIRION DELIVERY	5MG	N209777	001	Apr 20, 2017	May	CAHN
>D>	@	15MG	N209777	002	Apr 20, 2017	May	CAHN
>D>	@	30MG	N209777	003	Apr 20, 2017	May	CAHN
>A>	@ OHEMO LIFE	5MG	N209777	001	Apr 20, 2017	May	CAHN
>A>	@	15MG	N209777	002	Apr 20, 2017	May	CAHN
>A>	@	30MG	N209777	003	Apr 20, 2017	May	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013	Mar	DISC
	@	7.5MG	A079046	001	Dec 13, 2010	Mar	DISC
	@	10MG	A079046	004	Jul 11, 2013	Mar	DISC
	@	15MG	A079046	002	Dec 13, 2010	Mar	DISC
	@	20MG	A079046	005	Jul 11, 2013	Mar	DISC
	@	30MG	A079046	006	Jul 11, 2013	Mar	DISC
	@	40MG	A079046	007	Jul 11, 2013	Mar	DISC
>D> AB	SPECGX LLC	5MG	A202946	001	Jun 27, 2014	May	DISC
>A>	@	5MG	A202946	001	Jun 27, 2014	May	DISC
>D> AB		7.5MG	A202946	002	Jun 27, 2014	May	DISC
>A>	@	7.5MG	A202946	002	Jun 27, 2014	May	DISC
>D> AB		10MG	A202946	003	Jun 27, 2014	May	DISC
>A>	@	10MG	A202946	003	Jun 27, 2014	May	DISC
>D> AB		15MG	A202946	004	Jun 27, 2014	May	DISC
>A>	@	15MG	A202946	004	Jun 27, 2014	May	DISC
>D> AB		20MG	A202946	005	Jun 27, 2014	May	DISC
>A>	@	20MG	A202946	005	Jun 27, 2014	May	DISC
>D> AB		30MG	A202946	006	Jun 27, 2014	May	DISC
>A>	@	30MG	A202946	006	Jun 27, 2014	May	DISC
>D> AB		40MG	A202946	007	Jun 27, 2014	May	DISC
>A>	@	40MG	A202946	007	Jun 27, 2014	May	DISC

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+	CELGENE INTL	0.23MG	N209899	001	Mar 25, 2020	Mar	NEWA
+		0.46MG	N209899	002	Mar 25, 2020	Mar	NEWA
+	!	0.92MG	N209899	003	Mar 25, 2020	Mar	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>A> AP	INGENUS PHARMS LLC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	May	NEWA
--------	--------------------	--	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

	@ TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002	Mar	DISC
	@	90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002	Mar	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL  
PANTOPRAZOLE SODIUM

>D>	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012	May	DISC
>A>	@		EQ 20MG BASE	A200821	001	Feb 16, 2012	May	DISC
>D>	AB		EQ 40MG BASE	A200821	002	Feb 16, 2012	May	DISC
>A>	@		EQ 40MG BASE	A200821	002	Feb 16, 2012	May	DISC
>D>	AB	TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007	May	DISC
>A>	@		EQ 20MG BASE	A077056	001	Aug 02, 2007	May	DISC
>D>	AB		EQ 40MG BASE	A077056	002	Aug 02, 2007	May	DISC
>A>	@		EQ 40MG BASE	A077056	002	Aug 02, 2007	May	DISC

PAROXETINE HYDROCHLORIDE

TABLET;ORAL  
PAROXETINE HYDROCHLORIDE

@	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Jan	DISC
@		EQ 20MG BASE	A205528	002	Nov 27, 2015	Jan	DISC
@		EQ 30MG BASE	A205528	003	Nov 27, 2015	Jan	DISC
@		EQ 40MG BASE	A205528	004	Nov 27, 2015	Jan	DISC

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS  
SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012	Feb	CAHN
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012	Feb	CAHN
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012	Feb	CAHN

PASIREOTIDE PAMOATE

FOR SUSPENSION;INTRAMUSCULAR  
SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018	Feb	CAHN
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Feb	CAHN
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018	Feb	CAHN
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Feb	CAHN
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Feb	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL  
VOTRIENT

+	@ NOVARTIS	EQ 400MG BASE	N022465	002	Oct 19, 2009	Jan	CRLD
---	------------	---------------	---------	-----	--------------	-----	------

PEMETREXED

SOLUTION;INTRAVENOUS  
PEMFEXY

+	!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020	Feb	NEWA
---	---	--------------	----------------------	---------	-----	--------------	-----	------

PEMIGATINIB

TABLET;ORAL  
PEMAZYRE

+	INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020	Apr	NEWA
+		9MG	N213736	002	Apr 17, 2020	Apr	NEWA
+	!	13.5MG	N213736	003	Apr 17, 2020	Apr	NEWA

PENICILLAMINE

CAPSULE;ORAL  
PENICILLAMINE

AB	ANI PHARMS INC	250MG	A209921	001	May 07, 2019	Jan	CAHN
AB	APOTEX	250MG	A213310	001	Apr 28, 2020	Apr	NEWA

TABLET;ORAL  
PENICILLAMINE

AB	TEVA PHARMS USA	250MG	A211497	001	Feb 13, 2020	Feb	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

PERMETHRIN

CREAM;TOPICAL  
ELIMITE

+	@ MYLAN	5%	N019855	001	Aug 25, 1989	Feb	DISC	
AB	!	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	Feb	CHRS

PERPHENAZINE

TABLET;ORAL		PERPHENAZINE					
AB	ZYDUS PHARMS	2MG	A205232	001	Apr 06, 2020	Mar	NEWA
AB		4MG	A205232	002	Apr 06, 2020	Mar	NEWA
AB		8MG	A205232	003	Apr 06, 2020	Mar	NEWA
AB		16MG	A205232	004	Apr 06, 2020	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL		PHENDIMETRAZINE TARTRATE					
AA	NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017	Mar	CAHN
AA		35MG	A203600	001	Dec 27, 2017	Mar	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL		PHENTERMINE HYDROCHLORIDE					
	@ BARR	15MG	A090591	001	Mar 18, 2010	Mar	DISC
	@	30MG	A090591	002	Mar 18, 2010	Mar	DISC
TABLET;ORAL		PHENTERMINE HYDROCHLORIDE					
	@ BARR	37.5MG	A090470	001	Aug 31, 2009	Mar	DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS		PHENYLEPHRINE HYDROCHLORIDE					
AP1	RICONPHARMA LLC	10MG/ML (10MG/ML)	A209967	001	Jan 16, 2020	Jan	NEWA
AP1		50MG/5ML (10MG/ML)	A209967	002	Jan 16, 2020	Jan	NEWA
AP1		100MG/10ML (10MG/ML)	A209967	003	Jan 16, 2020	Jan	NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL		EXTENDED PHENYTOIN SODIUM					
	@ LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019	Apr	DISC

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL		PILOCARPINE HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Mar	CMFD
	@	5MG	A212377	001	Aug 13, 2019	Feb	DISC
AB		7.5MG	A212377	002	Aug 13, 2019	Mar	CMFD
	@	7.5MG	A212377	002	Aug 13, 2019	Feb	DISC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL		PIOGLITAZONE HYDROCHLORIDE					
	@ MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Jan	DISC
	@	EQ 30MG BASE	A076801	002	Aug 17, 2012	Jan	DISC
	@	EQ 45MG BASE	A076801	003	Aug 17, 2012	Jan	DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION		PIPERACILLIN AND TAZOBACTAM					
AP	ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr	CMFD
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Apr	CMFD
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr	CMFD

PIROXICAM

CAPSULE;ORAL		PIROXICAM					
AB	STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Mar	CAHN
AB		20MG	A206136	002	Jun 20, 2017	Mar	CAHN

PODOFILOX

SOLUTION;TOPICAL  
CONDYLOX

AT +! TEVA BRANDED PHARM 0.5% N019795 001 Dec 13, 1990 Jan CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION  
AEROSPORIN

@ GLAXOSMITHKLINE EQ 500,000 UNITS BASE/VIAL A062036 001 Jan CMS1  
POLYMYXIN B SULFATE  
AP XGEN PHARMS EQ 500,000 UNITS BASE/VIAL A063000 001 Sep 30, 1994 Feb CAHN

POSACONAZOLE

SUSPENSION;ORAL  
NOXAFIL

>D> +! SCHERING 40MG/ML N022003 001 Sep 15, 2006 May CFTG  
>A> AB +! 40MG/ML N022003 001 Sep 15, 2006 May CFTG  
>A> POSACONAZOLE  
>A> AB HIKMA 40MG/ML A208773 001 May 15, 2020 May NFTG

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MICRO-K

>D> AB + NESHER PHARMS 8MEQ N018238 001 May DISC  
>A> + @ 8MEQ N018238 001 May DISC  
>D> MICRO-K 10  
>D> AB + NESHER PHARMS 10MEQ N018238 002 May 14, 1984 May DISC  
>A> + @ 10MEQ N018238 002 May 14, 1984 May DISC

POTASSIUM CHLORIDE

AB STRIDES PHARMA 8MEQ A205549 001 Dec 08, 2015 Mar CAHN  
AB 10MEQ A205549 002 Dec 08, 2015 Mar CAHN

FOR SUSPENSION, EXTENDED RELEASE;ORAL  
MICRO-K LS

+ @ KV PHARM 20MEQ/PACKET N019561 003 Aug 26, 1988 Feb CRLD

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1 AMNEAL 10MEQ A212861 001 May 08, 2020 Apr NEWA  
AB1 15MEQ A212861 002 May 08, 2020 Apr NEWA  
AB1 20MEQ A212861 003 May 08, 2020 Apr NEWA  
AB2 GRANULES PHARMS 8MEQ A211797 001 Mar 04, 2020 Feb NEWA  
AB2 10MEQ A211797 002 Mar 04, 2020 Feb NEWA  
@ STRIDES PHARMA 8MEQ A206881 001 Jan 22, 2019 Feb CAHN  
@ 10MEQ A206881 002 Jan 22, 2019 Feb CAHN  
@ 10MEQ A210097 001 Jun 17, 2019 Feb CAHN  
@ 20MEQ A210098 001 Apr 26, 2019 Feb CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CITRATE

AB RISING 5MEQ A077440 001 Jun 09, 2006 Apr CAHN  
AB 10MEQ A077440 002 Jun 09, 2006 Apr CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>D> AB CSPC OUYI 0.25MG A211088 001 Oct 03, 2018 May CAHN  
>D> AB 0.5MG A211088 002 Oct 03, 2018 May CAHN  
>D> AB 0.75MG A211088 003 Oct 03, 2018 May CAHN  
>D> AB 1MG A211088 004 Oct 03, 2018 May CAHN  
>D> AB 1.5MG A211088 005 Oct 03, 2018 May CAHN  
>A> AB GRAVITI PHARMS 0.25MG A211088 001 Oct 03, 2018 May CAHN  
>A> AB 0.5MG A211088 002 Oct 03, 2018 May CAHN  
>A> AB 0.75MG A211088 003 Oct 03, 2018 May CAHN  
>A> AB 1MG A211088 004 Oct 03, 2018 May CAHN  
>A> AB 1.5MG A211088 005 Oct 03, 2018 May CAHN  
@ HERITAGE PHARMA 0.125MG A077724 001 Feb 19, 2008 Apr DISC  
@ 0.25MG A077724 002 Feb 19, 2008 Apr DISC  
@ 0.5MG A077724 003 Feb 19, 2008 Apr DISC  
@ 1MG A077724 004 Feb 19, 2008 Apr DISC  
@ 1.5MG A077724 005 Feb 19, 2008 Apr DISC  
@ MYLAN 0.125MG A077854 001 Oct 08, 2010 Jan DISC

<u>TABLET;ORAL</u>							
PRAMIPEXOLE DIHYDROCHLORIDE							
	@	0.25MG		A077854	002	Oct 08, 2010	Jan DISC
	@	0.5MG		A077854	003	Oct 08, 2010	Jan DISC
	@	0.75MG		A090764	001	Apr 09, 2010	Jan DISC
	@	1MG		A077854	004	Oct 08, 2010	Jan DISC
	@	1.5MG		A077854	005	Oct 08, 2010	Jan DISC
AB	ZENNOVA	0.125MG		A090151	001	Apr 30, 2012	Feb CAHN
AB		0.25MG		A090151	002	Apr 30, 2012	Feb CAHN
AB		0.5MG		A090151	003	Apr 30, 2012	Feb CAHN
AB		0.75MG		A090151	006	Apr 30, 2012	Feb CAHN
AB		1MG		A090151	004	Apr 30, 2012	Feb CAHN
AB		1.5MG		A090151	005	Apr 30, 2012	Feb CAHN
<u>PREDNICARBATE</u>							
CREAM;TOPICAL							
DERMATOP E EMOLLIENT							
	+ @	VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993	Apr DISC
PREDNICARBATE							
	@	FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006	Apr DISC
OINTMENT;TOPICAL							
DERMATOP							
	+ @	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Feb DISC
PREDNICARBATE							
	!	FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Feb CTEC
AB	!		0.1%	A077236	001	Mar 09, 2007	Feb CHRS
<u>PREDNISOLONE ACETATE</u>							
SUSPENSION/DROPS;OPHTHALMIC							
OMNIPRED							
AB	+!	NOVARTIS	1%	N017469	001		Jan CHRS
AB	+		1%	N017469	001		Jan CRLD
<u>PREDNISOLONE SODIUM PHOSPHATE</u>							
SOLUTION;ORAL							
PREDNISOLONE SODIUM PHOSPHATE							
		PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020	Feb NEWA
<u>PREDNISON</u>							
TABLET, DELAYED RELEASE;ORAL							
PREDNISON							
	@	ACTAVIS LABS FL INC	1MG	A204867	001	Apr 25, 2017	Apr DISC
	@		2MG	A204867	002	Apr 25, 2017	Apr DISC
	@		5MG	A204867	003	Apr 25, 2017	Apr DISC
RAYOS							
	+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr CTEC
	+		2MG	N202020	002	Jul 26, 2012	Apr CTEC
	+!		5MG	N202020	003	Jul 26, 2012	Apr CTEC
<u>PREGABALIN</u>							
CAPSULE;ORAL							
PREGABALIN							
AB	CELLTRION	50MG		A212865	001	Mar 20, 2020	Mar NEWA
AB		75MG		A212865	002	Mar 20, 2020	Mar NEWA
AB		100MG		A212865	003	Mar 20, 2020	Mar NEWA
AB		150MG		A212865	004	Mar 20, 2020	Mar NEWA
AB	HIKAL	25MG		A213423	001	Mar 23, 2020	Mar NEWA
AB		50MG		A213423	002	Mar 23, 2020	Mar NEWA
AB		75MG		A213423	003	Mar 23, 2020	Mar NEWA
AB		100MG		A213423	004	Mar 23, 2020	Mar NEWA
AB		150MG		A213423	005	Mar 23, 2020	Mar NEWA
AB		200MG		A213423	006	Mar 23, 2020	Mar NEWA
AB		225MG		A213423	007	Mar 23, 2020	Mar NEWA
AB		300MG		A213423	008	Mar 23, 2020	Mar NEWA
	@	MYLAN	25MG	A091228	001	Sep 20, 2019	Feb DISC
	@		50MG	A091228	002	Sep 20, 2019	Feb DISC
	@		75MG	A091228	003	Sep 20, 2019	Feb DISC
	@		100MG	A091228	004	Sep 20, 2019	Feb DISC
	@		150MG	A091228	005	Sep 20, 2019	Feb DISC
	@		200MG	A091228	006	Sep 20, 2019	Feb DISC
	@		225MG	A091228	007	Sep 20, 2019	Feb DISC
	@		300MG	A091228	008	Sep 20, 2019	Feb DISC

PROCHLORPERAZINE MALEATE

	TABLET; ORAL							
	COMPazine							
	+ @ GLAXOSMITHKLINE	EQ 5MG BASE	N010571	001				Mar CRLD
	+ @	EQ 10MG BASE	N010571	002				Mar CRLD
	+ @	EQ 25MG BASE	N010571	003				Mar CRLD
	PROCHLORPERAZINE MALEATE							
	@ SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996			Mar DISC
	@	EQ 10MG BASE	A040101	002	Jul 19, 1996			Mar DISC
	PROCOMP							
AB	! JUBILANT CADISTA	EQ 10MG BASE	A040268	002	Feb 27, 1998			Mar CHRS

PROGESTERONE

	SYSTEM; VAGINAL							
	MILPROSA							
	+! FERRING PHARMS INC	1.78GM	N201110	001	Apr 29, 2020			Apr NEWA

PROMETHAZINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	PROMETHAZINE HYDROCHLORIDE							
AP	XGEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008			Feb CAHN
AP		50MG/ML	A040737	002	Apr 24, 2008			Feb CAHN
	SUPPOSITORY; RECTAL							
	PROMETHAZINE HYDROCHLORIDE							
	@ WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003			Mar DISC
	@	25MG	A040479	002	Jun 24, 2003			Mar DISC

PYRAZINAMIDE

	TABLET; ORAL							
	PYRAZINAMIDE							
	! AKORN	500MG	A081319	001	Jun 30, 1992			Feb CHRS
		500MG	A081319	001	Jun 30, 1992			Feb CTEC
	@ DAVA PHARMS INC	500MG	A080157	001				Feb DISC

PYRIMETHAMINE

	TABLET; ORAL							
	DARAPRIM							
AB	+! VYERA PHARMS LLC	25MG	N008578	001				Feb CFTG
	PYRIMETHAMINE							
AB	CEROVENE INC	25MG	A207127	001	Feb 28, 2020			Feb NFTG

QUETIAPINE FUMARATE

	TABLET; ORAL							
	QUETIAPINE FUMARATE							
AB	ZENNOVA	EQ 25MG BASE	A090960	001	Mar 27, 2012			Feb CAHN
AB		EQ 50MG BASE	A090960	002	Mar 27, 2012			Feb CAHN
AB		EQ 100MG BASE	A090960	003	Mar 27, 2012			Feb CAHN
AB		EQ 200MG BASE	A090960	004	Mar 27, 2012			Feb CAHN
AB		EQ 300MG BASE	A090960	005	Mar 27, 2012			Feb CAHN
AB		EQ 400MG BASE	A090960	006	Mar 27, 2012			Feb CAHN

QUINAPRIL HYDROCHLORIDE

	TABLET; ORAL							
	QUINAPRIL HYDROCHLORIDE							
	@ MYLAN	EQ 5MG BASE	A076694	001	Dec 23, 2004			Mar DISC
	@	EQ 10MG BASE	A076694	002	Dec 23, 2004			Mar DISC
	@	EQ 20MG BASE	A076694	003	Dec 23, 2004			Mar DISC
	@	EQ 40MG BASE	A076694	004	Dec 23, 2004			Mar DISC

QUINIDINE SULFATE

	TABLET; ORAL							
	QUINIDINE SULFATE							
>D>	AB SANDOZ	200MG	A088072	002				May CTEC
>A>	!	200MG	A088072	002				May CHRS
>A>		200MG	A088072	002				May CTEC
	!	300MG	A088072	001	Sep 26, 1983			Apr CHRS
		300MG	A088072	001	Sep 26, 1983			Apr CTEC
	@ WATSON LABS	200MG	A083288	001				Apr DISC
	@	300MG	A085583	001				Apr DISC

RAMELTEON

TABLET;ORAL  
 RAMELTEON  
 AB I3 PHARMS 8MG A212650 001 Apr 10, 2020 Mar NEWA

RAMIPRIL

CAPSULE;ORAL  
 RAMIPRIL  
 @ TEVA PHARMS 1.25MG A077470 001 Jun 18, 2008 Mar DISC  
 @ 2.5MG A077470 002 Jun 18, 2008 Mar DISC  
 @ 5MG A077470 003 Jun 18, 2008 Mar DISC  
 @ 10MG A077470 004 Jun 18, 2008 Mar DISC

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL  
 RANITIDINE HYDROCHLORIDE  
 >D> AB APPCO EQ 150MG BASE A211893 001 Apr 05, 2019 May DISC  
 >A> @ EQ 150MG BASE A211893 001 Apr 05, 2019 May DISC  
 >D> AB EQ 300MG BASE A211893 002 Apr 05, 2019 May DISC  
 >A> @ EQ 300MG BASE A211893 002 Apr 05, 2019 May DISC  
 SYRUP;ORAL  
 RANITIDINE HYDROCHLORIDE  
 >D> AA @ AMNEAL PHARMS EQ 15MG BASE/ML A078312 001 Sep 02, 2008 Apr DISC  
 >A> HI TECH PHARMA EQ 15MG BASE/ML A091078 001 Mar 22, 2011 May DISC  
 >D> AA @ EQ 15MG BASE/ML A091078 001 Mar 22, 2011 May DISC  
 >A> TARO EQ 15MG BASE/ML A077476 001 Jun 13, 2011 May DISC  
 >A> @ EQ 15MG BASE/ML A077476 001 Jun 13, 2011 May DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE  
 @ AMNEAL PHARMS NY EQ 150MG BASE A077824 001 Oct 13, 2006 Jan DISC  
 @ EQ 300MG BASE A077824 002 Oct 13, 2006 Jan DISC  
 @ HERITAGE PHARMA EQ 150MG BASE A075165 001 Sep 30, 1998 Apr DISC  
 @ EQ 300MG BASE A075165 002 Sep 30, 1998 Apr DISC  
 @ STRIDES PHARMA EQ 150MG BASE A205512 001 Aug 22, 2016 Apr DISC  
 @ EQ 150MG BASE A210010 001 Aug 01, 2018 Jan DISC  
 @ EQ 300MG BASE A205512 002 Aug 22, 2016 Apr DISC  
 AB ! EQ 300MG BASE A205512 002 Aug 22, 2016 Jan CHRS  
 @ EQ 300MG BASE A210010 002 Aug 01, 2018 Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL  
 RANOLAZINE  
 AB ANI PHARMS INC 500MG A210482 001 Oct 29, 2019 Jan CAHN  
 AB 1GM A210482 002 Oct 29, 2019 Jan CAHN  
 AB MANKIND PHARMA 500MG A212284 001 Feb 12, 2020 Jan NEWA  
 AB 1GM A212284 002 Feb 12, 2020 Jan NEWA  
 AB MICRO LABS 500MG A211745 001 Feb 27, 2020 Feb NEWA  
 AB 1GM A211745 002 Feb 27, 2020 Feb NEWA  
 AB SUNGEN PHARMA 500MG A212781 001 Mar 23, 2020 Mar NEWA  
 AB 1GM A212781 002 Mar 23, 2020 Mar NEWA  
 AB SUNSHINE LAKE 500MG A211865 001 Mar 23, 2020 Mar NEWA  
 AB 1GM A211865 002 Mar 23, 2020 Mar NEWA

RASAGILINE MESYLATE

TABLET;ORAL  
 RASAGILINE MESYLATE  
 @ WATSON LABS INC EQ 0.5MG BASE A201823 001 Jul 01, 2013 Mar DISC  
 @ EQ 1MG BASE A201823 002 Jul 01, 2013 Mar DISC

REPAGLINIDE

TABLET;ORAL  
 REPAGLINIDE  
 @ ACTAVIS TOTOWA 0.5MG A090008 001 Jan 22, 2014 Mar DISC  
 @ 1MG A090008 002 Jan 22, 2014 Mar DISC  
 @ 2MG A090008 003 Jan 22, 2014 Mar DISC

RIBAVIRIN

CAPSULE;ORAL

RIBASPHERE

@	KADMON PHARMS LLC	200MG	A076203	001	Apr 06, 2004	Feb	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

RIBAVIRIN

@	TEVA	200MG	A076277	001	Oct 04, 2004	Mar	DISC
---	------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

RIBAVIRIN

@	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb	DISC
---	--------------------	-------	---------	-----	--------------	-----	------

@		400MG	A202546	002	Aug 12, 2014	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@		500MG	A202546	003	Aug 12, 2014	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@		600MG	A202546	004	Aug 12, 2014	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@	KADMON PHARMS LLC	200MG	A077456	001	Dec 05, 2005	Feb	DISC
---	-------------------	-------	---------	-----	--------------	-----	------

@		400MG	A077456	002	Dec 05, 2005	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@		600MG	A077456	003	Dec 05, 2005	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@	ZYDUS PHARMS USA	400MG	A077094	002	Mar 16, 2007	Feb	DISC
---	------------------	-------	---------	-----	--------------	-----	------

@		500MG	A077094	004	Apr 18, 2008	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

@		600MG	A077094	003	Mar 16, 2007	Feb	DISC
---	--	-------	---------	-----	--------------	-----	------

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

>D>	AP	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	May	DISC
-----	----	-------------------	------------	---------	-----	--------------	-----	------

>A>		@	600MG/VIAL	A204101	001	Aug 18, 2014	May	DISC
-----	--	---	------------	---------	-----	--------------	-----	------

RILUZOLE

TABLET;ORAL

RILUZOLE

AB		KENTON	50MG	A206045	001	Dec 09, 2019	Mar	CAHN
----	--	--------	------	---------	-----	--------------	-----	------

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

NURTEC ODT

+	!	BIOHAVEN PHARM	EQ 75MG BASE	N212728	001	Feb 27, 2020	Feb	NEWA
---	---	----------------	--------------	---------	-----	--------------	-----	------

>A> RIPRETINIB

&gt;A&gt; TABLET;ORAL

&gt;A&gt; QINLOCK

>A>	+	!	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020	May	NEWA
-----	---	---	------------------	------	---------	-----	--------------	-----	------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

@	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011	Mar	DISC
---	---------------------	-------	---------	-----	--------------	-----	------

@		1MG	A076996	002	Apr 19, 2011	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		2MG	A076996	003	Apr 19, 2011	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		3MG	A076996	004	Apr 19, 2011	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@		4MG	A076996	005	Apr 19, 2011	Mar	DISC
---	--	-----	---------	-----	--------------	-----	------

@	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	Apr	DISC
---	-----------------	-------	---------	-----	--------------	-----	------

@		1MG	A076908	002	Mar 12, 2012	Apr	DISC
---	--	-----	---------	-----	--------------	-----	------

@		2MG	A076908	003	Mar 12, 2012	Apr	DISC
---	--	-----	---------	-----	--------------	-----	------

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

YUTOPAR

@	ASTRAZENECA	15MG/ML	N018580	002	Sep 27, 1984	Jan	CMS1
---	-------------	---------	---------	-----	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

>D>	AB	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013	May	DISC
-----	----	------------	---------------	---------	-----	--------------	-----	------

>A>		@	EQ 1.5MG BASE	A091072	001	May 16, 2013	May	DISC
-----	--	---	---------------	---------	-----	--------------	-----	------

>D>	AB		EQ 3MG BASE	A091072	002	May 16, 2013	May	DISC
-----	----	--	-------------	---------	-----	--------------	-----	------

>A>		@	EQ 3MG BASE	A091072	002	May 16, 2013	May	DISC
-----	--	---	-------------	---------	-----	--------------	-----	------

>D>	AB		EQ 4.5MG BASE	A091072	003	May 16, 2013	May	DISC
-----	----	--	---------------	---------	-----	--------------	-----	------

>A>		@	EQ 4.5MG BASE	A091072	003	May 16, 2013	May	DISC
-----	--	---	---------------	---------	-----	--------------	-----	------

>D>	AB		EQ 6MG BASE	A091072	004	May 16, 2013	May	DISC
-----	----	--	-------------	---------	-----	--------------	-----	------

>A>		@	EQ 6MG BASE	A091072	004	May 16, 2013	May	DISC
-----	--	---	-------------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL  
RIZATRIPTAN BENZOATE

@ MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012	Feb	DISC
@	EQ 10MG BASE	A078173	002	Dec 31, 2012	Feb	DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ROCURONIUM BROMIDE

@ TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008	Mar	DISC
@	100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008	Mar	DISC

ROFLUMILAST

TABLET;ORAL  
ROFLUMILAST

AB	STRIDES PHARMA	500MCG	A208247	001	Mar 30, 2020	Mar	NEWA
----	----------------	--------	---------	-----	--------------	-----	------

ROMIDEPSIN

SOLUTION;INTRAVENOUS  
ROMIDEPSIN

+	TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574	001	Mar 13, 2020	Mar	NEWA
+	!	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Mar	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL  
ROPINIROLE HYDROCHLORIDE

@ HIKMA	EQ 0.25MG BASE	A077852	001	May 05, 2008	Feb	DISC
@	EQ 0.5MG BASE	A077852	002	May 05, 2008	Feb	DISC
@	EQ 1MG BASE	A077852	003	May 05, 2008	Feb	DISC
@	EQ 2MG BASE	A077852	004	May 05, 2008	Feb	DISC
@	EQ 3MG BASE	A077852	005	May 05, 2008	Feb	DISC
@	EQ 4MG BASE	A077852	006	May 05, 2008	Feb	DISC
@	EQ 5MG BASE	A077852	007	May 19, 2008	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

+	@ GLAXOSMITHKLINE LLC	EQ 8MG BASE	N022008	004	Jun 13, 2008	Mar	DISC
---	-----------------------	-------------	---------	-----	--------------	-----	------

ROPINIROLE HYDROCHLORIDE

@ WATSON LABS INC	EQ 2MG BASE	A200431	001	Jun 06, 2012	Mar	DISC
@	EQ 4MG BASE	A200431	002	Jun 06, 2012	Mar	DISC
@	EQ 6MG BASE	A200431	003	Jun 06, 2012	Mar	DISC
@	EQ 8MG BASE	A200431	004	Jun 06, 2012	Mar	DISC
@	EQ 12MG BASE	A200431	005	Jun 06, 2012	Mar	DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION  
ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020	Mar	NEWA
AP		100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020	Mar	NEWA
AP		150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020	Mar	NEWA
AP		200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020	Mar	NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL  
ROSUVASTATIN CALCIUM

AB	SUNSHINE LAKE	5MG	A210667	001	Apr 01, 2020	Mar	NEWA
AB		10MG	A210667	002	Apr 01, 2020	Mar	NEWA
AB		20MG	A210667	003	Apr 01, 2020	Mar	NEWA
AB		40MG	A210667	004	Apr 01, 2020	Mar	NEWA
@	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr	DISC
@		10MG	A212059	002	Nov 04, 2019	Apr	DISC
@		20MG	A212059	003	Nov 04, 2019	Apr	DISC
@		40MG	A212059	004	Nov 04, 2019	Apr	DISC

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL  
SELEGILINE HYDROCHLORIDE

@ DAVA PHARMS INC	5MG	A075352	001	Nov 30, 1998	Feb	DISC
-------------------	-----	---------	-----	--------------	-----	------

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ MLV	5MG	A074672	001	Apr 01, 1997	Mar	CAHN
-------	-----	---------	-----	--------------	-----	------

SELEXIPAG

TABLET;ORAL  
UPTRAVI

+!	ACTELION PHARMS LTD	0.4MG	N207947	002	Dec 21, 2015	Jan	CHRS
+		1.6MG	N207947	008	Dec 21, 2015	Jan	CHRS

>A> SELPERCATINIB

CAPSULE;ORAL  
RETEVMO

>A>	+	LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020	May	NEWA
>A>	+!		80MG	N213246	002	May 08, 2020	May	NEWA

SELUMETINIB SULFATE

CAPSULE;ORAL  
KOSELUGO

+	ASTRAZENECA PHARMS	EQ 10MG BASE	N213756	001	Apr 10, 2020	Apr	NEWA
+!		EQ 25MG BASE	N213756	002	Apr 10, 2020	Apr	NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS  
OZEMPIC

+!	NOVO	4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019	Jan	NEWA
----	------	---------------------	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL  
SERTRALINE HYDROCHLORIDE

AB	VIWIT PHARM	EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar	CAHN
AB		EQ 25MG BASE	A076882	001	Feb 06, 2007	Mar	CAHN
AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar	CAHN
AB		EQ 50MG BASE	A076882	002	Feb 06, 2007	Mar	CAHN
AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar	CAHN
AB		EQ 100MG BASE	A076882	003	Feb 06, 2007	Mar	CAHN

SEVELAMER CARBONATE

TABLET;ORAL  
SEVELAMER CARBONATE

AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar	NEWA
----	-------	-------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL  
SILDENAFIL CITRATE

>A>	AB	TEVA PHARMS USA	EQ 10MG BASE/ML	A211534	001	May 29, 2020	May	NEWA
-----	----	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL  
SILDENAFIL CITRATE

AB	APPCO	EQ 25MG BASE	A207178	001	Mar 02, 2020	Apr	CPOT
AB		25MG	A207178	001	Mar 02, 2020	Feb	NEWA
AB		EQ 50MG BASE	A207178	002	Mar 02, 2020	Apr	CPOT
AB		50MG	A207178	002	Mar 02, 2020	Feb	NEWA
AB		EQ 100MG BASE	A207178	003	Mar 02, 2020	Apr	CPOT
AB		100MG	A207178	003	Mar 02, 2020	Feb	NEWA
AB	PERRIGO R AND D	EQ 25MG BASE	A205791	001	Apr 23, 2020	Apr	NEWA
AB		EQ 50MG BASE	A205791	002	Apr 23, 2020	Apr	NEWA

SILODOSIN

CAPSULE;ORAL  
SILODOSIN

AB	HETERO LABS LTD V	4MG	A204793	001	Feb 14, 2020	Feb	NEWA
AB		8MG	A204793	002	Feb 14, 2020	Feb	NEWA

SODIUM CHLORIDE

INJECTABLE;INJECTION  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	NEPHRON	9MG/ML	A211968	001	Apr 23, 2020	Apr	NEWA
----	---------	--------	---------	-----	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE;ORAL  
SODIUM IODIDE I 123

AA	CURIUM	100uCi	A071909	001	Feb 28, 1989	Feb	CAHN
AA		200uCi	A071910	001	Feb 28, 1989	Feb	CAHN

SODIUM IODIDE I-131

	SOLUTION;ORAL							
	HICON							
AA	+!	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan	CFTG
		SODIUM IODIDE I 131						
AA		INTL ISOTOPES	250-1000mCi	A209166	001	Feb 05, 2020	Jan	NFTG

SODIUM PHENYLBUTYRATE

	TABLET;ORAL							
	SODIUM PHENYLBUTYRATE							
	@	ALVOGEN	500MG	A090910	001	Nov 18, 2011	Jan	DISC

SODIUM POLYSTYRENE SULFONATE

	SUSPENSION;ORAL, RECTAL							
	SODIUM POLYSTYRENE SULFONATE							
	@	HIKMA	15GM/60ML	A089049	001	Nov 17, 1986	Feb	DISC

SOFOSBUVIR; VELPATASVIR

	TABLET;ORAL							
	EPCLUSA							
	+	GILEAD SCIENCES INC	200MG;50MG	N208341	002	Mar 19, 2020	Mar	NEWA

SOLIFENACIN SUCCINATE

>A>	SUSPENSION;ORAL							
>A>	VESICARE LS							
>A>	+!	ASTELLAS	1MG/ML	N209529	001	May 26, 2020	May	NEWA
	TABLET;ORAL							
	SOLIFENACIN SUCCINATE							
>D>	AB	CSPC OUYI	5MG	A211423	001	Dec 11, 2019	May	CAHN
>D>	AB		10MG	A211423	002	Dec 11, 2019	May	CAHN
>A>	AB	GRAVITI PHARMS	5MG	A211423	001	Dec 11, 2019	May	CAHN
>A>	AB		10MG	A211423	002	Dec 11, 2019	May	CAHN
	AB	SUNSHINE LAKE	5MG	A213346	001	Apr 13, 2020	Mar	NEWA
	AB		10MG	A213346	002	Apr 13, 2020	Mar	NEWA

SOLRIAMFETOL HYDROCHLORIDE

	TABLET;ORAL							
	SUNOSI							
	+	JAZZ	EQ 75MG BASE	N211230	001	Jun 17, 2019	Jan	CPOT
	+		75MG	N211230	001	Jun 17, 2019	Jan	CAIN
	+!		EQ 150MG BASE	N211230	002	Jun 17, 2019	Apr	CHRS
	+		EQ 150MG BASE	N211230	002	Jun 17, 2019	Jan	CPOT
	+		150MG	N211230	002	Jun 17, 2019	Jan	CAIN

STREPTOMYCIN SULFATE

	INJECTABLE;INJECTION							
	STREPTOMYCIN SULFATE							
	!	XGEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998	Feb	CAHN

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE;INJECTION							
	QUELICIN PRESERVATIVE FREE							
	+	@ HOSPIRA	50MG/ML	N008845	002		Apr	CRLD
	+	@	100MG/ML	N008845	004		Apr	CRLD
	SUCCINYLCHOLINE CHLORIDE							
>A>	AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	May	NEWA
	AP	ASPIRO	20MG/ML	A213810	001	May 04, 2020	Apr	NEWA
>A>	AP	INDOCO REMEDIES	20MG/ML	A214308	001	May 22, 2020	May	NEWA
>A>	AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	May	NEWA
	SUOOSTRIN							
	+	@ APOTHECON	20MG/ML	N008847	001		Apr	CRLD
	+	@	100MG/ML	N008847	003		Apr	CRLD

SUCRALFATE

	TABLET;ORAL							
	SUCRALFATE							
>D>	@	NOSTRUM LABS INC	1GM	A074415	001	Jun 08, 1998	May	CMFD
>A>	AB		1GM	A074415	001	Jun 08, 1998	May	CMFD

<u>SULFACETAMIDE SODIUM</u>							
LOTION;TOPICAL							
KLARON							
AB	+	BAUSCH	10%	N019931	001	Dec 23, 1996	Mar CAHN
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>							
INJECTABLE; INJECTION							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AP		TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Mar CMFD
<u>SUMATRIPTAN SUCCINATE</u>							
TABLET;ORAL							
SUMATRIPTAN SUCCINATE							
AB		COREPHARMA	EQ 25MG BASE	A200263	001	Jun 19, 2012	Feb CAHN
AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Feb CAHN
AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Feb CAHN
<u>TAMSULOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
TAMSULOSIN HYDROCHLORIDE							
	@	ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Apr DISC
<u>TAPENTADOL HYDROCHLORIDE</u>							
SOLUTION;ORAL							
NUCYNTA							
	+	@ COLLEGIUM PHARM INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	Feb CAHN
TABLET;ORAL							
NUCYNTA							
	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	Feb CAHN
	+		EQ 75MG BASE	N022304	002	Nov 20, 2008	Feb CAHN
	+		EQ 100MG BASE	N022304	003	Nov 20, 2008	Feb CAHN
TABLET, EXTENDED RELEASE;ORAL							
NUCYNTA ER							
	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	Feb CAHN
	+		EQ 100MG BASE	N200533	002	Aug 25, 2011	Feb CAHN
	+		EQ 150MG BASE	N200533	003	Aug 25, 2011	Feb CAHN
	+		EQ 200MG BASE	N200533	004	Aug 25, 2011	Feb CAHN
	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	Feb CAHN
<u>TAZEMETOSTAT HYDROBROMIDE</u>							
TABLET;ORAL							
TAZVERIK							
	+	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020	Jan NEWA
<u>TECHNETIUM TC-99M DISOFENIN KIT</u>							
INJECTABLE; INJECTION							
HEPATOLITE							
	@	SUN PHARM INDS INC	N/A	N018467	001	Mar 16, 1982	Apr CAHN
<u>TECHNETIUM TC-99M MEBROFENIN KIT</u>							
INJECTABLE; INJECTION							
TECHNETIUM TC-99M MEBROFENIN							
AP		SUN PHARM INDS INC	N/A	A078242	001	Jan 29, 2008	Apr CAHN
<u>TECHNETIUM TC-99M MEDRONATE KIT</u>							
INJECTABLE; INJECTION							
CIS-MDP							
		SUN PHARM INDS INC	N/A	N018124	001		Apr CAHN
<u>TECHNETIUM TC-99M MERTIATIDE KIT</u>							
INJECTABLE; INJECTION							
TECHNETIUM TC99M MERTIATIDE KIT							
AP		SOMMER PHARMS II LLC	N/A	A206489	001	Feb 06, 2020	Jan NEWA
AP		SUN PHARM INDS INC	N/A	A208994	001	Jul 12, 2019	Apr CAHN

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION  
CIS-PYRO

AP	SUN PHARM INDS INC	N/A	N019039	001	Jun 30, 1987	Apr	CAHN
----	--------------------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION  
TECHNETIUM TC 99M SESTAMIBI

AP	CURIUM	N/A	A078098	001	Sep 22, 2008	Feb	CAHN
AP	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	Apr	CAHN

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL  
AN-SULFUR COLLOID

+!	SUN PHARM INDS INC	N/A	N017858	001		Apr	CAHN
----	--------------------	-----	---------	-----	--	-----	------

TELMISARTAN

TABLET; ORAL  
TELMISARTAN

	@ JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Jan	DISC
	@	40MG	A204164	002	Aug 22, 2016	Jan	DISC
	@	80MG	A204164	003	Aug 22, 2016	Jan	DISC
AB	MICRO LABS	20MG	A207016	001	Oct 03, 2017	Apr	CMFD
AB		40MG	A207016	002	Oct 03, 2017	Apr	CMFD
AB		80MG	A207016	003	Oct 03, 2017	Apr	CMFD

TENAPANOR HYDROCHLORIDE

TABLET; ORAL  
IBSRELA

+ @	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Mar	DISC
-----	-------------	--------------	---------	-----	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
TENOFOVIR DISOPROXIL FUMARATE

@	MYLAN	150MG	A206569	001	Nov 27, 2018	Feb	DISC
@		200MG	A206569	002	Nov 27, 2018	Feb	DISC
@		250MG	A206569	003	Nov 27, 2018	Feb	DISC
@		300MG	A206569	004	Nov 27, 2018	Feb	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL  
TERAZOSIN HYDROCHLORIDE

@	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Feb	DISC
@		EQ 2MG BASE	A075614	001	Jan 30, 2001	Feb	DISC
@		EQ 5MG BASE	A075614	003	Jan 30, 2001	Feb	DISC
@		EQ 10MG BASE	A075614	004	Jan 30, 2001	Feb	DISC

TERIFLUNOMIDE

TABLET; ORAL  
TERIFLUNOMIDE

	@ MYLAN	7MG	A209702	001	Feb 28, 2020	Mar	DISC
AB		7MG	A209702	001	Feb 28, 2020	Feb	NEWA
	@	14MG	A209702	002	Feb 28, 2020	Mar	DISC
AB		14MG	A209702	002	Feb 28, 2020	Feb	NEWA

TERIPARATIDE

INJECTABLE; SUBCUTANEOUS  
FORTEO

+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CAIN
@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CAIN

SOLUTION; SUBCUTANEOUS  
BONSITY

	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Jan	CAIN
--	---------	---------------------------	---------	-----	--------------	-----	------

FORTEO

+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Jan	CDFR
@		0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002	Jan	CDFR

TESTOSTERONE

	GEL, METERED; TRANSDERMAL						
	ANDROGEL						
	+ @	ABBVIE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Mar DISC
	TESTOSTERONE						
BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar CHRS
BX			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Mar CTEC
AB		XIROMED	1.62% (20.25MG/1.25GM ACTUATION)	A210835	001	Apr 16, 2020	Apr NEWA

TETRABENAZINE

	TABLET; ORAL						
	TETRABENAZINE						
AB		APOTEX	12.5MG	A206093	001	Mar 17, 2020	Mar NEWA
AB			25MG	A206093	002	Mar 17, 2020	Mar NEWA
AB		PIRAMAL HLTHCARE UK	12.5MG	A213316	001	Jan 22, 2020	Jan NEWA
AB			25MG	A213316	002	Jan 22, 2020	Jan NEWA

TETRACYCLINE HYDROCHLORIDE

	CAPSULE; ORAL						
	TETRACYCLINE HYDROCHLORIDE						
AB		STRIDES PHARMA	250MG	A212635	001	Mar 03, 2020	Feb NEWA
AB			500MG	A212635	002	Mar 03, 2020	Feb NEWA

THALLOUS CHLORIDE TL-201

	INJECTABLE; INTRAVENOUS						
	THALLOUS CHLORIDE TL 201						
	@	CURIUM	2mCi/ML	A077698	001	Nov 09, 2006	Feb CAHN

THIORIDAZINE HYDROCHLORIDE

	TABLET; ORAL						
	THIORIDAZINE HYDROCHLORIDE						
AB		MYLAN	10MG	A088004	002	Mar 15, 1983	Mar CTEC
AB			25MG	A088004	003	Mar 15, 1983	Mar CTEC
AB			50MG	A088004	004	Mar 15, 1983	Mar CTEC
AB	!		100MG	A088004	001	Nov 18, 1983	Mar CTEC
AB		SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Mar CMFD
AB			25MG	A089953	003	Aug 01, 1986	Mar CMFD
AB			50MG	A089953	002	Aug 01, 1986	Mar CMFD
AB			100MG	A089953	001	Oct 07, 1988	Mar CMFD

THIOTEPA

	POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL							
	TEPADINA							
>A>	AP	+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	May CPOT
>A>	AP	+!		100MG/VIAL	N208264	002	Jan 26, 2017	May CPOT
	THIOTEPA							
>A>	AP		MSN	15MG/VIAL	A213049	001	Mar 04, 2020	May CPOT
>A>	AP			100MG/VIAL	A213049	002	Mar 04, 2020	May CPOT
	POWDER; INTRAVENOUS							
	TEPADINA							
>D>	AP	+!	ADIENNE SA	15MG/VIAL	N208264	001	Jan 26, 2017	May CPOT
	AP	+!		15MG/VIAL	N208264	001	Jan 26, 2017	Feb CFTG
>D>	AP	+!		100MG/VIAL	N208264	002	Jan 26, 2017	May CPOT
	AP	+!		100MG/VIAL	N208264	002	Jan 26, 2017	Feb CFTG
	THIOTEPA							
>D>	AP		MSN	15MG/VIAL	A213049	001	Mar 04, 2020	May CPOT
	AP			15MG/VIAL	A213049	001	Mar 04, 2020	Feb NFTG
>D>	AP			100MG/VIAL	A213049	002	Mar 04, 2020	May CPOT
	AP			100MG/VIAL	A213049	002	Mar 04, 2020	Feb NFTG

TICAGRELOR

	TABLET; ORAL						
	TICAGRELOR						
AB		HEC PHARM CO LTD	90MG	A208508	001	Apr 06, 2020	Mar NEWA
AB		SIGMAPHARM LABS LLC	90MG	A208596	001	Apr 07, 2020	Mar NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2MG BASE	A213544	001	Mar 24, 2020	Mar	NEWA
AB		EQ 4MG BASE	A213544	002	Mar 24, 2020	Mar	NEWA
AB		EQ 6MG BASE	A213544	003	Mar 24, 2020	Mar	NEWA
>A>	RUBICON	EQ 2MG BASE	A213798	001	May 27, 2020	May	NEWA
>A>		EQ 4MG BASE	A213798	002	May 27, 2020	May	NEWA
>A>		EQ 6MG BASE	A213798	003	May 27, 2020	May	NEWA

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

@ MYLAN

300MG/5ML

A209554 001 Oct 13, 2017 Feb DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

AP ! XGEN PHARMS EQ 1.2GM BASE/VIAL

A065013 001 Aug 17, 2001 Feb CAHN

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ MYLAN PHARMS INC

250MG

A070259 001 Jan 02, 1986 Mar DISC

@

500MG

A070259 003 Mar 17, 1986 Mar DISC

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

>A> AB AJANTA PHARMA LTD 2MG

A213397 001 May 19, 2020 May NEWA

>A> AB 4MG

A213397 002 May 19, 2020 May NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

@ MYLAN PHARMS INC

1MG

A202641 001 Nov 27, 2012 Jan DISC

@

2MG

A202641 002 Nov 27, 2012 Jan DISC

AB UNIQUE PHARM LABS 1MG

A204721 001 Jan 24, 2020 Jan NEWA

AB 2MG

A204721 002 Jan 24, 2020 Jan NEWA

TOLVAPTAN

TABLET; ORAL

SAMSCA

>D> +! OTSUKA AMERICA PHARM 30MG

N022275 002 May 19, 2009 May CFTG

>A> AB +! 30MG

N022275 002 May 19, 2009 May CFTG

TOLVAPTAN

>A> AB ALKEM LABS LTD 30MG

A211891 001 May 19, 2020 May NEWA

>A> AB 60MG

A211891 002 May 19, 2020 May NFTG

>A> AB APOTEX 30MG

A207605 001 May 19, 2020 May NFTG

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB VIWIT PHARM 25MG

A077733 001 Mar 27, 2009 Mar CAHN

AB 25MG

A077733 001 Mar 27, 2009 Mar CAHN

AB 50MG

A077733 002 Mar 27, 2009 Mar CAHN

AB 50MG

A077733 002 Mar 27, 2009 Mar CAHN

AB 100MG

A077733 003 Mar 27, 2009 Mar CAHN

AB 100MG

A077733 003 Mar 27, 2009 Mar CAHN

AB 200MG

A077733 004 Mar 27, 2009 Mar CAHN

AB 200MG

A077733 004 Mar 27, 2009 Mar CAHN

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB COREPHARMA 5MG

A076894 001 May 31, 2005 Feb CAHN

AB 10MG

A076894 002 May 31, 2005 Feb CAHN

AB 20MG

A076894 003 May 31, 2005 Feb CAHN

AB 100MG

A076894 004 May 31, 2005 Feb CAHN

TRAMADOL HYDROCHLORIDE

	TABLET; ORAL						
	TRAMADOL HYDROCHLORIDE						
>D>	AB	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	May DISC
>A>		@	50MG	A205702	001	Sep 25, 2015	May DISC

TRANEXAMIC ACID

	INJECTABLE; INJECTION						
	TRANEXAMIC ACID						
		@ CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jan DISC
AP		XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013	Feb CAHN
	TABLET; ORAL						
	TRANEXAMIC ACID						
		@ ANI PHARMS INC	650MG	A203256	001	Jul 25, 2016	Jan CAHN

TRAZODONE HYDROCHLORIDE

	TABLET; ORAL						
	TRAZODONE HYDROCHLORIDE						
AB		AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Jan NEWA
AB			100MG	A204852	002	Feb 05, 2020	Jan NEWA
AB			150MG	A204852	003	Feb 05, 2020	Jan NEWA
AB			300MG	A204852	004	Feb 05, 2020	Jan NEWA

TREPROSTINIL

	INJECTABLE; IV (INFUSION), SUBCUTANEOUS						
	TREPROSTINIL						
>A>	AP	DR REDDYS	1MG/ML	A210214	001	May 22, 2020	May NEWA
>A>	AP		2.5MG/ML	A210214	002	May 22, 2020	May NEWA
>A>	AP		5MG/ML	A210214	003	May 22, 2020	May NEWA
>A>	AP		10MG/ML	A210214	004	May 22, 2020	May NEWA

TRIAMCINOLONE ACETONIDE

	LOTION; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT		SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	Mar CAHN
	OINTMENT; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
AT		MACLEODS PHARMS LTD	0.025%	A209828	001	Nov 23, 2018	Mar CTNA
AT			0.1%	A209828	002	Nov 23, 2018	Mar CTNA
AT			0.5%	A209828	003	Nov 23, 2018	Mar CTNA
>A>	AT	STRIDES PHARMA	0.05%	A212356	001	Jun 01, 2020	May NEWA
AT			0.1%	A211315	001	Mar 18, 2020	Mar NEWA
AT			0.5%	A211315	002	Mar 18, 2020	Mar NEWA

TRIAZOLAM

	TABLET; ORAL						
	TRIAZOLAM						
		@ MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994	Jan DISC
		@	0.25MG	A074031	002	Mar 25, 1994	Jan DISC

TRIENTINE HYDROCHLORIDE

	CAPSULE; ORAL						
	TRIENTINE HYDROCHLORIDE						
>A>	AB	LUPIN LTD	250MG	A211637	001	May 21, 2020	May NEWA
AB		RISING	250MG	A212238	001	Feb 20, 2020	Feb NEWA

TRIFAROTENE

	CREAM; TOPICAL						
	AKLIEF						
>A>	+	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019	May CAHN
>D>	+	GALDERMA R AND D	0.005%	N211527	001	Oct 04, 2019	May CAHN

TROSPIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL						
	TROSPIUM CHLORIDE						
AB		GRANULES PHARMS	60MG	A213185	001	Apr 23, 2020	Apr NEWA

TUCATINIB

TABLET;ORAL

TUKYSA

	+	SEATTLE GENETICS	50MG	N213411	001	Apr 17, 2020	Apr NEWA
	+	!	150MG	N213411	002	Apr 17, 2020	Apr NEWA

URSODIOL

CAPSULE;ORAL

URSODIOL

		NEXGEN PHARMA INC	200MG	A205789	001	May 08, 2020	Apr NFTG
			400MG	A205789	002	May 08, 2020	Apr NFTG
AB		RISING	300MG	A213200	001	Feb 12, 2020	Jan NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	@	TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010	Jan DISC
	@		EQ 1GM BASE	A077655	002	May 24, 2010	Jan DISC
AB		YILING PHARM LTD	EQ 500MG BASE	A209553	001	Mar 18, 2020	Mar NEWA
AB			EQ 1GM BASE	A209553	002	Mar 18, 2020	Mar NEWA

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		GRANULES PHARMS	50MG/ML	A213306	001	Jan 31, 2020	Jan NEWA
----	--	-----------------	---------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan CAHN
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan CAHN

SOLUTION;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

>D>	+	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	May CPOT
>A>	+		EQ 500MG BASE/100ML (EQ 5MG	N211962	001	Feb 15, 2019	May CPOT
			BASE/ML)				
>A>	+		EQ 750MG BASE/150ML (EQ 5MG	N211962	005	May 13, 2020	May NEWA
			BASE/ML)				
>D>	+		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	May CPOT
>A>	+		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	May CPOT
>A>	+		EQ 1.25GM BASE/250ML (EQ 5MG	N211962	006	May 13, 2020	May NEWA
			BASE/ML)				
>D>	+		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	May CPOT
>A>	+		EQ 1.5GM BASE/300ML (EQ 5MG	N211962	003	Feb 15, 2019	May CPOT
			BASE/ML)				
>A>	+		EQ 1.75GM BASE/350ML (EQ 5MG	N211962	007	May 13, 2020	May NEWA
			BASE/ML)				
>D>	+		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	May CPOT
>A>	+		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	May CPOT

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

VARDENAFIL HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	10MG	A205988	001	Mar 10, 2020	Feb NEWA
----	--	---------------------	------	---------	-----	--------------	----------

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

	+	PAR STERILE PRODUCTS	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Apr NEWA
	+		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		INVENTIA HLTHCARE	EQ 37.5MG BASE	A203332	001	Mar 12, 2020	Mar NEWA
AB			EQ 75MG BASE	A203332	002	Mar 12, 2020	Mar NEWA
AB			EQ 150MG BASE	A203332	003	Mar 12, 2020	Mar NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS							
VERAPAMIL HYDROCHLORIDE							
AP	AREVA PHARMS	10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Mar	NEWA
AP	CAPLIN	5MG/2ML (2.5MG/ML)	A213232	001	Mar 25, 2020	Mar	NEWA
AP		10MG/4ML (2.5MG/ML)	A213232	002	Mar 25, 2020	Mar	NEWA

VIGABATRIN

FOR SOLUTION; ORAL							
VIGABATRIN							
AA	GRANULES PHARMS	500MG/PACKET	A213469	001	Apr 24, 2020	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL							
VILAZODONE HYDROCHLORIDE							
	@ TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Mar	DISC
	@	20MG	A208212	002	Sep 30, 2019	Mar	DISC
	@	40MG	A208212	003	Sep 30, 2019	Mar	DISC

VINCRISTINE SULFATE

INJECTABLE; INJECTION							
VINCRISTINE SULFATE PFS							
AP	! HOSPIRA	1MG/ML	A071484	001	Apr 19, 1988	Feb	CTEC
AP	TEVA PHARMS USA	1MG/ML	A075493	001	Sep 01, 1999	Feb	CMFD

VORICONAZOLE

INJECTABLE; INTRAVENOUS							
VORICONAZOLE							
AP	GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020	Mar	NEWA

ZALEPLON

CAPSULE; ORAL							
ZALEPLON							
	@ TEVA PHARMS	5MG	A077239	001	Jun 06, 2008	Mar	DISC
	@	10MG	A077239	002	Jun 06, 2008	Mar	DISC

ZIDOVUDINE

TABLET; ORAL							
ZIDOVUDINE							
	@ MYLAN LABS LTD	100MG	N200732	001	Feb 23, 2011	Apr	CAHN

ZINC SULFATE

SOLUTION; INTRAVENOUS							
ZINC SULFATE							
	AM REAGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020	Apr	NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL							
ZIPRASIDONE HYDROCHLORIDE							
AB	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Mar	CMFD
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Mar	CMFD
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Mar	CMFD
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Mar	CMFD

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS								
ZOLEDRONIC ACID								
>D>	AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May	CAHN
		@ EMCURE PHARMS LTD	EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Apr	DISC
	AP	INGENUS PHARMS LLC	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Feb	NEWA
>A>	AP	PUNISKA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May	CAHN

ZOLMITRIPTAN

TABLET; ORAL							
ZOLMITRIPTAN							
AB	APPCO	2.5MG	A206973	001	Jun 30, 2017	Mar	CAHN
AB		5MG	A206973	002	Jun 30, 2017	Mar	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL							
ZOLMITRIPTAN							
	@ MYLAN	2.5MG	A202855	001	Sep 20, 2019	Feb	DISC
	@	5MG	A202855	002	Sep 20, 2019	Feb	DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

@ YUNG SHIN PHARM

5MG

A 077990 001 Apr 23, 2007 Apr DISC

@

10MG

A 077990 002 Apr 23, 2007 Apr DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB AUROBINDO PHARMA LTD 25MG

A 077645 002 Sep 29, 2006 Mar CMFD

AB 50MG

A 077645 003 Sep 29, 2006 Mar CMFD

AB 100MG

A 077645 001 Dec 22, 2005 Mar CMFD

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+!	GLAXOSMITHKLINE	250MG;125MG	N211733	001	Feb 28, 2020	Apr	CAHN
+!	PFIZER INC	250MG;125MG	N211733	001	Feb 28, 2020	Feb	NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

	GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010	Mar	CMS1
	P AND L	0.1%	A090962	001	Jun 02, 2010	Apr	CMS1

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	Mar	CMFD
--	-----------------	-----------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	Apr	CMS1
	VOLTAREN ARTHRITIS PAIN						
+!	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CTNA
+!		1%	N022122	001	Oct 17, 2007	Mar	CMS1

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	HETERO LABS LTD III	EQ 20MG BASE	A208939	001	May 28, 2020	May	NEWA
>A>		EQ 20MG BASE	A212507	001	Jun 02, 2020	May	NEWA
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020	Apr	NEWA

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	DR REDDYS LABS LTD	EQ 20MG BASE	A211571	001	May 14, 2020	May	NEWA
-----	--------------------	--------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001	Jan	CMS1
	@ MYLAN	10MG	A075674	001	Dec 21, 2001	Jan	DISC
	@ TEVA	10MG	A075312	001	May 31, 2001	Mar	DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020	Feb	NEWA
		180MG	A212971	002	Feb 24, 2020	Feb	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

>D>	GRANULES INDIA LTD	60MG	A211075	001	Oct 18, 2019	May	DISC
>A>	@	60MG	A211075	001	Oct 18, 2019	May	DISC
>D>		180MG	A211075	002	Oct 18, 2019	May	DISC
>A>	@	180MG	A211075	002	Oct 18, 2019	May	DISC

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	GRANULES INDIA LTD	600MG	A213420	001	May 08, 2020	Apr	NEWA
		1.2GM	A213420	002	May 08, 2020	Apr	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020	Mar	NEWA
		1.2GM;120MG	A213203	002	Mar 25, 2020	Mar	NEWA
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020	Apr	NEWA
		1.2GM;120MG	A212542	002	Apr 28, 2020	Apr	NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC  
 KETOTIFEN FUMARATE  
 >A> BAYSHORE PHARMS LLC EQ 0.025% BASE A204059 001 Jun 01, 2020 May NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL  
 LEVOCETIRIZINE DIHYDROCHLORIDE  
 HETERO LABS LTD III 5MG A213513 001 Apr 29, 2020 Apr NEWA  
 PERRIGO R AND D 5MG A211983 001 Mar 28, 2019 Feb CMFD

LEVONORGESTREL

TABLET;ORAL  
 LEVONORGESTREL  
 APOTEX 1.5MG A205329 001 Sep 18, 2018 Jan CMFD  
 LABORATOIRE HRA 1.5MG A204044 001 Jul 03, 2018 Jan CAHN  
 XIROMED 1.5MG A205329 001 Sep 18, 2018 Feb CAHN

LORATADINE

CAPSULE;ORAL  
 LORATADINE  
 >D> @ BIONPHARMA INC 10MG A202538 001 Dec 21, 2018 May CMFD  
 >A> @ BIONPHARMA INC 10MG A202538 001 Dec 21, 2018 May CMFD  
 SYRUP;ORAL  
 LORATADINE  
 @ TEVA 1MG/ML A075505 001 Nov 07, 2003 Apr DISC  
 TABLET;ORAL  
 LORATADINE  
 @ MYLAN 10MG A075790 001 Nov 07, 2008 Jan DISC  
 @ 10MG A078447 001 Aug 12, 2011 Jan DISC  
 TABLET, ORALLY DISINTEGRATING;ORAL  
 LORATADINE  
 @ ACTAVIS LABS FL INC 10MG A075990 001 Nov 03, 2003 Apr DISC

NAPROXEN SODIUM

TABLET;ORAL  
 NAPROXEN SODIUM  
 @ YICHANG HUMANWELL 220MG A212033 001 Aug 30, 2019 Mar DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL  
 NICOTINE POLACRILEX  
 DR REDDYS LABS SA EQ 2MG BASE A212983 001 Feb 21, 2020 Feb NEWA  
 EQ 4MG BASE A212983 002 Feb 21, 2020 Feb NEWA  
 >A> P AND L EQ 2MG BASE A212057 001 May 14, 2020 May NEWA  
 >A> P AND L EQ 4MG BASE A212057 002 May 14, 2020 May NEWA

NONOXYNOL-9

SPONGE;VAGINAL  
 TODAY  
 + @ MAYER LABS INC 1GM N018683 001 Apr 01, 1983 Mar DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 >A> OLOPATADINE HYDROCHLORIDE  
 >A> GLAND PHARMA LTD EQ 0.2% BASE A209752 001 May 20, 2020 May NFTG  
 PATADAY ONCE DAILY RELIEF  
 +! NOVARTIS EQ 0.2% BASE N021545 001 Dec 22, 2004 Mar CTNA  
 +! NOVARTIS EQ 0.2% BASE N021545 001 Dec 22, 2004 Mar CMS1  
 PATADAY TWICE DAILY RELIEF  
 +! NOVARTIS EQ 0.1% BASE N020688 001 Dec 18, 1996 Mar CTNA  
 +! NOVARTIS EQ 0.1% BASE N020688 001 Dec 18, 1996 Mar CMS1

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL  
 OMEPRAZOLE MAGNESIUM  
 HETERO LABS LTD III EQ 20MG BASE A211732 001 Mar 25, 2020 Mar NEWA  
 >A> P AND L EQ 20MG BASE A206582 001 Jun 01, 2020 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@ ACTAVIS ELIZABETH 20MG;1.1GM

A204137 001 Jul 15, 2016 Mar DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

LANNETT CO INC

17GM/PACKET

A090600 001 Oct 06, 2009 Jan CMFD

17GM/SCOOPFUL

A090600 002 Oct 06, 2009 Jan CMFD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

&gt;D&gt;

APOTEX INC

EQ 75MG BASE

A075167 001 May 04, 2000 May DISC

&gt;A&gt;

@

EQ 75MG BASE

A075167 001 May 04, 2000 May DISC

@

EQ 150MG BASE

A200172 001 May 31, 2012 Apr DISC

@

STRIDES PHARMA

EQ 75MG BASE

A201745 001 Feb 29, 2012 Apr DISC

@

EQ 75MG BASE

A209160 001 Mar 05, 2018 Apr DISC

@

EQ 150MG BASE

A200536 001 Jun 28, 2011 Apr DISC

@

EQ 150MG BASE

A209161 001 Feb 22, 2018 Apr DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 05 MAY 2020**

NO MAY 2020 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2020 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; BUTALBITAL - BUTALBITAL AND ACETAMINOPHEN</u>						
A 213115	001				CGT	Jul 28, 2020
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733	001				NP	Feb 28, 2023
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450	001	10588895	Jul 07, 2020	U-2772	M-256	Mar 29, 2022
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595	001	10588895	Jan 14, 2022	U-2772		
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457	001	10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636	001	10561808	Jan 01, 2032	DP		
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636	002	10561808	Jan 01, 2032	DP		
		10569034	Aug 16, 2036	DP		
<u>ALCAFTADINE - LASTACAFT</u>						
N 022134	001	10617695	Mar 19, 2027	DP U-1493		
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434	001	10350214	Apr 24, 2035	DP		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510	001	10525033	Mar 10, 2031	DP	NCE	Feb 26, 2025
		9084765	Mar 10, 2031	U-1744		
		9084765	Mar 10, 2031	U-2754		
		9545426	Mar 10, 2031	U-1744		
		9545426	Mar 10, 2031	U-2754		
		9889118	Mar 10, 2031	U-1744		
		9889118	Mar 10, 2031	U-2754		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	001	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360	002	10548943	Dec 16, 2029	U-2739		
		10548943	Dec 16, 2029	U-2740		
<u>APREMILAST - OTEZLA</u>						
N 205437	001				M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437	002				M-257	Apr 10, 2023
<u>APREMILAST - OTEZLA</u>						
N 205437	003				M-257	Apr 10, 2023
<u>APREPITANT - CINVANTI</u>						
N 209296	001	10624850	Sep 18, 2035	U-2161		
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971	001	10525057	Mar 08, 2034	U-1632		
		10525057	Mar 08, 2034	U-2723		
		10525057	Mar 08, 2034	U-543		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001				>A> NCE		May 26, 2025
				>A> ODE-290		May 26, 2027
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	>A> 10646512	Mar 25, 2032	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10583121	Jul 25, 2033	DP U-2763			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10583121	Jul 25, 2033	DP U-2763			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-2726			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244			
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE</u>						
A 207712 001					PC	Aug 29, 2020
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	>A> 10633397	Apr 27, 2036	U-2816			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	>A> 10633397	Apr 27, 2036	U-2816			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10561808	Jan 01, 2032	DP			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	7335799	Dec 03, 2025	DS		NP	Feb 26, 2023
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	>A> 10632197	Nov 15, 2037	DP U-2755			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10624918	Jun 03, 2029	U-916			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001 >A>	8784789	Jan 13, 2025	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10617698	Jun 10, 2031	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10548846	Nov 08, 2036	DP			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7033605	Oct 20, 2020	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			
	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569 001					NCE ODE-282	Dec 20, 2024 Dec 20, 2026
<u>BUPRENORPHINE - BUPRENORPHINE</u>						
A 211586 002				>A> CGT		Oct 13, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10592168	Jun 06, 2031	U-2489			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001					NPP	Nov 05, 2022
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 8222219	Apr 11, 2025	U-2441			
	>A> 8222219	Apr 11, 2025	U-2632			
	>A> 8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 8222219	Apr 11, 2025	U-2441			
	>A> 8222219	Apr 11, 2025	U-2632			
	>A> 8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 8222219	Apr 11, 2025	U-2441			
	>A> 8222219	Apr 11, 2025	U-2632			
	>A> 8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	>A> 7943582	Feb 26, 2029	DS DP U-2441			
	>A> 7943582	Feb 26, 2029	DS DP U-2632			
	>A> 7943582	Feb 26, 2029	DS DP U-493			
	>A> 8222219	Apr 11, 2025	U-2441			
	>A> 8222219	Apr 11, 2025	U-2632			
	>A> 8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	>A> 7767675	Nov 19, 2027	DS DP	>A> NCE		May 06, 2025
	>A> 8420645	Jun 05, 2031	DS DP	>A> ODE-291		May 06, 2027
	>A> 8461330	Nov 19, 2027	DS DP			
	>A> 8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	>A> 7767675	Nov 19, 2027	DS DP	>A> NCE		May 06, 2025
	>A> 8420645	Jun 05, 2031	DS DP	>A> ODE-291		May 06, 2027
	>A> 8461330	Nov 19, 2027	DS DP			
	>A> 8901123	May 20, 2029	U-2813			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	Sep 13, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	Sep 13, 2022
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	>A> 10376527	May 27, 2036	DP U-2718	>A> NP		May 05, 2023
	>A> 9572819	May 27, 2036	DP U-2718			
	>A> 9795620	May 27, 2036	DP U-2718			
	>A> 9949990	May 27, 2036	DP U-2718			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	6642245	Nov 04, 2020	U-2352			
	6642245	Nov 04, 2020	U-2765			
	7803788	Feb 02, 2022	U-2352			
	7803788	Feb 02, 2022	U-2765			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10590102	Jun 30, 2036	DS DP U-1776			
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 11, 2026	DS DP		NCE	Dec 14, 2021
	8039451*PED	Dec 11, 2026			NPP	Mar 23, 2023
	8168614	Jan 20, 2030	U-1932		PED	Jun 14, 2022
	8168614*PED	Jul 20, 2030			PED	Sep 23, 2023
	8501712	Feb 16, 2027	U-1932			
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027	U-1932			
	9682092*PED	Aug 16, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		M-216	Dec 22, 2020
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2021
	10548859	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	9173851	Jun 17, 2034	DP			
	9192590	Jan 26, 2027	U-1399			
	9198882	Jan 26, 2027	U-1399			
	9233077	Jun 17, 2034	DP			
	9925156	Jan 26, 2027	DP U-1399			
	9925157	Jan 26, 2027	DP U-1399			
	9925158	Jan 26, 2027	DP U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001					>A> ODE-287	Aug 03, 2024
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			
	9763876	Mar 27, 2029	DP U-2727			
<u>DICYCLOMINE HYDROCHLORIDE - DICYCLOMINE HYDROCHLORIDE</u>						
A 212286 001					>A> CGT	Nov 18, 2020
<u>DIHYDROERGOTAMINE MESYLATE - DIHYDROERGOTAMINE MESYLATE</u>						
A 212907 001					>A> CGT	Nov 19, 2020
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001					M-260	Feb 05, 2023
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002					M-260	Feb 05, 2023
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001					I-827	Sep 19, 2022
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10548871	Apr 11, 2028	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10548871	Apr 11, 2028	U-620			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	10537572	Sep 01, 2036	U-2735			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8673927	May 04, 2027	U-1652	Y	M-252	Mar 20, 2023
	9173859	May 04, 2027	DP U-1772	Y	M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	8673927	May 04, 2027	U-1652	Y	M-252	Mar 20, 2023
	9173859	May 04, 2027	DP U-1772	Y	M-258	Jul 03, 2022
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP		U-2732	
	10258637	Apr 03, 2034			U-2731	
	10406172	Jun 15, 2030	DP		U-2733	
	10596120	Mar 07, 2032	DP		U-2776	
	10596120	Mar 07, 2032	DP		U-2790	
	6488962	Jun 20, 2020	DP			
	7407955	May 02, 2025	DS DP			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023			U-1652	
	8178541	Aug 12, 2023	DP		U-1652	
	8551957	Oct 14, 2029	DP		U-2730	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034			U-2731	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 10610489	Sep 30, 2030	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 10596120	Mar 07, 2032	DP U-2775			
	>A> 10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 10596120	Mar 07, 2032	DP U-2775			
	>A> 10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 10596120	Mar 07, 2032	DP U-2775			
	>A> 10596120	Mar 07, 2032	DP U-2792			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 10596120	Mar 07, 2032	DP U-2775			
	>A> 10596120	Mar 07, 2032	DP U-2792			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					NPP ODE-284 ODE-285	Sep 25, 2020 Sep 28, 2024 Sep 28, 2024
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10610125	Jun 21, 2030	U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10610125	Jun 21, 2030	U-2087			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-826	Apr 08, 2023
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10258622	Nov 21, 2032	U-2802			
	>A> 8541575	Feb 26, 2030	DS DP U-2335			
	>A> 8541575	Feb 26, 2030	DS DP U-2802			
	>A> 8541575	Feb 26, 2030	DS DP U-2803			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9474754	Aug 05, 2033	DP U-2802			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10561651	Feb 19, 2035	U-2745			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10561651	Feb 19, 2035	U-2745			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENACLICK</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10639375	Nov 21, 2032	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10533174	May 04, 2021	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10533174	May 04, 2021	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	7045145	Mar 14, 2021	DP U-2751		NP	Feb 14, 2023
	7384650	Mar 14, 2021	DP			
	8221784	Mar 14, 2021	DP			
	8221785	Mar 14, 2021	DP			
	8246978	Aug 26, 2028	DP			
	8747888	Jul 10, 2028	DP			
	8883196	Nov 22, 2020	DP U-2751			
	9050348	Jul 10, 2028	DP			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039	U-2786			
	10632066	Feb 01, 2039	U-2787			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6414126	Oct 04, 2020	DS DP U-2588			
	6515117	Oct 04, 2020	DS DP U-2588			
	6872700	Jan 14, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589			
	6872700	Jan 14, 2020	U-2590			
	6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-2592			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-2592			
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2598			
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	DP U-2588			
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10610523	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10610523	Jan 25, 2027	DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS U-2709			
	10519252	Oct 20, 2023	DS U-2710			
	10519252	Oct 20, 2023	DS U-2711			
	10519252	Oct 20, 2023	DS U-2712			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	5753706	Feb 03, 2021	DP U-1577			
<u>FERRIC DERISOMALTOSIDE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7906489	Mar 04, 2027	U-2741		NPP	Jan 24, 2023
	7906489	Mar 04, 2027	U-319		PED	Jul 24, 2023
	7906489*PED	Sep 04, 2027				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			PED	Jul 24, 2023
	7863249	Jul 31, 2027	DP			
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	10543179	Dec 25, 2027	U-2719			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	6715485	Sep 03, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10561808	Jan 01, 2032	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001 >A>	10624911	Jun 02, 2037	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001						

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10533174	May 04, 2021	DP		ODE-280	Dec 12, 2026
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	10556010	Dec 19, 2036	U-2250			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10493103	Apr 21, 2035	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	>A> 10631746	Aug 04, 2035	DP U-2815			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	>A> 10646481	Aug 13, 2029	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10597384	Dec 04, 2028	DS DP U-2777			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784			
	10610125	Jun 21, 2030	U-2785			
<u>LACTITOL - PIZENSY</u>						
N 211281 001					NCE	Feb 12, 2025
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	7423050	Apr 06, 2025	DS DP U-1719		NCE	Jan 31, 2025
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-2773			
<u>LEMBorexant - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBorexant - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LETermovir - PREVYMIS</u>						
N 209939 001	RE46791	May 22, 2024	DS DP			
<u>LETermovir - PREVYMIS</u>						
N 209939 002	RE46791	May 22, 2024	DS DP			
<u>LETermovir - PREVYMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP			
	7196086	May 22, 2024	DS DP	Y		
	RE46791	May 22, 2024	DS DP			
<u>LETermovir - PREVYMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP			
	7196086	May 22, 2024	DS DP	Y		
	RE46791	May 22, 2024	DS DP			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001					>A> I-829	May 01, 2023
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	10603293	Jan 14, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503	Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	8673927 9173859	May 04, 2027 May 04, 2027	U-1503 DP U-1503	Y Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	8673927 9173859	May 04, 2027 May 04, 2027	U-1503 DP U-1503	Y Y	M-252 M-258	Mar 30, 2023 Jul 03, 2022
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10555938	Mar 07, 2025	U-1316			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10555938	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10555938	Mar 07, 2025	U-1316			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001	10596107	Dec 23, 2036	DP U-2764			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	7183282	Jun 15, 2020	DS DP			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE39680	Jun 15, 2020	DS DP U-543			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP			
	10596278	Jul 25, 2038	DP			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	8512727	Dec 25, 2022	DP U-2750			
	9974746	May 26, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10561675	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-244	Aug 12, 2022
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003					M-244	Aug 12, 2022
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10610485	Jan 02, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10617651	Mar 23, 2032	U-2357			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10617651	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10568841	Oct 30, 2035	DP U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10568841	Oct 30, 2035	DP U-2357			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	>A> 10596155	Jun 28, 2032	DP			
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 001					>A> PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MICAFUNGIN SODIUM</u>						
A 207344 002					>A> PC	Nov 07, 2020
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003					I-821 PED	Dec 20, 2022 Jun 20, 2023
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	>A> 10660904	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10525045	Apr 28, 2028	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10517882	Oct 01, 2030	U-2647			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		>A> ODE-289	Apr 15, 2027
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	>A> 10098863	Feb 27, 2035	DP U-1384			
	>A> 10105335	Feb 27, 2035	DP			
	>A> 10105336	Feb 27, 2035	DP U-1384			
	>A> 10105337	Feb 27, 2035	DP			
	>A> 9326947	Feb 27, 2035	DP			
	>A> 9326965	Feb 27, 2035	U-1384			
	>A> 9511043	Feb 27, 2035	U-1384			
	>A> 9517209	Feb 27, 2035	DP			
	>A> 9566259	Feb 27, 2035	DP			
	>A> 9636318	Feb 27, 2035	U-1384			
	>A> 9636319	Feb 27, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	>A> 9814691	Feb 27, 2035	U-1384			
	>A> 9814692	Feb 27, 2035	U-1384			
	>A> 9820960	Feb 27, 2035	DP			
	>A> 9820961	Feb 27, 2035	DP U-1384			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE</u>						
A 213209 001					CGT	Sep 14, 2020
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001					I-823	Feb 25, 2023
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	6297375	Mar 17, 2023	DS			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001					I-825	Mar 09, 2023
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002					I-825	Mar 09, 2023
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10213572	Feb 12, 2036	DP			
	9604028	Aug 13, 2029	U-2793			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2481			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2480			
	>A> 8912187	Mar 12, 2024	U-2481			
	>A> 8912187	Mar 12, 2024	U-2482			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			
	>A> 8912187	Mar 12, 2024	U-2824			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8143241	Aug 12, 2027	U-2101		ODE-283	Dec 27, 2026
	>A> 8143241	Aug 12, 2027	U-2103			
	>A> 8143241	Aug 12, 2027	U-2480			
	>A> 8143241	Aug 12, 2027	U-2481			
	>A> 8143241	Aug 12, 2027	U-2482			
	>A> 8143241	Aug 12, 2027	U-2483			
	>A> 8143241	Aug 12, 2027	U-2716			
	>A> 8143241	Aug 12, 2027	U-2819			
	>A> 8143241	Aug 12, 2027	U-2820			
	>A> 8143241	Aug 12, 2027	U-2821			
	>A> 8143241	Aug 12, 2027	U-2822			
	>A> 8143241	Aug 12, 2027	U-2823			
	>A> 8143241	Aug 12, 2027	U-2824			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8912187	Mar 12, 2024	U-2101			
	>A> 8912187	Mar 12, 2024	U-2480			
	>A> 8912187	Mar 12, 2024	U-2481			
	>A> 8912187	Mar 12, 2024	U-2482			
	>A> 8912187	Mar 12, 2024	U-2483			
	>A> 8912187	Mar 12, 2024	U-2819			
	>A> 8912187	Mar 12, 2024	U-2820			
	>A> 8912187	Mar 12, 2024	U-2821			
	>A> 8912187	Mar 12, 2024	U-2822			
	>A> 8912187	Mar 12, 2024	U-2823			
	>A> 8912187	Mar 12, 2024	U-2824			
	9566276	Mar 12, 2024	U-2716			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	>A> 10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	>A> 10357468	May 27, 2035	U-2812			
	>A> 10583130	Mar 31, 2030	U-2811			
	>A> 8168793	Apr 02, 2029	DS DP U-2811			
	>A> 8524746	Jul 14, 2029	U-2811			
	>A> 8907099	May 12, 2027	DS			
	>A> 9550759	Jul 26, 2026	U-2811			
	>A> 9550759	Jul 26, 2026	U-2817			
	>A> 9550759	Jul 26, 2026	U-2818			
	>A> 9630955	Dec 12, 2032	DS DP U-2811			
	>A> 9745290	Oct 10, 2027	DP U-2811			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	>A> 10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	>A> 10357468	May 27, 2035	U-2812			
	>A> 10583130	Mar 31, 2030	U-2811			
	>A> 8168793	Apr 02, 2029	DS DP U-2811			
	>A> 8524746	Jul 14, 2029	U-2811			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	>A> 8907099	May 12, 2027	DS			
	>A> 9550759	Jul 26, 2026		U-2811		
	>A> 9550759	Jul 26, 2026		U-2817		
	>A> 9550759	Jul 26, 2026		U-2818		
	>A> 9630955	Dec 12, 2032	DS DP	U-2811		
	>A> 9745290	Oct 10, 2027	DP	U-2811		
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001					M-251	Aug 02, 2022
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002					M-251	Aug 02, 2022
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	8314097	Mar 27, 2029	DS DP		ODE-286	Mar 06, 2027
	8609862	Jan 13, 2031		U-2770		
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	>A> 10646485	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	>A> 10646485	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	>A> 10646485	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	>A> 10646485	Sep 02, 2036	DP	U-1556		
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	>A> 10646485	Sep 02, 2036	DP	U-1556		
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 001					M-14	Oct 25, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
N 021611 002					M-14	Oct 25, 2022
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2021	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP		Y	
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	6936612	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	6936612	Jan 16, 2023	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	7772209	May 24, 2022	U-2728			
	7772209	May 24, 2022	U-2729			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	>A> 10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	>A> 9611267	Jan 30, 2035	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	>A> 10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	>A> 9611267	Jan 30, 2035	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	>A> 10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
	>A> 9611267	Jan 30, 2035	DS DP			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	>A> 10646480	Aug 27, 2038	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	>A> 10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	>A> 10548904	Feb 03, 2029	U-2810			
	>A> 8580293	Jan 21, 2030	U-2810			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10550081	Jul 14, 2030	DS			
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	>A> 8603514	Apr 03, 2024	DP			
	>A> 8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 22, 2031	DS DP U-2718		NCE	Feb 27, 2025
	8759372	Feb 25, 2033	DS DP			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-2142			
	>A> 9415053	Nov 13, 2024	DP U-2640			
	>A> 9539218	Feb 17, 2034	U-1957			
	>A> 9539218	Feb 17, 2034	U-2143			
	>A> 9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9539218	Feb 17, 2034	U-1953			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9539218	Feb 17, 2034	U-1953			
	>A> 9539218	Feb 17, 2034	U-1954			
	>A> 9539218	Feb 17, 2034	U-1955			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-824	Oct 11, 2021
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10544108	Jul 26, 2032	U-2584			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					>A> NCE	May 08, 2025
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002					>A> NCE	May 08, 2025
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS	U-2800		
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS	U-2800		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002					I-822	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001					M-252	Jan 16, 2023
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002					M-252	Jan 16, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051	003				M-252	Jan 16, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	001				>A> M-261	Apr 24, 2023
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078	002				>A> M-261	Apr 24, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001				NPP	Mar 19, 2023
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	002	10086011	Jan 30, 2034	U-1470	NS	Mar 19, 2023
		7964580	Mar 26, 2029	DS DP U-1470		
		8334270	Mar 21, 2028	DS DP U-1470		
		8575135	Nov 16, 2032	DS DP U-1470		
		8580765	Mar 21, 2028	DS DP U-1470		
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8735372	Mar 21, 2028	U-1470		
		8889159	Mar 26, 2029	DP U-1470		
		8921341	Nov 16, 2032	DS DP U-1470		
		8940718	Nov 16, 2032	DS DP U-1470		
		9085573	Mar 21, 2028	DS DP U-1470		
		9284342	Sep 13, 2030	DS DP U-1470		
		9757406	Jan 30, 2034	DP		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	001	10512609	Sep 05, 2037	U-2548		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	002	10512609	Sep 05, 2037	U-2548		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306	001	10512620	Aug 18, 2038	U-2769		
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478	001	10624906	Oct 28, 2036	DP		
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109	001	10624855	Nov 26, 2034	DP		
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884	001	10603305	Jun 16, 2030	DP U-1719		
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223	001	10537554	Jan 29, 2036	U-72		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	002				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	003				M-253	Jan 29, 2023
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	004				M-253	Jan 29, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N 050708	001				>A> ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708	002				>A> ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050708	003				>A> ODE-294	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 050709	001				>A> ODE-294	May 24, 2025
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	001	8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	002	8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	003	8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	10610510	Jan 25, 2033	U-2805		
		10610511	Oct 10, 2034	U-2806		
<u>TAZAROTENE - FABIOR</u>						
N 202428	001	10568859	Feb 24, 2030	DP U-2760		
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723	001	10155002	Apr 13, 2032	U-2736	NCE	Jan 23, 2025
		10245269	Apr 11, 2033	U-2737		
		10369155	Oct 16, 2035	U-2736		
		10420775	Apr 13, 2032	U-2736		
		8410088	Apr 13, 2032	DS DP		
		9090562	Apr 13, 2032	DS DP		
		9394283	Apr 11, 2033	DS DP		
		9522152	Apr 13, 2032	U-2738		
		9549931	Apr 13, 2032	U-2736		
		9688665	Aug 22, 2034	U-2736		
		9855275	Apr 13, 2032	U-2736		
		9872862	Apr 11, 2033	U-2738		
		9889138	Oct 16, 2035	U-2736		
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001	6409990	May 12, 2025	DS		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001	>A> 7816379	Apr 20, 2026	DS DP U-2507		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001	>A> 7816379	Apr 20, 2026	DS DP U-2507		
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464	001				M-255	Feb 04, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	>A> RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	7301023	Dec 08, 2020	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	>A> 10639309	Mar 14, 2034	DP			
	7301023	Dec 08, 2020	DS			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	>A> 10653656	Aug 22, 2038	DP U-2368			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP			
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10519164	Oct 17, 2036	DP			
	10597400	Oct 17, 2036	U-2616			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	>A> 10039804	Nov 06, 2035	DP U-282			
	>A> 10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	>A> 10039804	Nov 06, 2035	DP U-282			
	>A> 10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	>A> 10039804	Nov 06, 2035	DP U-282			
	>A> 10188697	Nov 06, 2035	DP U-282			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2020

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8722657	Jan 29, 2032	DS			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8722657	Jan 29, 2032	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		ODE-281	Nov 25, 2026
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 40<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)